id	sid	tid	token	lemma	pos
bam-12937	1	1	layout	layout	NOUN
bam-12937	1	2	1	1	NUM
bam-12937	1	3	the	the	DET
bam-12937	1	4	therapeutic	therapeutic	ADJ
bam-12937	1	5	effect	effect	NOUN
bam-12937	1	6	of	of	ADP
bam-12937	1	7	pcsk9	pcsk9	NOUN
bam-12937	1	8	inhibitors	inhibitor	NOUN
bam-12937	1	9	on	on	ADP
bam-12937	1	10	dyslipidemia	dyslipidemia	NOUN
bam-12937	1	11	:	:	PUNCT
bam-12937	1	12	one	one	NUM
bam-12937	1	13	-	-	PUNCT
bam-12937	1	14	year	year	NOUN
bam-12937	1	15	follow	follow	VERB
bam-12937	1	16	up	up	ADP
bam-12937	1	17	eur	eur	PROPN
bam-12937	1	18	j	j	PROPN
bam-12937	1	19	transl	transl	PROPN
bam-12937	1	20	myol	myol	NOUN
bam-12937	1	21	34	34	NUM
bam-12937	1	22	(	(	PUNCT
bam-12937	1	23	3	3	NUM
bam-12937	1	24	)	)	PUNCT
bam-12937	1	25	12937	12937	NUM
bam-12937	1	26	,	,	PUNCT
bam-12937	1	27	2024	2024	NUM
bam-12937	1	28	doi	doi	NOUN
bam-12937	1	29	:	:	PUNCT
bam-12937	1	30	10.4081	10.4081	NUM
bam-12937	1	31	/	/	SYM
bam-12937	1	32	ejtm.2024.12937	ejtm.2024.12937	NOUN
bam-12937	1	33	familial	familial	ADJ
bam-12937	1	34	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	1	35	(	(	PUNCT
bam-12937	1	36	fh	fh	PROPN
bam-12937	1	37	)	)	PUNCT
bam-12937	1	38	,	,	PUNCT
bam-12937	1	39	an	an	DET
bam-12937	1	40	autosomal	autosomal	ADJ
bam-12937	1	41	dominant	dominant	ADJ
bam-12937	1	42	genetic	genetic	ADJ
bam-12937	1	43	disorder	disorder	NOUN
bam-12937	1	44	,	,	PUNCT
bam-12937	1	45	causes	cause	VERB
bam-12937	1	46	high	high	ADJ
bam-12937	1	47	levels	level	NOUN
bam-12937	1	48	of	of	ADP
bam-12937	1	49	lowdensity	lowdensity	NOUN
bam-12937	1	50	lipoprotein	lipoprotein	ADJ
bam-12937	1	51	cholesterol	cholesterol	NOUN
bam-12937	1	52	(	(	PUNCT
bam-12937	1	53	ldl	ldl	NOUN
bam-12937	1	54	-	-	PUNCT
bam-12937	1	55	c	c	NOUN
bam-12937	1	56	)	)	PUNCT
bam-12937	1	57	due	due	ADP
bam-12937	1	58	to	to	ADP
bam-12937	1	59	mutations	mutation	NOUN
bam-12937	1	60	in	in	ADP
bam-12937	1	61	genes	gene	NOUN
bam-12937	1	62	controlling	control	VERB
bam-12937	1	63	cholesterol	cholesterol	NOUN
bam-12937	1	64	regulation	regulation	NOUN
bam-12937	1	65	.	.	PUNCT
bam-12937	2	1	the	the	DET
bam-12937	2	2	most	most	ADV
bam-12937	2	3	common	common	ADJ
bam-12937	2	4	mutation	mutation	NOUN
bam-12937	2	5	affects	affect	VERB
bam-12937	2	6	the	the	DET
bam-12937	2	7	ldlr	ldlr	ADJ
bam-12937	2	8	gene	gene	NOUN
bam-12937	2	9	,	,	PUNCT
bam-12937	2	10	responsible	responsible	ADJ
bam-12937	2	11	for	for	ADP
bam-12937	2	12	building	build	VERB
bam-12937	2	13	ldl	ldl	NOUN
bam-12937	2	14	receptors	receptor	NOUN
bam-12937	2	15	that	that	PRON
bam-12937	2	16	remove	remove	VERB
bam-12937	2	17	ldl	ldl	NOUN
bam-12937	2	18	cholesterol	cholesterol	NOUN
bam-12937	2	19	from	from	ADP
bam-12937	2	20	the	the	DET
bam-12937	2	21	blood.1	blood.1	NOUN
bam-12937	2	22	these	these	DET
bam-12937	2	23	mutations	mutation	NOUN
bam-12937	2	24	hinder	hinder	VERB
bam-12937	2	25	ldl	ldl	NOUN
bam-12937	2	26	receptor	receptor	NOUN
bam-12937	2	27	function	function	NOUN
bam-12937	2	28	or	or	CCONJ
bam-12937	2	29	production	production	NOUN
bam-12937	2	30	.	.	PUNCT
bam-12937	3	1	while	while	SCONJ
bam-12937	3	2	ldlr	ldlr	ADJ
bam-12937	3	3	mutations	mutation	NOUN
bam-12937	3	4	are	be	AUX
bam-12937	3	5	most	most	ADV
bam-12937	3	6	frequent	frequent	ADJ
bam-12937	3	7	,	,	PUNCT
bam-12937	3	8	abnormalities	abnormality	NOUN
bam-12937	3	9	in	in	ADP
bam-12937	3	10	apob	apob	ADJ
bam-12937	3	11	,	,	PUNCT
bam-12937	3	12	ldlrap1	ldlrap1	NOUN
bam-12937	3	13	,	,	PUNCT
bam-12937	3	14	and	and	CCONJ
bam-12937	3	15	pcsk9	pcsk9	NOUN
bam-12937	3	16	genes	gene	NOUN
bam-12937	3	17	can	can	AUX
bam-12937	3	18	also	also	ADV
bam-12937	3	19	contribute	contribute	VERB
bam-12937	3	20	to	to	ADP
bam-12937	3	21	fh	fh	PROPN
bam-12937	3	22	.	.	PUNCT
bam-12937	4	1	pcsk9	pcsk9	PROPN
bam-12937	4	2	,	,	PUNCT
bam-12937	4	3	a	a	DET
bam-12937	4	4	liver	liver	NOUN
bam-12937	4	5	-	-	PUNCT
bam-12937	4	6	secreted	secrete	VERB
bam-12937	4	7	serine	serine	NOUN
bam-12937	4	8	protease	protease	NOUN
bam-12937	4	9	,	,	PUNCT
bam-12937	4	10	plays	play	VERB
bam-12937	4	11	a	a	DET
bam-12937	4	12	crucial	crucial	ADJ
bam-12937	4	13	role	role	NOUN
bam-12937	4	14	by	by	ADP
bam-12937	4	15	regulating	regulate	VERB
bam-12937	4	16	ldl	ldl	NOUN
bam-12937	4	17	cholesterol	cholesterol	NOUN
bam-12937	4	18	levels	level	NOUN
bam-12937	4	19	.	.	PUNCT
bam-12937	5	1	its	its	PRON
bam-12937	5	2	binding	binding	NOUN
bam-12937	5	3	to	to	PART
bam-12937	5	4	ldl	ldl	VERB
bam-12937	5	5	abstract	abstract	ADV
bam-12937	5	6	despite	despite	SCONJ
bam-12937	5	7	the	the	DET
bam-12937	5	8	availability	availability	NOUN
bam-12937	5	9	of	of	ADP
bam-12937	5	10	statins	statin	NOUN
bam-12937	5	11	and	and	CCONJ
bam-12937	5	12	lifestyle	lifestyle	NOUN
bam-12937	5	13	modifications	modification	NOUN
bam-12937	5	14	,	,	PUNCT
bam-12937	5	15	many	many	ADJ
bam-12937	5	16	patients	patient	NOUN
bam-12937	5	17	with	with	ADP
bam-12937	5	18	dyslipidemia	dyslipidemia	NOUN
bam-12937	5	19	struggle	struggle	NOUN
bam-12937	5	20	to	to	PART
bam-12937	5	21	achieve	achieve	VERB
bam-12937	5	22	optimal	optimal	ADJ
bam-12937	5	23	low	low	ADJ
bam-12937	5	24	-	-	PUNCT
bam-12937	5	25	density	density	NOUN
bam-12937	5	26	lipoprotein	lipoprotein	ADJ
bam-12937	5	27	cholesterol	cholesterol	NOUN
bam-12937	5	28	(	(	PUNCT
bam-12937	5	29	ldl	ldl	NOUN
bam-12937	5	30	-	-	PUNCT
bam-12937	5	31	c	c	NOUN
bam-12937	5	32	)	)	PUNCT
bam-12937	5	33	control	control	NOUN
bam-12937	5	34	.	.	PUNCT
bam-12937	6	1	pcsk9	pcsk9	NOUN
bam-12937	6	2	inhibitors	inhibitor	NOUN
bam-12937	6	3	offer	offer	VERB
bam-12937	6	4	a	a	DET
bam-12937	6	5	promising	promising	ADJ
bam-12937	6	6	new	new	ADJ
bam-12937	6	7	therapeutic	therapeutic	ADJ
bam-12937	6	8	option	option	NOUN
bam-12937	6	9	with	with	ADP
bam-12937	6	10	superior	superior	ADJ
bam-12937	6	11	ldl	ldl	NOUN
bam-12937	6	12	-	-	PUNCT
bam-12937	6	13	c	c	NOUN
bam-12937	6	14	lowering	lower	VERB
bam-12937	6	15	efficacy	efficacy	NOUN
bam-12937	6	16	compared	compare	VERB
bam-12937	6	17	to	to	ADP
bam-12937	6	18	statins	statins	PROPN
bam-12937	6	19	.	.	PUNCT
bam-12937	7	1	however	however	ADV
bam-12937	7	2	,	,	PUNCT
bam-12937	7	3	data	datum	NOUN
bam-12937	7	4	on	on	ADP
bam-12937	7	5	their	their	PRON
bam-12937	7	6	real	real	ADJ
bam-12937	7	7	-	-	PUNCT
bam-12937	7	8	world	world	NOUN
bam-12937	7	9	use	use	NOUN
bam-12937	7	10	,	,	PUNCT
bam-12937	7	11	particularly	particularly	ADV
bam-12937	7	12	in	in	ADP
bam-12937	7	13	iran	iran	PROPN
bam-12937	7	14	,	,	PUNCT
bam-12937	7	15	is	be	AUX
bam-12937	7	16	limited	limited	ADJ
bam-12937	7	17	.	.	PUNCT
bam-12937	8	1	this	this	DET
bam-12937	8	2	study	study	NOUN
bam-12937	8	3	aims	aim	VERB
bam-12937	8	4	to	to	PART
bam-12937	8	5	address	address	VERB
bam-12937	8	6	this	this	DET
bam-12937	8	7	gap	gap	NOUN
bam-12937	8	8	by	by	ADP
bam-12937	8	9	investigating	investigate	VERB
bam-12937	8	10	the	the	DET
bam-12937	8	11	one	one	NUM
bam-12937	8	12	-	-	PUNCT
bam-12937	8	13	year	year	NOUN
bam-12937	8	14	effects	effect	NOUN
bam-12937	8	15	of	of	ADP
bam-12937	8	16	evolocumab	evolocumab	NOUN
bam-12937	8	17	on	on	ADP
bam-12937	8	18	lipid	lipid	ADJ
bam-12937	8	19	profiles	profile	NOUN
bam-12937	8	20	and	and	CCONJ
bam-12937	8	21	potential	potential	ADJ
bam-12937	8	22	cardiovascular	cardiovascular	ADJ
bam-12937	8	23	outcomes	outcome	NOUN
bam-12937	8	24	in	in	ADP
bam-12937	8	25	iranian	iranian	ADJ
bam-12937	8	26	patients	patient	NOUN
bam-12937	8	27	with	with	ADP
bam-12937	8	28	familial	familial	ADJ
bam-12937	8	29	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	8	30	(	(	PUNCT
bam-12937	8	31	fh).this	fh).this	DET
bam-12937	8	32	singlecenter	singlecenter	NOUN
bam-12937	8	33	,	,	PUNCT
bam-12937	8	34	prospective	prospective	ADJ
bam-12937	8	35	study	study	NOUN
bam-12937	8	36	evaluated	evaluate	VERB
bam-12937	8	37	evolocumab	evolocumab	ADP
bam-12937	8	38	effectiveness	effectiveness	NOUN
bam-12937	8	39	in	in	ADP
bam-12937	8	40	lowering	lower	VERB
bam-12937	8	41	ldl	ldl	NOUN
bam-12937	8	42	-	-	PUNCT
bam-12937	8	43	c	c	NOUN
bam-12937	8	44	in	in	ADP
bam-12937	8	45	50	50	NUM
bam-12937	8	46	iranian	iranian	ADJ
bam-12937	8	47	adults	adult	NOUN
bam-12937	8	48	with	with	ADP
bam-12937	8	49	fh	fh	PROPN
bam-12937	8	50	.	.	PUNCT
bam-12937	9	1	participants	participant	NOUN
bam-12937	9	2	with	with	ADP
bam-12937	9	3	a	a	DET
bam-12937	9	4	documented	document	VERB
bam-12937	9	5	ldl	ldl	NOUN
bam-12937	9	6	-	-	PUNCT
bam-12937	9	7	c	c	NOUN
bam-12937	9	8	>	>	SYM
bam-12937	9	9	190	190	NUM
bam-12937	9	10	mg	mg	PROPN
bam-12937	9	11	/	/	SYM
bam-12937	9	12	dl	dl	PROPN
bam-12937	9	13	on	on	ADP
bam-12937	9	14	existing	exist	VERB
bam-12937	9	15	cholesterol	cholesterol	NOUN
bam-12937	9	16	medications	medication	NOUN
bam-12937	9	17	(	(	PUNCT
bam-12937	9	18	excluding	exclude	VERB
bam-12937	9	19	pcsk9	pcsk9	NOUN
bam-12937	9	20	inhibitors	inhibitor	NOUN
bam-12937	9	21	)	)	PUNCT
bam-12937	9	22	and	and	CCONJ
bam-12937	9	23	a	a	DET
bam-12937	9	24	clinical	clinical	ADJ
bam-12937	9	25	fh	fh	PROPN
bam-12937	9	26	diagnosis	diagnosis	NOUN
bam-12937	9	27	was	be	AUX
bam-12937	9	28	included	include	VERB
bam-12937	9	29	.	.	PUNCT
bam-12937	10	1	after	after	ADP
bam-12937	10	2	baseline	baseline	NOUN
bam-12937	10	3	assessments	assessment	NOUN
bam-12937	10	4	(	(	PUNCT
bam-12937	10	5	medical	medical	ADJ
bam-12937	10	6	history	history	NOUN
bam-12937	10	7	,	,	PUNCT
bam-12937	10	8	demographics	demographic	NOUN
bam-12937	10	9	,	,	PUNCT
bam-12937	10	10	lipid	lipid	NOUN
bam-12937	10	11	profile	profile	NOUN
bam-12937	10	12	)	)	PUNCT
bam-12937	10	13	,	,	PUNCT
bam-12937	10	14	evolocumab	evolocumab	NOUN
bam-12937	10	15	was	be	AUX
bam-12937	10	16	administered	administer	VERB
bam-12937	10	17	subcutaneously	subcutaneously	ADV
bam-12937	10	18	every	every	DET
bam-12937	10	19	two	two	NUM
bam-12937	10	20	weeks	week	NOUN
bam-12937	10	21	for	for	ADP
bam-12937	10	22	one	one	NUM
bam-12937	10	23	year	year	NOUN
bam-12937	10	24	.	.	PUNCT
bam-12937	11	1	follow	follow	VERB
bam-12937	11	2	-	-	PUNCT
bam-12937	11	3	up	up	ADP
bam-12937	11	4	assessments	assessment	NOUN
bam-12937	11	5	at	at	ADP
bam-12937	11	6	year	year	NOUN
bam-12937	11	7	one	one	NUM
bam-12937	11	8	measured	measure	VERB
bam-12937	11	9	changes	change	NOUN
bam-12937	11	10	in	in	ADP
bam-12937	11	11	ldl	ldl	NOUN
bam-12937	11	12	-	-	PUNCT
bam-12937	11	13	c	c	NOUN
bam-12937	11	14	,	,	PUNCT
bam-12937	11	15	high	high	ADJ
bam-12937	11	16	-	-	PUNCT
bam-12937	11	17	density	density	NOUN
bam-12937	11	18	lipoprotein	lipoprotein	ADJ
bam-12937	11	19	cholesterol	cholesterol	NOUN
bam-12937	11	20	(	(	PUNCT
bam-12937	11	21	hdl	hdl	NOUN
bam-12937	11	22	-	-	PUNCT
bam-12937	11	23	c	c	NOUN
bam-12937	11	24	)	)	PUNCT
bam-12937	11	25	,	,	PUNCT
bam-12937	11	26	and	and	CCONJ
bam-12937	11	27	triglycerides	triglyceride	NOUN
bam-12937	11	28	.	.	PUNCT
bam-12937	12	1	the	the	DET
bam-12937	12	2	study	study	NOUN
bam-12937	12	3	enrolled	enrol	VERB
bam-12937	12	4	50	50	NUM
bam-12937	12	5	participants	participant	NOUN
bam-12937	12	6	with	with	ADP
bam-12937	12	7	an	an	DET
bam-12937	12	8	average	average	ADJ
bam-12937	12	9	age	age	NOUN
bam-12937	12	10	of	of	ADP
bam-12937	12	11	55	55	NUM
bam-12937	12	12	years	year	NOUN
bam-12937	12	13	old	old	ADJ
bam-12937	12	14	(	(	PUNCT
bam-12937	12	15	range	range	NOUN
bam-12937	12	16	35	35	NUM
bam-12937	12	17	-	-	SYM
bam-12937	12	18	80	80	NUM
bam-12937	12	19	years	year	NOUN
bam-12937	12	20	)	)	PUNCT
bam-12937	12	21	.	.	PUNCT
bam-12937	13	1	treatment	treatment	NOUN
bam-12937	13	2	with	with	ADP
bam-12937	13	3	evolocumab	evolocumab	NOUN
bam-12937	13	4	led	lead	VERB
bam-12937	13	5	to	to	ADP
bam-12937	13	6	significant	significant	ADJ
bam-12937	13	7	improvements	improvement	NOUN
bam-12937	13	8	in	in	ADP
bam-12937	13	9	lipid	lipid	ADJ
bam-12937	13	10	profiles	profile	NOUN
bam-12937	13	11	at	at	ADV
bam-12937	13	12	all	all	ADV
bam-12937	13	13	follow	follow	VERB
bam-12937	13	14	-	-	PUNCT
bam-12937	13	15	up	up	ADP
bam-12937	13	16	points	point	NOUN
bam-12937	13	17	compared	compare	VERB
bam-12937	13	18	to	to	PART
bam-12937	13	19	baseline	baseline	VERB
bam-12937	13	20	.	.	PUNCT
bam-12937	14	1	on	on	ADP
bam-12937	14	2	average	average	ADJ
bam-12937	14	3	,	,	PUNCT
bam-12937	14	4	ldl	ldl	NOUN
bam-12937	14	5	-	-	PUNCT
bam-12937	14	6	c	c	NOUN
bam-12937	14	7	levels	level	NOUN
bam-12937	14	8	decreased	decrease	VERB
bam-12937	14	9	by	by	ADP
bam-12937	14	10	105.24	105.24	NUM
bam-12937	14	11	mg	mg	PROPN
bam-12937	14	12	/	/	SYM
bam-12937	14	13	dl	dl	PROPN
bam-12937	14	14	,	,	PUNCT
bam-12937	14	15	triglycerides	triglyceride	NOUN
bam-12937	14	16	decreased	decrease	VERB
bam-12937	14	17	by	by	ADP
bam-12937	14	18	59.20	59.20	NUM
bam-12937	14	19	mg	mg	PROPN
bam-12937	14	20	/	/	SYM
bam-12937	14	21	dl	dl	PROPN
bam-12937	14	22	,	,	PUNCT
bam-12937	14	23	and	and	CCONJ
bam-12937	14	24	hdl	hdl	PROPN
bam-12937	14	25	-	-	PUNCT
bam-12937	14	26	c	c	PROPN
bam-12937	14	27	levels	level	NOUN
bam-12937	14	28	increased	increase	VERB
bam-12937	14	29	by	by	ADP
bam-12937	14	30	a	a	DET
bam-12937	14	31	modest	modest	ADJ
bam-12937	14	32	but	but	CCONJ
bam-12937	14	33	significant	significant	ADJ
bam-12937	14	34	4.5	4.5	NUM
bam-12937	14	35	mg	mg	PROPN
bam-12937	14	36	/	/	SYM
bam-12937	14	37	dl	dl	PROPN
bam-12937	14	38	after	after	ADP
bam-12937	14	39	one	one	NUM
bam-12937	14	40	year(p<0.001	year(p<0.001	NOUN
bam-12937	14	41	)	)	PUNCT
bam-12937	14	42	.	.	PUNCT
bam-12937	15	1	subgroup	subgroup	NOUN
bam-12937	15	2	analysis	analysis	NOUN
bam-12937	15	3	revealed	reveal	VERB
bam-12937	15	4	no	no	DET
bam-12937	15	5	statistically	statistically	ADV
bam-12937	15	6	significant	significant	ADJ
bam-12937	15	7	interactions	interaction	NOUN
bam-12937	15	8	between	between	ADP
bam-12937	15	9	baseline	baseline	ADJ
bam-12937	15	10	demographics	demographic	NOUN
bam-12937	15	11	(	(	PUNCT
bam-12937	15	12	age	age	NOUN
bam-12937	15	13	,	,	PUNCT
bam-12937	15	14	sex	sex	NOUN
bam-12937	15	15	,	,	PUNCT
bam-12937	15	16	bmi	bmi	NOUN
bam-12937	15	17	)	)	PUNCT
bam-12937	15	18	or	or	CCONJ
bam-12937	15	19	lifestyle	lifestyle	NOUN
bam-12937	15	20	habits	habit	NOUN
bam-12937	15	21	(	(	PUNCT
bam-12937	15	22	smoking	smoking	NOUN
bam-12937	15	23	,	,	PUNCT
bam-12937	15	24	alcohol	alcohol	NOUN
bam-12937	15	25	)	)	PUNCT
bam-12937	15	26	and	and	CCONJ
bam-12937	15	27	changes	change	NOUN
bam-12937	15	28	in	in	ADP
bam-12937	15	29	lipid	lipid	ADJ
bam-12937	15	30	levels(p>0.05	levels(p>0.05	NOUN
bam-12937	15	31	)	)	PUNCT
bam-12937	15	32	.	.	PUNCT
bam-12937	16	1	however	however	ADV
bam-12937	16	2	,	,	PUNCT
bam-12937	16	3	a	a	DET
bam-12937	16	4	significant	significant	ADJ
bam-12937	16	5	interaction	interaction	NOUN
bam-12937	16	6	emerged	emerge	VERB
bam-12937	16	7	between	between	ADP
bam-12937	16	8	baseline	baseline	NOUN
bam-12937	16	9	lipid	lipid	NOUN
bam-12937	16	10	levels	level	NOUN
bam-12937	16	11	and	and	CCONJ
bam-12937	16	12	their	their	PRON
bam-12937	16	13	corresponding	correspond	VERB
bam-12937	16	14	reductions	reduction	NOUN
bam-12937	16	15	,	,	PUNCT
bam-12937	16	16	suggesting	suggest	VERB
bam-12937	16	17	greater	great	ADJ
bam-12937	16	18	improvement	improvement	NOUN
bam-12937	16	19	in	in	ADP
bam-12937	16	20	patients	patient	NOUN
bam-12937	16	21	with	with	ADP
bam-12937	16	22	higher	high	ADJ
bam-12937	16	23	baseline	baseline	ADJ
bam-12937	16	24	values(p<0.05	values(p<0.05	NOUN
bam-12937	16	25	)	)	PUNCT
bam-12937	16	26	.	.	PUNCT
bam-12937	17	1	it	it	PRON
bam-12937	17	2	is	be	AUX
bam-12937	17	3	noteworthy	noteworthy	ADJ
bam-12937	17	4	that	that	SCONJ
bam-12937	17	5	no	no	DET
bam-12937	17	6	new	new	ADJ
bam-12937	17	7	cardiovascular	cardiovascular	ADJ
bam-12937	17	8	events	event	NOUN
bam-12937	17	9	were	be	AUX
bam-12937	17	10	reported	report	VERB
bam-12937	17	11	during	during	ADP
bam-12937	17	12	the	the	DET
bam-12937	17	13	study	study	NOUN
bam-12937	17	14	period	period	NOUN
bam-12937	17	15	.	.	PUNCT
bam-12937	18	1	this	this	DET
bam-12937	18	2	study	study	NOUN
bam-12937	18	3	demonstrates	demonstrate	VERB
bam-12937	18	4	the	the	DET
bam-12937	18	5	effectiveness	effectiveness	NOUN
bam-12937	18	6	of	of	ADP
bam-12937	18	7	evolocumab	evolocumab	NOUN
bam-12937	18	8	in	in	ADP
bam-12937	18	9	improving	improve	VERB
bam-12937	18	10	lipid	lipid	ADJ
bam-12937	18	11	profiles	profile	NOUN
bam-12937	18	12	in	in	ADP
bam-12937	18	13	iranian	iranian	ADJ
bam-12937	18	14	patients	patient	NOUN
bam-12937	18	15	with	with	ADP
bam-12937	18	16	fh	fh	PROPN
bam-12937	18	17	.	.	PUNCT
bam-12937	19	1	the	the	DET
bam-12937	19	2	observed	observe	VERB
bam-12937	19	3	reductions	reduction	NOUN
bam-12937	19	4	in	in	ADP
bam-12937	19	5	ldl	ldl	NOUN
bam-12937	19	6	-	-	PUNCT
bam-12937	19	7	c	c	PROPN
bam-12937	19	8	and	and	CCONJ
bam-12937	19	9	triglycerides	triglyceride	NOUN
bam-12937	19	10	,	,	PUNCT
bam-12937	19	11	along	along	ADP
bam-12937	19	12	with	with	ADP
bam-12937	19	13	a	a	DET
bam-12937	19	14	modest	modest	ADJ
bam-12937	19	15	increase	increase	NOUN
bam-12937	19	16	in	in	ADP
bam-12937	19	17	hdl	hdl	PROPN
bam-12937	19	18	-	-	PUNCT
bam-12937	19	19	c	c	PROPN
bam-12937	19	20	,	,	PUNCT
bam-12937	19	21	suggest	suggest	VERB
bam-12937	19	22	potential	potential	ADJ
bam-12937	19	23	benefits	benefit	NOUN
bam-12937	19	24	for	for	ADP
bam-12937	19	25	cardiovascular	cardiovascular	ADJ
bam-12937	19	26	risk	risk	NOUN
bam-12937	19	27	reduction	reduction	NOUN
bam-12937	19	28	.	.	PUNCT
bam-12937	20	1	the	the	DET
bam-12937	20	2	absence	absence	NOUN
bam-12937	20	3	of	of	ADP
bam-12937	20	4	new	new	ADJ
bam-12937	20	5	cardiovascular	cardiovascular	ADJ
bam-12937	20	6	events	event	NOUN
bam-12937	20	7	during	during	ADP
bam-12937	20	8	the	the	DET
bam-12937	20	9	study	study	NOUN
bam-12937	20	10	is	be	AUX
bam-12937	20	11	encouraging	encouraging	ADJ
bam-12937	20	12	,	,	PUNCT
bam-12937	20	13	but	but	CCONJ
bam-12937	20	14	further	further	ADJ
bam-12937	20	15	research	research	NOUN
bam-12937	20	16	with	with	ADP
bam-12937	20	17	larger	large	ADJ
bam-12937	20	18	and	and	CCONJ
bam-12937	20	19	longer	long	ADJ
bam-12937	20	20	-	-	PUNCT
bam-12937	20	21	term	term	NOUN
bam-12937	20	22	follow	follow	NOUN
bam-12937	20	23	-	-	PUNCT
bam-12937	20	24	up	up	NOUN
bam-12937	20	25	is	be	AUX
bam-12937	20	26	needed	need	VERB
bam-12937	20	27	to	to	PART
bam-12937	20	28	confirm	confirm	VERB
bam-12937	20	29	these	these	DET
bam-12937	20	30	findings	finding	NOUN
bam-12937	20	31	and	and	CCONJ
bam-12937	20	32	assess	assess	VERB
bam-12937	20	33	the	the	DET
bam-12937	20	34	long	long	ADJ
bam-12937	20	35	-	-	PUNCT
bam-12937	20	36	term	term	NOUN
bam-12937	20	37	safety	safety	NOUN
bam-12937	20	38	and	and	CCONJ
bam-12937	20	39	impact	impact	NOUN
bam-12937	20	40	on	on	ADP
bam-12937	20	41	quality	quality	NOUN
bam-12937	20	42	of	of	ADP
bam-12937	20	43	life	life	NOUN
bam-12937	20	44	.	.	PUNCT
bam-12937	21	1	key	key	ADJ
bam-12937	21	2	words	word	NOUN
bam-12937	21	3	:	:	PUNCT
bam-12937	21	4	dyslipidemia	dyslipidemia	NOUN
bam-12937	21	5	;	;	PUNCT
bam-12937	21	6	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	21	7	;	;	PUNCT
bam-12937	21	8	pcsk9	pcsk9	NOUN
bam-12937	21	9	inhibitors	inhibitor	NOUN
bam-12937	21	10	;	;	PUNCT
bam-12937	21	11	lipid	lipid	NOUN
bam-12937	21	12	profile	profile	NOUN
bam-12937	21	13	;	;	PUNCT
bam-12937	21	14	cardiovascular	cardiovascular	ADJ
bam-12937	21	15	disease	disease	NOUN
bam-12937	21	16	.	.	PUNCT
bam-12937	22	1	eur	eur	PROPN
bam-12937	22	2	j	j	PROPN
bam-12937	22	3	transl	transl	PROPN
bam-12937	22	4	myol	myol	NOUN
bam-12937	22	5	34	34	NUM
bam-12937	22	6	(	(	PUNCT
bam-12937	22	7	3	3	NUM
bam-12937	22	8	)	)	PUNCT
bam-12937	22	9	12937	12937	NUM
bam-12937	22	10	,	,	PUNCT
bam-12937	22	11	2024	2024	NUM
bam-12937	22	12	doi	doi	NOUN
bam-12937	22	13	:	:	PUNCT
bam-12937	22	14	10.4081	10.4081	NUM
bam-12937	22	15	/	/	SYM
bam-12937	22	16	ejtm.2024.12937	ejtm.2024.12937	NOUN
bam-12937	22	17	the	the	DET
bam-12937	22	18	therapeutic	therapeutic	ADJ
bam-12937	22	19	effect	effect	NOUN
bam-12937	22	20	of	of	ADP
bam-12937	22	21	pcsk9	pcsk9	NOUN
bam-12937	22	22	inhibitors	inhibitor	NOUN
bam-12937	22	23	on	on	ADP
bam-12937	22	24	dyslipidemia	dyslipidemia	NOUN
bam-12937	22	25	:	:	PUNCT
bam-12937	22	26	one	one	NUM
bam-12937	22	27	-	-	PUNCT
bam-12937	22	28	year	year	NOUN
bam-12937	22	29	follow	follow	NOUN
bam-12937	22	30	up	up	ADP
bam-12937	22	31	maryam	maryam	PROPN
bam-12937	22	32	moshkani	moshkani	PROPN
bam-12937	22	33	farahani,1	farahani,1	PROPN
bam-12937	22	34	alireza	alireza	PROPN
bam-12937	22	35	nasiri,1	nasiri,1	VERB
bam-12937	22	36	mahdi	mahdi	PROPN
bam-12937	22	37	salari,2	salari,2	PROPN
bam-12937	23	1	ali	ali	PROPN
bam-12937	23	2	shamsedini1	shamsedini1	PROPN
bam-12937	23	3	1atherosclerosis	1atherosclerosis	NUM
bam-12937	23	4	research	research	NOUN
bam-12937	23	5	center	center	NOUN
bam-12937	23	6	,	,	PUNCT
bam-12937	23	7	baqiayatallah	baqiayatallah	PROPN
bam-12937	23	8	university	university	PROPN
bam-12937	23	9	of	of	ADP
bam-12937	23	10	medical	medical	ADJ
bam-12937	23	11	sciences	sciences	PROPN
bam-12937	23	12	,	,	PUNCT
bam-12937	23	13	tehran	tehran	PROPN
bam-12937	23	14	,	,	PUNCT
bam-12937	23	15	iran	iran	PROPN
bam-12937	23	16	;	;	PUNCT
bam-12937	23	17	2shafa	2shafa	NUM
bam-12937	23	18	cardiovascular	cardiovascular	ADJ
bam-12937	23	19	medical	medical	ADJ
bam-12937	23	20	and	and	CCONJ
bam-12937	23	21	research	research	NOUN
bam-12937	23	22	center	center	NOUN
bam-12937	23	23	,	,	PUNCT
bam-12937	23	24	kerman	kerman	PROPN
bam-12937	23	25	university	university	PROPN
bam-12937	23	26	of	of	ADP
bam-12937	23	27	medical	medical	ADJ
bam-12937	23	28	sciences	sciences	PROPN
bam-12937	23	29	,	,	PUNCT
bam-12937	23	30	kemran	kemran	NOUN
bam-12937	23	31	,	,	PUNCT
bam-12937	23	32	iran	iran	PROPN
bam-12937	23	33	.	.	PUNCT
bam-12937	24	1	this	this	DET
bam-12937	24	2	article	article	NOUN
bam-12937	24	3	is	be	AUX
bam-12937	24	4	distributed	distribute	VERB
bam-12937	24	5	under	under	ADP
bam-12937	24	6	the	the	DET
bam-12937	24	7	terms	term	NOUN
bam-12937	24	8	of	of	ADP
bam-12937	24	9	the	the	DET
bam-12937	24	10	creative	creative	ADJ
bam-12937	24	11	commons	common	NOUN
bam-12937	24	12	attribution	attribution	NOUN
bam-12937	24	13	noncommercial	noncommercial	ADJ
bam-12937	24	14	license	license	NOUN
bam-12937	24	15	(	(	PUNCT
bam-12937	24	16	cc	cc	NOUN
bam-12937	24	17	by	by	ADP
bam-12937	24	18	-	-	PUNCT
bam-12937	24	19	nc	nc	PROPN
bam-12937	24	20	4.0	4.0	NUM
bam-12937	24	21	)	)	PUNCT
bam-12937	24	22	which	which	PRON
bam-12937	24	23	permits	permit	VERB
bam-12937	24	24	any	any	DET
bam-12937	24	25	noncommercial	noncommercial	ADJ
bam-12937	24	26	use	use	NOUN
bam-12937	24	27	,	,	PUNCT
bam-12937	24	28	distribution	distribution	NOUN
bam-12937	24	29	,	,	PUNCT
bam-12937	24	30	and	and	CCONJ
bam-12937	24	31	reproduction	reproduction	NOUN
bam-12937	24	32	in	in	ADP
bam-12937	24	33	any	any	DET
bam-12937	24	34	medium	medium	NOUN
bam-12937	24	35	,	,	PUNCT
bam-12937	24	36	provided	provide	VERB
bam-12937	24	37	the	the	DET
bam-12937	24	38	original	original	ADJ
bam-12937	24	39	author(s	author(s	NOUN
bam-12937	24	40	)	)	PUNCT
bam-12937	24	41	and	and	CCONJ
bam-12937	24	42	source	source	NOUN
bam-12937	24	43	are	be	AUX
bam-12937	24	44	credited	credit	VERB
bam-12937	24	45	.	.	PUNCT
bam-12937	25	1	113	113	NUM
bam-12937	25	2	non	non	ADJ
bam-12937	25	3	-co	-co	PROPN
bam-12937	25	4	mmerc	mmerc	PROPN
bam-12937	25	5	ial	ial	PROPN
bam-12937	25	6	us	us	PROPN
bam-12937	25	7	e	e	NOUN
bam-12937	25	8	o	o	X
bam-12937	25	9	nly	nly	ADV
bam-12937	25	10	the	the	DET
bam-12937	25	11	therapeutic	therapeutic	ADJ
bam-12937	25	12	effect	effect	NOUN
bam-12937	25	13	of	of	ADP
bam-12937	25	14	pcsk9	pcsk9	NOUN
bam-12937	25	15	inhibitors	inhibitor	NOUN
bam-12937	25	16	on	on	ADP
bam-12937	25	17	dyslipidemia	dyslipidemia	NOUN
bam-12937	25	18	:	:	PUNCT
bam-12937	25	19	one	one	NUM
bam-12937	25	20	-	-	PUNCT
bam-12937	25	21	year	year	NOUN
bam-12937	25	22	follow	follow	VERB
bam-12937	25	23	up	up	ADP
bam-12937	25	24	eur	eur	PROPN
bam-12937	25	25	j	j	PROPN
bam-12937	25	26	transl	transl	PROPN
bam-12937	25	27	myol	myol	NOUN
bam-12937	25	28	34	34	NUM
bam-12937	25	29	(	(	PUNCT
bam-12937	25	30	3	3	NUM
bam-12937	25	31	)	)	PUNCT
bam-12937	25	32	12937	12937	NUM
bam-12937	25	33	,	,	PUNCT
bam-12937	25	34	2024	2024	NUM
bam-12937	25	35	doi	doi	NOUN
bam-12937	25	36	:	:	PUNCT
bam-12937	25	37	10.4081	10.4081	NUM
bam-12937	25	38	/	/	SYM
bam-12937	25	39	ejtm.2024.12937	ejtm.2024.12937	NOUN
bam-12937	25	40	receptors	receptor	NOUN
bam-12937	25	41	triggers	trigger	VERB
bam-12937	25	42	their	their	PRON
bam-12937	25	43	degradation	degradation	NOUN
bam-12937	25	44	,	,	PUNCT
bam-12937	25	45	reducing	reduce	VERB
bam-12937	25	46	ldl	ldl	NOUN
bam-12937	25	47	-	-	PUNCT
bam-12937	25	48	c	c	NOUN
bam-12937	25	49	clearance	clearance	NOUN
bam-12937	25	50	from	from	ADP
bam-12937	25	51	the	the	DET
bam-12937	25	52	bloodstream.2,3	bloodstream.2,3	PROPN
bam-12937	25	53	not	not	PART
bam-12937	25	54	all	all	DET
bam-12937	25	55	cases	case	NOUN
bam-12937	25	56	will	will	AUX
bam-12937	25	57	have	have	VERB
bam-12937	25	58	a	a	DET
bam-12937	25	59	clear	clear	ADJ
bam-12937	25	60	genetic	genetic	ADJ
bam-12937	25	61	cause	cause	NOUN
bam-12937	25	62	,	,	PUNCT
bam-12937	25	63	and	and	CCONJ
bam-12937	25	64	some	some	PRON
bam-12937	25	65	may	may	AUX
bam-12937	25	66	involve	involve	VERB
bam-12937	25	67	a	a	DET
bam-12937	25	68	combination	combination	NOUN
bam-12937	25	69	of	of	ADP
bam-12937	25	70	factors.4,6	factors.4,6	NOUN
bam-12937	25	71	early	early	ADJ
bam-12937	25	72	diagnosis	diagnosis	NOUN
bam-12937	25	73	and	and	CCONJ
bam-12937	25	74	treatment	treatment	NOUN
bam-12937	25	75	of	of	ADP
bam-12937	25	76	fh	fh	PROPN
bam-12937	25	77	are	be	AUX
bam-12937	25	78	crucial	crucial	ADJ
bam-12937	25	79	to	to	PART
bam-12937	25	80	significantly	significantly	ADV
bam-12937	25	81	reduce	reduce	VERB
bam-12937	25	82	the	the	DET
bam-12937	25	83	risk	risk	NOUN
bam-12937	25	84	of	of	ADP
bam-12937	25	85	developing	develop	VERB
bam-12937	25	86	chd	chd	NOUN
bam-12937	25	87	and	and	CCONJ
bam-12937	25	88	other	other	ADJ
bam-12937	25	89	cardiovascular	cardiovascular	ADJ
bam-12937	25	90	problems	problem	NOUN
bam-12937	25	91	.	.	PUNCT
bam-12937	26	1	despite	despite	SCONJ
bam-12937	26	2	the	the	DET
bam-12937	26	3	well	well	ADV
bam-12937	26	4	-	-	PUNCT
bam-12937	26	5	established	establish	VERB
bam-12937	26	6	benefits	benefit	NOUN
bam-12937	26	7	,	,	PUNCT
bam-12937	26	8	screening	screen	VERB
bam-12937	26	9	rates	rate	NOUN
bam-12937	26	10	for	for	ADP
bam-12937	26	11	fh	fh	PROPN
bam-12937	26	12	remain	remain	VERB
bam-12937	26	13	low	low	ADJ
bam-12937	26	14	,	,	PUNCT
bam-12937	26	15	leading	lead	VERB
bam-12937	26	16	to	to	ADP
bam-12937	26	17	suboptimal	suboptimal	ADJ
bam-12937	26	18	management	management	NOUN
bam-12937	26	19	in	in	ADP
bam-12937	26	20	this	this	DET
bam-12937	26	21	patient	patient	ADJ
bam-12937	26	22	population	population	NOUN
bam-12937	26	23	.	.	PUNCT
bam-12937	27	1	due	due	ADP
bam-12937	27	2	to	to	ADP
bam-12937	27	3	the	the	DET
bam-12937	27	4	high	high	ADJ
bam-12937	27	5	prevalence	prevalence	NOUN
bam-12937	27	6	of	of	ADP
bam-12937	27	7	fh	fh	PROPN
bam-12937	27	8	,	,	PUNCT
bam-12937	27	9	widespread	widespread	ADJ
bam-12937	27	10	screening	screening	NOUN
bam-12937	27	11	is	be	AUX
bam-12937	27	12	essential	essential	ADJ
bam-12937	27	13	to	to	PART
bam-12937	27	14	identify	identify	VERB
bam-12937	27	15	affected	affect	VERB
bam-12937	27	16	individuals	individual	NOUN
bam-12937	27	17	and	and	CCONJ
bam-12937	27	18	their	their	PRON
bam-12937	27	19	relatives	relative	NOUN
bam-12937	27	20	.	.	PUNCT
bam-12937	28	1	this	this	PRON
bam-12937	28	2	allows	allow	VERB
bam-12937	28	3	for	for	SCONJ
bam-12937	28	4	appropriate	appropriate	ADJ
bam-12937	28	5	genetic	genetic	ADJ
bam-12937	28	6	evaluation	evaluation	NOUN
bam-12937	28	7	and	and	CCONJ
bam-12937	28	8	management	management	NOUN
bam-12937	28	9	to	to	PART
bam-12937	28	10	be	be	AUX
bam-12937	28	11	initiated	initiate	VERB
bam-12937	28	12	promptly	promptly	ADV
bam-12937	28	13	.	.	PUNCT
bam-12937	29	1	screening	screen	VERB
bam-12937	29	2	can	can	AUX
bam-12937	29	3	be	be	AUX
bam-12937	29	4	done	do	VERB
bam-12937	29	5	simply	simply	ADV
bam-12937	29	6	by	by	ADP
bam-12937	29	7	measuring	measure	VERB
bam-12937	29	8	ldl	ldl	NOUN
bam-12937	29	9	-	-	PUNCT
bam-12937	29	10	c	c	NOUN
bam-12937	29	11	levels	level	NOUN
bam-12937	29	12	,	,	PUNCT
bam-12937	29	13	making	make	VERB
bam-12937	29	14	it	it	PRON
bam-12937	29	15	a	a	DET
bam-12937	29	16	cost	cost	NOUN
bam-12937	29	17	-	-	PUNCT
bam-12937	29	18	effective	effective	ADJ
bam-12937	29	19	approach	approach	NOUN
bam-12937	29	20	.	.	PUNCT
bam-12937	30	1	effective	effective	ADJ
bam-12937	30	2	fh	fh	PROPN
bam-12937	30	3	screening	screen	VERB
bam-12937	30	4	programs	program	NOUN
bam-12937	30	5	require	require	VERB
bam-12937	30	6	healthcare	healthcare	PROPN
bam-12937	30	7	providers	provider	NOUN
bam-12937	30	8	’	'	PUNCT
bam-12937	30	9	familiarity	familiarity	NOUN
bam-12937	30	10	with	with	ADP
bam-12937	30	11	fh	fh	PROPN
bam-12937	30	12	diagnostic	diagnostic	ADJ
bam-12937	30	13	criteria	criterion	NOUN
bam-12937	30	14	,	,	PUNCT
bam-12937	30	15	particularly	particularly	ADV
bam-12937	30	16	the	the	DET
bam-12937	30	17	widely	widely	ADV
bam-12937	30	18	accepted	accept	VERB
bam-12937	30	19	simon	simon	PROPN
bam-12937	30	20	broome	broome	PROPN
bam-12937	30	21	criteria	criteria	PROPN
bam-12937	30	22	.	.	PUNCT
bam-12937	31	1	these	these	DET
bam-12937	31	2	criteria	criterion	NOUN
bam-12937	31	3	consider	consider	VERB
bam-12937	31	4	factors	factor	NOUN
bam-12937	31	5	like	like	ADP
bam-12937	31	6	ldl	ldl	NOUN
bam-12937	31	7	-	-	PUNCT
bam-12937	31	8	c	c	NOUN
bam-12937	31	9	levels	level	NOUN
bam-12937	31	10	,	,	PUNCT
bam-12937	31	11	family	family	NOUN
bam-12937	31	12	history	history	NOUN
bam-12937	31	13	of	of	ADP
bam-12937	31	14	premature	premature	ADJ
bam-12937	31	15	coronary	coronary	ADJ
bam-12937	31	16	heart	heart	NOUN
bam-12937	31	17	disease	disease	NOUN
bam-12937	31	18	,	,	PUNCT
bam-12937	31	19	and	and	CCONJ
bam-12937	31	20	physical	physical	ADJ
bam-12937	31	21	signs	sign	NOUN
bam-12937	31	22	like	like	ADP
bam-12937	31	23	tendon	tendon	PROPN
bam-12937	31	24	xanthomas	xanthomas	PROPN
bam-12937	31	25	and	and	CCONJ
bam-12937	31	26	corneal	corneal	VERB
bam-12937	31	27	arcus.7	arcus.7	VERB
bam-12937	31	28	genetic	genetic	ADJ
bam-12937	31	29	testing	testing	NOUN
bam-12937	31	30	complements	complement	NOUN
bam-12937	31	31	this	this	DET
bam-12937	31	32	approach	approach	NOUN
bam-12937	31	33	by	by	ADP
bam-12937	31	34	enabling	enable	VERB
bam-12937	31	35	the	the	DET
bam-12937	31	36	identification	identification	NOUN
bam-12937	31	37	of	of	ADP
bam-12937	31	38	disease	disease	NOUN
bam-12937	31	39	-	-	PUNCT
bam-12937	31	40	causing	cause	VERB
bam-12937	31	41	mutations	mutation	NOUN
bam-12937	31	42	in	in	ADP
bam-12937	31	43	the	the	DET
bam-12937	31	44	ldl	ldl	NOUN
bam-12937	31	45	receptor	receptor	NOUN
bam-12937	31	46	,	,	PUNCT
bam-12937	31	47	apob	apob	PROPN
bam-12937	31	48	,	,	PUNCT
bam-12937	31	49	and	and	CCONJ
bam-12937	31	50	pcsk9	pcsk9	NOUN
bam-12937	31	51	genes	gene	NOUN
bam-12937	31	52	.	.	PUNCT
bam-12937	32	1	this	this	DET
bam-12937	32	2	method	method	NOUN
bam-12937	32	3	is	be	AUX
bam-12937	32	4	considered	consider	VERB
bam-12937	32	5	the	the	DET
bam-12937	32	6	gold	gold	ADJ
bam-12937	32	7	standard	standard	NOUN
bam-12937	32	8	for	for	ADP
bam-12937	32	9	definitive	definitive	ADJ
bam-12937	32	10	fh	fh	PROPN
bam-12937	32	11	diagnosis	diagnosis	NOUN
bam-12937	32	12	and	and	CCONJ
bam-12937	32	13	is	be	AUX
bam-12937	32	14	particularly	particularly	ADV
bam-12937	32	15	useful	useful	ADJ
bam-12937	32	16	when	when	SCONJ
bam-12937	32	17	clinical	clinical	ADJ
bam-12937	32	18	criteria	criterion	NOUN
bam-12937	32	19	are	be	AUX
bam-12937	32	20	inconclusive	inconclusive	ADJ
bam-12937	32	21	or	or	CCONJ
bam-12937	32	22	when	when	SCONJ
bam-12937	32	23	there	there	PRON
bam-12937	32	24	is	be	VERB
bam-12937	32	25	a	a	DET
bam-12937	32	26	strong	strong	ADJ
bam-12937	32	27	family	family	NOUN
bam-12937	32	28	history	history	NOUN
bam-12937	32	29	of	of	ADP
bam-12937	32	30	fh.8,12,13	fh.8,12,13	NOUN
bam-12937	32	31	pcsk9	pcsk9	PROPN
bam-12937	32	32	inhibitors	inhibitor	NOUN
bam-12937	32	33	,	,	PUNCT
bam-12937	32	34	such	such	ADJ
bam-12937	32	35	as	as	ADP
bam-12937	32	36	evolocumab	evolocumab	NOUN
bam-12937	32	37	and	and	CCONJ
bam-12937	32	38	alirocumab	alirocumab	NOUN
bam-12937	32	39	,	,	PUNCT
bam-12937	32	40	are	be	AUX
bam-12937	32	41	monoclonal	monoclonal	NOUN
bam-12937	32	42	antibodies	antibody	NOUN
bam-12937	32	43	that	that	PRON
bam-12937	32	44	lower	low	ADJ
bam-12937	32	45	ldl	ldl	NOUN
bam-12937	32	46	-	-	PUNCT
bam-12937	32	47	c	c	NOUN
bam-12937	32	48	levels	level	NOUN
bam-12937	32	49	by	by	ADP
bam-12937	32	50	blocking	block	VERB
bam-12937	32	51	the	the	DET
bam-12937	32	52	pcsk9	pcsk9	NOUN
bam-12937	32	53	protein	protein	NOUN
bam-12937	32	54	.	.	PUNCT
bam-12937	33	1	pcsk9	pcsk9	PROPN
bam-12937	33	2	normally	normally	ADV
bam-12937	33	3	binds	bind	VERB
bam-12937	33	4	to	to	PART
bam-12937	33	5	ldl	ldl	VERB
bam-12937	33	6	receptors	receptor	NOUN
bam-12937	33	7	on	on	ADP
bam-12937	33	8	liver	liver	NOUN
bam-12937	33	9	cells	cell	NOUN
bam-12937	33	10	,	,	PUNCT
bam-12937	33	11	promoting	promote	VERB
bam-12937	33	12	their	their	PRON
bam-12937	33	13	degradation	degradation	NOUN
bam-12937	33	14	and	and	CCONJ
bam-12937	33	15	hindering	hinder	VERB
bam-12937	33	16	ldl	ldl	PROPN
bam-12937	33	17	-	-	PUNCT
bam-12937	33	18	c	c	NOUN
bam-12937	33	19	clearance	clearance	NOUN
bam-12937	33	20	from	from	ADP
bam-12937	33	21	the	the	DET
bam-12937	33	22	bloodstream	bloodstream	NOUN
bam-12937	33	23	.	.	PUNCT
bam-12937	34	1	blocking	block	VERB
bam-12937	34	2	this	this	DET
bam-12937	34	3	interaction	interaction	NOUN
bam-12937	34	4	leads	lead	VERB
bam-12937	34	5	to	to	ADP
bam-12937	34	6	an	an	DET
bam-12937	34	7	increase	increase	NOUN
bam-12937	34	8	in	in	ADP
bam-12937	34	9	functional	functional	ADJ
bam-12937	34	10	ldlrs	ldlrs	NOUN
bam-12937	34	11	on	on	ADP
bam-12937	34	12	the	the	DET
bam-12937	34	13	liver	liver	NOUN
bam-12937	34	14	surface	surface	NOUN
bam-12937	34	15	,	,	PUNCT
bam-12937	34	16	enhancing	enhance	VERB
bam-12937	34	17	ldl	ldl	NOUN
bam-12937	34	18	-	-	PUNCT
bam-12937	34	19	c	c	NOUN
bam-12937	34	20	uptake	uptake	NOUN
bam-12937	34	21	and	and	CCONJ
bam-12937	34	22	removal	removal	NOUN
bam-12937	34	23	,	,	PUNCT
bam-12937	34	24	ultimately	ultimately	ADV
bam-12937	34	25	resulting	result	VERB
bam-12937	34	26	in	in	ADP
bam-12937	34	27	lower	low	ADJ
bam-12937	34	28	ldl	ldl	NOUN
bam-12937	34	29	-	-	PUNCT
bam-12937	34	30	c	c	NOUN
bam-12937	34	31	levels.9,10	levels.9,10	PROPN
bam-12937	34	32	approved	approve	VERB
bam-12937	34	33	for	for	ADP
bam-12937	34	34	fh	fh	PROPN
bam-12937	34	35	management	management	NOUN
bam-12937	34	36	in	in	ADP
bam-12937	34	37	various	various	ADJ
bam-12937	34	38	countries	country	NOUN
bam-12937	34	39	,	,	PUNCT
bam-12937	34	40	including	include	VERB
bam-12937	34	41	the	the	DET
bam-12937	34	42	united	united	ADJ
bam-12937	34	43	states,11	states,11	NOUN
bam-12937	34	44	pcsk9	pcsk9	NOUN
bam-12937	34	45	inhibitors	inhibitor	NOUN
bam-12937	34	46	offer	offer	VERB
bam-12937	34	47	a	a	DET
bam-12937	34	48	valuable	valuable	ADJ
bam-12937	34	49	therapeutic	therapeutic	ADJ
bam-12937	34	50	option	option	NOUN
bam-12937	34	51	for	for	ADP
bam-12937	34	52	patients	patient	NOUN
bam-12937	34	53	who	who	PRON
bam-12937	34	54	struggle	struggle	VERB
bam-12937	34	55	to	to	PART
bam-12937	34	56	achieve	achieve	VERB
bam-12937	34	57	optimal	optimal	ADJ
bam-12937	34	58	ldl	ldl	NOUN
bam-12937	34	59	-	-	PUNCT
bam-12937	34	60	c	c	NOUN
bam-12937	34	61	control	control	NOUN
bam-12937	34	62	with	with	ADP
bam-12937	34	63	traditional	traditional	ADJ
bam-12937	34	64	therapies	therapy	NOUN
bam-12937	34	65	.	.	PUNCT
bam-12937	35	1	studies	study	NOUN
bam-12937	35	2	have	have	AUX
bam-12937	35	3	shown	show	VERB
bam-12937	35	4	significant	significant	ADJ
bam-12937	35	5	reductions	reduction	NOUN
bam-12937	35	6	(	(	PUNCT
bam-12937	35	7	50	50	NUM
bam-12937	35	8	-	-	SYM
bam-12937	35	9	60	60	NUM
bam-12937	35	10	%	%	NOUN
bam-12937	35	11	)	)	PUNCT
bam-12937	35	12	in	in	ADP
bam-12937	35	13	ldl	ldl	NOUN
bam-12937	35	14	-	-	PUNCT
bam-12937	35	15	c	c	NOUN
bam-12937	35	16	levels	level	NOUN
bam-12937	35	17	for	for	ADP
bam-12937	35	18	patients	patient	NOUN
bam-12937	35	19	with	with	ADP
bam-12937	35	20	hefh.6,12,13	hefh.6,12,13	NOUN
bam-12937	35	21	however	however	ADV
bam-12937	35	22	,	,	PUNCT
bam-12937	35	23	the	the	DET
bam-12937	35	24	effectiveness	effectiveness	NOUN
bam-12937	35	25	is	be	AUX
bam-12937	35	26	less	less	ADV
bam-12937	35	27	pronounced	pronounced	ADJ
bam-12937	35	28	in	in	ADP
bam-12937	35	29	patients	patient	NOUN
bam-12937	35	30	with	with	ADP
bam-12937	35	31	hofh	hofh	NOUN
bam-12937	35	32	,	,	PUNCT
bam-12937	35	33	especially	especially	ADV
bam-12937	35	34	those	those	PRON
bam-12937	35	35	with	with	ADP
bam-12937	35	36	minimal	minimal	ADJ
bam-12937	35	37	residual	residual	ADJ
bam-12937	35	38	ldlr	ldlr	NOUN
bam-12937	35	39	activity.14	activity.14	ADV
bam-12937	35	40	despite	despite	SCONJ
bam-12937	35	41	promising	promise	VERB
bam-12937	35	42	evidence	evidence	NOUN
bam-12937	35	43	for	for	ADP
bam-12937	35	44	pcsk9	pcsk9	NOUN
bam-12937	35	45	inhibitors	inhibitor	NOUN
bam-12937	35	46	,	,	PUNCT
bam-12937	35	47	data	datum	NOUN
bam-12937	35	48	on	on	ADP
bam-12937	35	49	their	their	PRON
bam-12937	35	50	real	real	ADJ
bam-12937	35	51	-	-	PUNCT
bam-12937	35	52	world	world	NOUN
bam-12937	35	53	use	use	NOUN
bam-12937	35	54	,	,	PUNCT
bam-12937	35	55	particularly	particularly	ADV
bam-12937	35	56	at	at	ADP
bam-12937	35	57	the	the	DET
bam-12937	35	58	national	national	ADJ
bam-12937	35	59	level	level	NOUN
bam-12937	35	60	and	and	CCONJ
bam-12937	35	61	for	for	ADP
bam-12937	35	62	long	long	ADJ
bam-12937	35	63	-	-	PUNCT
bam-12937	35	64	term	term	NOUN
bam-12937	35	65	effects	effect	NOUN
bam-12937	35	66	in	in	ADP
bam-12937	35	67	iranian	iranian	ADJ
bam-12937	35	68	patients	patient	NOUN
bam-12937	35	69	with	with	ADP
bam-12937	35	70	dyslipidemia	dyslipidemia	NOUN
bam-12937	35	71	,	,	PUNCT
bam-12937	35	72	remains	remain	VERB
bam-12937	35	73	limited	limited	ADJ
bam-12937	35	74	.	.	PUNCT
bam-12937	36	1	this	this	DET
bam-12937	36	2	knowledge	knowledge	NOUN
bam-12937	36	3	gap	gap	NOUN
bam-12937	36	4	hinders	hinder	VERB
bam-12937	36	5	understanding	understanding	NOUN
bam-12937	36	6	of	of	ADP
bam-12937	36	7	how	how	SCONJ
bam-12937	36	8	effectively	effectively	ADV
bam-12937	36	9	these	these	DET
bam-12937	36	10	medications	medication	NOUN
bam-12937	36	11	reach	reach	VERB
bam-12937	36	12	high	high	ADJ
bam-12937	36	13	-	-	PUNCT
bam-12937	36	14	risk	risk	NOUN
bam-12937	36	15	patients	patient	NOUN
bam-12937	36	16	and	and	CCONJ
bam-12937	36	17	their	their	PRON
bam-12937	36	18	long	long	ADJ
bam-12937	36	19	-	-	PUNCT
bam-12937	36	20	term	term	NOUN
bam-12937	36	21	impact	impact	NOUN
bam-12937	36	22	in	in	ADP
bam-12937	36	23	countries	country	NOUN
bam-12937	36	24	like	like	ADP
bam-12937	36	25	iran	iran	PROPN
bam-12937	36	26	.	.	PUNCT
bam-12937	37	1	this	this	DET
bam-12937	37	2	study	study	NOUN
bam-12937	37	3	aims	aim	VERB
bam-12937	37	4	to	to	PART
bam-12937	37	5	address	address	VERB
bam-12937	37	6	these	these	DET
bam-12937	37	7	limitations	limitation	NOUN
bam-12937	37	8	by	by	ADP
bam-12937	37	9	investigating	investigate	VERB
bam-12937	37	10	the	the	DET
bam-12937	37	11	one	one	NUM
bam-12937	37	12	-	-	PUNCT
bam-12937	37	13	year	year	NOUN
bam-12937	37	14	effects	effect	NOUN
bam-12937	37	15	of	of	ADP
bam-12937	37	16	pcsk9	pcsk9	NOUN
bam-12937	37	17	inhibitor	inhibitor	NOUN
bam-12937	37	18	therapy	therapy	NOUN
bam-12937	37	19	on	on	ADP
bam-12937	37	20	lipid	lipid	NOUN
bam-12937	37	21	levels	level	NOUN
bam-12937	37	22	,	,	PUNCT
bam-12937	37	23	cardiovascular	cardiovascular	ADJ
bam-12937	37	24	events	event	NOUN
bam-12937	37	25	,	,	PUNCT
bam-12937	37	26	and	and	CCONJ
bam-12937	37	27	quality	quality	NOUN
bam-12937	37	28	of	of	ADP
bam-12937	37	29	life	life	NOUN
bam-12937	37	30	in	in	ADP
bam-12937	37	31	iranian	iranian	ADJ
bam-12937	37	32	patients	patient	NOUN
bam-12937	37	33	with	with	ADP
bam-12937	37	34	fh	fh	PROPN
bam-12937	37	35	.	.	PUNCT
bam-12937	38	1	by	by	ADP
bam-12937	38	2	examining	examine	VERB
bam-12937	38	3	both	both	CCONJ
bam-12937	38	4	the	the	DET
bam-12937	38	5	nationallevel	nationallevel	NOUN
bam-12937	38	6	implications	implication	NOUN
bam-12937	38	7	of	of	ADP
bam-12937	38	8	pcsk9	pcsk9	NOUN
bam-12937	38	9	inhibitor	inhibitor	NOUN
bam-12937	38	10	recommendations	recommendation	NOUN
bam-12937	38	11	and	and	CCONJ
bam-12937	38	12	the	the	DET
bam-12937	38	13	long	long	ADJ
bam-12937	38	14	-	-	PUNCT
bam-12937	38	15	term	term	NOUN
bam-12937	38	16	effects	effect	NOUN
bam-12937	38	17	in	in	ADP
bam-12937	38	18	iranian	iranian	ADJ
bam-12937	38	19	patients	patient	NOUN
bam-12937	38	20	,	,	PUNCT
bam-12937	38	21	this	this	DET
bam-12937	38	22	research	research	NOUN
bam-12937	38	23	has	have	VERB
bam-12937	38	24	the	the	DET
bam-12937	38	25	potential	potential	NOUN
bam-12937	38	26	to	to	PART
bam-12937	38	27	significantly	significantly	ADV
bam-12937	38	28	contribute	contribute	VERB
bam-12937	38	29	to	to	ADP
bam-12937	38	30	improving	improve	VERB
bam-12937	38	31	dyslipidemiamanagement	dyslipidemiamanagement	NOUN
bam-12937	38	32	in	in	ADP
bam-12937	38	33	iran	iran	PROPN
bam-12937	38	34	.	.	PUNCT
bam-12937	39	1	this	this	DET
bam-12937	39	2	comprehensive	comprehensive	ADJ
bam-12937	39	3	approach	approach	NOUN
bam-12937	39	4	can	can	AUX
bam-12937	39	5	provide	provide	VERB
bam-12937	39	6	valuable	valuable	ADJ
bam-12937	39	7	insights	insight	NOUN
bam-12937	39	8	for	for	ADP
bam-12937	39	9	physicians	physician	NOUN
bam-12937	39	10	,	,	PUNCT
bam-12937	39	11	ultimately	ultimately	ADV
bam-12937	39	12	ensuring	ensure	VERB
bam-12937	39	13	these	these	DET
bam-12937	39	14	therapies	therapy	NOUN
bam-12937	39	15	reach	reach	VERB
bam-12937	39	16	those	those	PRON
bam-12937	39	17	who	who	PRON
bam-12937	39	18	can	can	AUX
bam-12937	39	19	benefit	benefit	VERB
bam-12937	39	20	most	most	ADV
bam-12937	39	21	and	and	CCONJ
bam-12937	39	22	improve	improve	VERB
bam-12937	39	23	clinical	clinical	ADJ
bam-12937	39	24	practice	practice	NOUN
bam-12937	39	25	and	and	CCONJ
bam-12937	39	26	patient	patient	ADJ
bam-12937	39	27	care	care	NOUN
bam-12937	39	28	for	for	ADP
bam-12937	39	29	dyslipidemia	dyslipidemia	NOUN
bam-12937	39	30	management	management	NOUN
bam-12937	39	31	in	in	ADP
bam-12937	39	32	iran	iran	PROPN
bam-12937	39	33	.	.	PUNCT
bam-12937	40	1	materials	material	NOUN
bam-12937	40	2	and	and	CCONJ
bam-12937	40	3	methods	method	NOUN
bam-12937	40	4	study	study	NOUN
bam-12937	40	5	design	design	NOUN
bam-12937	40	6	and	and	CCONJ
bam-12937	40	7	participants	participant	NOUN
bam-12937	40	8	this	this	PRON
bam-12937	40	9	was	be	AUX
bam-12937	40	10	a	a	DET
bam-12937	40	11	single	single	ADJ
bam-12937	40	12	-	-	PUNCT
bam-12937	40	13	center	center	NOUN
bam-12937	40	14	,	,	PUNCT
bam-12937	40	15	prospective	prospective	ADJ
bam-12937	40	16	,	,	PUNCT
bam-12937	40	17	one	one	NUM
bam-12937	40	18	-	-	PUNCT
bam-12937	40	19	year	year	NOUN
bam-12937	40	20	follow	follow	NOUN
bam-12937	40	21	-	-	PUNCT
bam-12937	40	22	up	up	ADP
bam-12937	40	23	study	study	NOUN
bam-12937	40	24	evaluating	evaluate	VERB
bam-12937	40	25	the	the	DET
bam-12937	40	26	efficacy	efficacy	NOUN
bam-12937	40	27	of	of	ADP
bam-12937	40	28	evolocumab	evolocumab	NOUN
bam-12937	40	29	in	in	ADP
bam-12937	40	30	lowering	lower	VERB
bam-12937	40	31	ldl	ldl	NOUN
bam-12937	40	32	-	-	PUNCT
bam-12937	40	33	c	c	NOUN
bam-12937	40	34	levels	level	NOUN
bam-12937	40	35	in	in	ADP
bam-12937	40	36	patients	patient	NOUN
bam-12937	40	37	with	with	ADP
bam-12937	40	38	dyslipidemia	dyslipidemia	NOUN
bam-12937	40	39	diagnosed	diagnose	VERB
bam-12937	40	40	with	with	ADP
bam-12937	40	41	fh	fh	PROPN
bam-12937	40	42	.	.	PROPN
bam-12937	41	1	fifty	fifty	NUM
bam-12937	41	2	participants	participant	NOUN
bam-12937	41	3	over	over	ADP
bam-12937	41	4	18	18	NUM
bam-12937	41	5	years	year	NOUN
bam-12937	41	6	of	of	ADP
bam-12937	41	7	age	age	NOUN
bam-12937	41	8	were	be	AUX
bam-12937	41	9	selected	select	VERB
bam-12937	41	10	.	.	PUNCT
bam-12937	42	1	inclusion	inclusion	NOUN
bam-12937	42	2	criteria	criterion	NOUN
bam-12937	42	3	consisted	consist	VERB
bam-12937	42	4	of	of	ADP
bam-12937	42	5	documented	document	VERB
bam-12937	42	6	ldl	ldl	NOUN
bam-12937	42	7	-	-	PUNCT
bam-12937	42	8	c	c	NOUN
bam-12937	42	9	levels	level	NOUN
bam-12937	42	10	exceeding	exceed	VERB
bam-12937	42	11	190	190	NUM
bam-12937	42	12	mg	mg	PROPN
bam-12937	42	13	/	/	SYM
bam-12937	42	14	dl	dl	PROPN
bam-12937	42	15	on	on	ADP
bam-12937	42	16	a	a	DET
bam-12937	42	17	stable	stable	ADJ
bam-12937	42	18	regimen	regiman	NOUN
bam-12937	42	19	of	of	ADP
bam-12937	42	20	cholesterollowering	cholesterollowere	VERB
bam-12937	42	21	medications	medication	NOUN
bam-12937	42	22	(	(	PUNCT
bam-12937	42	23	excluding	exclude	VERB
bam-12937	42	24	pcsk9	pcsk9	NOUN
bam-12937	42	25	inhibitors	inhibitor	NOUN
bam-12937	42	26	)	)	PUNCT
bam-12937	42	27	and	and	CCONJ
bam-12937	42	28	a	a	DET
bam-12937	42	29	clinical	clinical	ADJ
bam-12937	42	30	diagnosis	diagnosis	NOUN
bam-12937	42	31	of	of	ADP
bam-12937	42	32	fh	fh	PROPN
bam-12937	42	33	based	base	VERB
bam-12937	42	34	on	on	ADP
bam-12937	42	35	established	establish	VERB
bam-12937	42	36	criteria	criterion	NOUN
bam-12937	42	37	(	(	PUNCT
bam-12937	42	38	based	base	VERB
bam-12937	42	39	on	on	ADP
bam-12937	42	40	physical	physical	ADJ
bam-12937	42	41	examination	examination	NOUN
bam-12937	42	42	,	,	PUNCT
bam-12937	42	43	previous	previous	ADJ
bam-12937	42	44	history	history	NOUN
bam-12937	42	45	of	of	ADP
bam-12937	42	46	fh	fh	PROPN
bam-12937	42	47	and	and	CCONJ
bam-12937	42	48	assessment	assessment	NOUN
bam-12937	42	49	of	of	ADP
bam-12937	42	50	ldl	ldl	NOUN
bam-12937	42	51	-	-	PUNCT
bam-12937	42	52	c	c	NOUN
bam-12937	42	53	level	level	NOUN
bam-12937	42	54	in	in	ADP
bam-12937	42	55	blood	blood	NOUN
bam-12937	42	56	)	)	PUNCT
bam-12937	42	57	.	.	PUNCT
bam-12937	43	1	patients	patient	NOUN
bam-12937	43	2	with	with	ADP
bam-12937	43	3	underlying	underlying	ADJ
bam-12937	43	4	medical	medical	ADJ
bam-12937	43	5	conditions	condition	NOUN
bam-12937	43	6	that	that	PRON
bam-12937	43	7	could	could	AUX
bam-12937	43	8	confound	confound	VERB
bam-12937	43	9	the	the	DET
bam-12937	43	10	study	study	NOUN
bam-12937	43	11	results	result	NOUN
bam-12937	43	12	were	be	AUX
bam-12937	43	13	excluded	exclude	VERB
bam-12937	43	14	.	.	PUNCT
bam-12937	44	1	additionally	additionally	ADV
bam-12937	44	2	,	,	PUNCT
bam-12937	44	3	participants	participant	NOUN
bam-12937	44	4	with	with	ADP
bam-12937	44	5	incomplete	incomplete	ADJ
bam-12937	44	6	medical	medical	ADJ
bam-12937	44	7	records	record	NOUN
bam-12937	44	8	were	be	AUX
bam-12937	44	9	not	not	PART
bam-12937	44	10	included	include	VERB
bam-12937	44	11	.	.	PUNCT
bam-12937	45	1	informed	informed	ADJ
bam-12937	45	2	consent	consent	NOUN
bam-12937	45	3	was	be	AUX
bam-12937	45	4	obtained	obtain	VERB
bam-12937	45	5	from	from	ADP
bam-12937	45	6	all	all	DET
bam-12937	45	7	participants	participant	NOUN
bam-12937	45	8	,	,	PUNCT
bam-12937	45	9	and	and	CCONJ
bam-12937	45	10	the	the	DET
bam-12937	45	11	study	study	NOUN
bam-12937	45	12	adhered	adhere	VERB
bam-12937	45	13	to	to	ADP
bam-12937	45	14	ethical	ethical	ADJ
bam-12937	45	15	guidelines	guideline	NOUN
bam-12937	45	16	for	for	ADP
bam-12937	45	17	patient	patient	ADJ
bam-12937	45	18	confidentiality	confidentiality	NOUN
bam-12937	45	19	.	.	PUNCT
bam-12937	46	1	baseline	baseline	ADJ
bam-12937	46	2	assessment	assessment	NOUN
bam-12937	46	3	and	and	CCONJ
bam-12937	46	4	intervention	intervention	NOUN
bam-12937	46	5	prior	prior	ADV
bam-12937	46	6	to	to	ADP
bam-12937	46	7	initiating	initiate	VERB
bam-12937	46	8	evolocumab	evolocumab	NOUN
bam-12937	46	9	therapy	therapy	NOUN
bam-12937	46	10	,	,	PUNCT
bam-12937	46	11	all	all	DET
bam-12937	46	12	participants	participant	NOUN
bam-12937	46	13	underwent	undergo	VERB
bam-12937	46	14	a	a	DET
bam-12937	46	15	comprehensive	comprehensive	ADJ
bam-12937	46	16	clinical	clinical	ADJ
bam-12937	46	17	examination	examination	NOUN
bam-12937	46	18	.	.	PUNCT
bam-12937	47	1	demographic	demographic	ADJ
bam-12937	47	2	data	datum	NOUN
bam-12937	47	3	,	,	PUNCT
bam-12937	47	4	medical	medical	ADJ
bam-12937	47	5	history	history	NOUN
bam-12937	47	6	,	,	PUNCT
bam-12937	47	7	including	include	VERB
bam-12937	47	8	cardiovascular	cardiovascular	ADJ
bam-12937	47	9	events	event	NOUN
bam-12937	47	10	(	(	PUNCT
bam-12937	47	11	myocardial	myocardial	ADJ
bam-12937	47	12	infarction	infarction	NOUN
bam-12937	47	13	(	(	PUNCT
bam-12937	47	14	mi	mi	NOUN
bam-12937	47	15	)	)	PUNCT
bam-12937	47	16	,	,	PUNCT
bam-12937	47	17	percutaneous	percutaneous	ADJ
bam-12937	47	18	coronary	coronary	ADJ
bam-12937	47	19	intervention	intervention	NOUN
bam-12937	47	20	(	(	PUNCT
bam-12937	47	21	pci	pci	ADJ
bam-12937	47	22	)	)	PUNCT
bam-12937	47	23	,	,	PUNCT
bam-12937	47	24	coronary	coronary	ADJ
bam-12937	47	25	artery	artery	NOUN
bam-12937	47	26	bypass	bypass	NOUN
bam-12937	47	27	grafting	grafting	NOUN
bam-12937	47	28	(	(	PUNCT
bam-12937	47	29	cabg	cabg	NOUN
bam-12937	47	30	)	)	PUNCT
bam-12937	47	31	,	,	PUNCT
bam-12937	47	32	peripheral	peripheral	ADJ
bam-12937	47	33	artery	artery	NOUN
bam-12937	47	34	disease(pad	disease(pad	PROPN
bam-12937	47	35	)	)	PUNCT
bam-12937	47	36	,	,	PUNCT
bam-12937	47	37	vascular	vascular	ADJ
bam-12937	47	38	involvement	involvement	NOUN
bam-12937	47	39	)	)	PUNCT
bam-12937	47	40	,	,	PUNCT
bam-12937	47	41	history	history	NOUN
bam-12937	47	42	of	of	ADP
bam-12937	47	43	angiography	angiography	NOUN
bam-12937	47	44	,	,	PUNCT
bam-12937	47	45	diabetes	diabetes	NOUN
bam-12937	47	46	,	,	PUNCT
bam-12937	47	47	and	and	CCONJ
bam-12937	47	48	prior	prior	ADJ
bam-12937	47	49	hospitalization	hospitalization	NOUN
bam-12937	47	50	in	in	ADP
bam-12937	47	51	the	the	DET
bam-12937	47	52	coronary	coronary	ADJ
bam-12937	47	53	care	care	NOUN
bam-12937	47	54	unit	unit	NOUN
bam-12937	47	55	(	(	PUNCT
bam-12937	47	56	ccu	ccu	PROPN
bam-12937	47	57	)	)	PUNCT
bam-12937	47	58	,	,	PUNCT
bam-12937	47	59	were	be	AUX
bam-12937	47	60	documented	document	VERB
bam-12937	47	61	.	.	PUNCT
bam-12937	48	1	blood	blood	NOUN
bam-12937	48	2	samples	sample	NOUN
bam-12937	48	3	were	be	AUX
bam-12937	48	4	collected	collect	VERB
bam-12937	48	5	to	to	PART
bam-12937	48	6	measure	measure	VERB
bam-12937	48	7	baseline	baseline	NOUN
bam-12937	48	8	levels	level	NOUN
bam-12937	48	9	of	of	ADP
bam-12937	48	10	ldl	ldl	NOUN
bam-12937	48	11	-	-	PUNCT
bam-12937	48	12	c	c	PROPN
bam-12937	48	13	,	,	PUNCT
bam-12937	48	14	hdl	hdl	PROPN
bam-12937	48	15	-	-	PUNCT
bam-12937	48	16	c	c	PROPN
bam-12937	48	17	,	,	PUNCT
bam-12937	48	18	and	and	CCONJ
bam-12937	48	19	triglycerides	triglyceride	NOUN
bam-12937	48	20	.	.	PUNCT
bam-12937	49	1	evolocumab	evolocumab	NOUN
bam-12937	49	2	was	be	AUX
bam-12937	49	3	administered	administer	VERB
bam-12937	49	4	subcutaneously	subcutaneously	ADV
bam-12937	49	5	at	at	ADP
bam-12937	49	6	a	a	DET
bam-12937	49	7	standard	standard	ADJ
bam-12937	49	8	dose	dose	NOUN
bam-12937	49	9	(	(	PUNCT
bam-12937	49	10	140	140	NUM
bam-12937	49	11	mg	mg	NUM
bam-12937	49	12	/	/	SYM
bam-12937	49	13	ml	ml	NOUN
bam-12937	49	14	)	)	PUNCT
bam-12937	49	15	with	with	ADP
bam-12937	49	16	a	a	DET
bam-12937	49	17	two	two	NUM
bam-12937	49	18	-	-	PUNCT
bam-12937	49	19	week	week	NOUN
bam-12937	49	20	interval	interval	NOUN
bam-12937	49	21	for	for	ADP
bam-12937	49	22	one	one	NUM
bam-12937	49	23	year	year	NOUN
bam-12937	49	24	.	.	PUNCT
bam-12937	50	1	after	after	ADP
bam-12937	50	2	one	one	NUM
bam-12937	50	3	year	year	NOUN
bam-12937	50	4	of	of	ADP
bam-12937	50	5	treatment	treatment	NOUN
bam-12937	50	6	,	,	PUNCT
bam-12937	50	7	participants	participant	NOUN
bam-12937	50	8	returned	return	VERB
bam-12937	50	9	for	for	ADP
bam-12937	50	10	a	a	DET
bam-12937	50	11	follow	follow	VERB
bam-12937	50	12	-	-	PUNCT
bam-12937	50	13	up	up	ADP
bam-12937	50	14	clinical	clinical	ADJ
bam-12937	50	15	examination	examination	NOUN
bam-12937	50	16	.	.	PUNCT
bam-12937	51	1	blood	blood	NOUN
bam-12937	51	2	samples	sample	NOUN
bam-12937	51	3	were	be	AUX
bam-12937	51	4	again	again	ADV
bam-12937	51	5	collected	collect	VERB
bam-12937	51	6	to	to	PART
bam-12937	51	7	assess	assess	VERB
bam-12937	51	8	changes	change	NOUN
bam-12937	51	9	in	in	ADP
bam-12937	51	10	ldl	ldl	NOUN
bam-12937	51	11	-	-	PUNCT
bam-12937	51	12	c	c	PROPN
bam-12937	51	13	,	,	PUNCT
bam-12937	51	14	hdl	hdl	PROPN
bam-12937	51	15	-	-	PUNCT
bam-12937	51	16	c	c	PROPN
bam-12937	51	17	,	,	PUNCT
bam-12937	51	18	and	and	CCONJ
bam-12937	51	19	triglyceride	triglyceride	ADJ
bam-12937	51	20	levels	level	NOUN
bam-12937	51	21	.	.	PUNCT
bam-12937	52	1	statistical	statistical	ADJ
bam-12937	52	2	analysis	analysis	NOUN
bam-12937	52	3	at	at	ADP
bam-12937	52	4	the	the	DET
bam-12937	52	5	inferential	inferential	ADJ
bam-12937	52	6	level	level	NOUN
bam-12937	52	7	to	to	PART
bam-12937	52	8	control	control	VERB
bam-12937	52	9	the	the	DET
bam-12937	52	10	presumption	presumption	NOUN
bam-12937	52	11	of	of	ADP
bam-12937	52	12	data	datum	NOUN
bam-12937	52	13	normality	normality	NOUN
bam-12937	52	14	the	the	DET
bam-12937	52	15	shapiro	shapiro	PROPN
bam-12937	52	16	-	-	PUNCT
bam-12937	52	17	wilk	wilk	NOUN
bam-12937	52	18	test	test	NOUN
bam-12937	52	19	was	be	AUX
bam-12937	52	20	used	use	VERB
bam-12937	52	21	;	;	PUNCT
bam-12937	52	22	if	if	SCONJ
bam-12937	52	23	this	this	DET
bam-12937	52	24	assumption	assumption	NOUN
bam-12937	52	25	was	be	AUX
bam-12937	52	26	established	establish	VERB
bam-12937	52	27	,	,	PUNCT
bam-12937	52	28	the	the	DET
bam-12937	52	29	test	test	NOUN
bam-12937	52	30	one	one	NUM
bam-12937	52	31	-	-	PUNCT
bam-12937	52	32	way	way	NOUN
bam-12937	52	33	anova	anova	X
bam-12937	52	34	along	along	ADP
bam-12937	52	35	with	with	ADP
bam-12937	52	36	bonferroni	bonferroni	PROPN
bam-12937	52	37	’s	’s	PART
bam-12937	52	38	post	post	X
bam-12937	52	39	hoc	hoc	X
bam-12937	52	40	test	test	NOUN
bam-12937	52	41	and	and	CCONJ
bam-12937	52	42	otherwise	otherwise	ADV
bam-12937	52	43	kruskal	kruskal	PROPN
bam-12937	52	44	-	-	PUNCT
bam-12937	52	45	wallis	wallis	PROPN
bam-12937	52	46	and	and	CCONJ
bam-12937	52	47	mann	mann	PROPN
bam-12937	52	48	-	-	PUNCT
bam-12937	52	49	whitney	whitney	PROPN
bam-12937	52	50	test	test	NOUN
bam-12937	52	51	were	be	AUX
bam-12937	52	52	performed	perform	VERB
bam-12937	52	53	.	.	PUNCT
bam-12937	53	1	to	to	PART
bam-12937	53	2	compare	compare	VERB
bam-12937	53	3	the	the	DET
bam-12937	53	4	qualitative	qualitative	ADJ
bam-12937	53	5	variables	variable	NOUN
bam-12937	53	6	between	between	ADP
bam-12937	53	7	patients	patient	NOUN
bam-12937	53	8	with	with	ADP
bam-12937	53	9	different	different	ADJ
bam-12937	53	10	severity	severity	NOUN
bam-12937	53	11	of	of	ADP
bam-12937	53	12	the	the	DET
bam-12937	53	13	disease	disease	NOUN
bam-12937	53	14	chi	chi	ADJ
bam-12937	53	15	-	-	PUNCT
bam-12937	53	16	square	square	PROPN
bam-12937	53	17	or	or	CCONJ
bam-12937	53	18	fisher	fisher	PROPN
bam-12937	53	19	’s	’s	PART
bam-12937	53	20	exact	exact	ADJ
bam-12937	53	21	test	test	NOUN
bam-12937	53	22	was	be	AUX
bam-12937	53	23	used	use	VERB
bam-12937	53	24	.	.	PUNCT
bam-12937	54	1	analyzes	analyze	NOUN
bam-12937	54	2	was	be	AUX
bam-12937	54	3	performed	perform	VERB
bam-12937	54	4	at	at	ADP
bam-12937	54	5	the	the	DET
bam-12937	54	6	5	5	NUM
bam-12937	54	7	%	%	NOUN
bam-12937	54	8	error	error	NOUN
bam-12937	54	9	level	level	NOUN
bam-12937	54	10	using	use	VERB
bam-12937	54	11	spss	spss	PROPN
bam-12937	54	12	software	software	NOUN
bam-12937	54	13	version	version	NOUN
bam-12937	54	14	24	24	NUM
bam-12937	54	15	.	.	PUNCT
bam-12937	55	1	results	result	VERB
bam-12937	55	2	baseline	baseline	VERB
bam-12937	55	3	demographics	demographic	NOUN
bam-12937	55	4	and	and	CCONJ
bam-12937	55	5	lifestyle	lifestyle	PROPN
bam-12937	55	6	habits	habit	NOUN
bam-12937	55	7	the	the	DET
bam-12937	55	8	study	study	NOUN
bam-12937	55	9	enrolled	enrol	VERB
bam-12937	55	10	50	50	NUM
bam-12937	55	11	participants	participant	NOUN
bam-12937	55	12	with	with	ADP
bam-12937	55	13	an	an	DET
bam-12937	55	14	average	average	ADJ
bam-12937	55	15	age	age	NOUN
bam-12937	55	16	of	of	ADP
bam-12937	55	17	55	55	NUM
bam-12937	55	18	years	year	NOUN
bam-12937	55	19	old	old	ADJ
bam-12937	55	20	(	(	PUNCT
bam-12937	55	21	range	range	NOUN
bam-12937	55	22	35	35	NUM
bam-12937	55	23	-	-	SYM
bam-12937	55	24	80	80	NUM
bam-12937	55	25	years	year	NOUN
bam-12937	55	26	)	)	PUNCT
bam-12937	55	27	.	.	PUNCT
bam-12937	56	1	the	the	DET
bam-12937	56	2	group	group	NOUN
bam-12937	56	3	was	be	AUX
bam-12937	56	4	predominantly	predominantly	ADV
bam-12937	56	5	male	male	ADJ
bam-12937	56	6	,	,	PUNCT
bam-12937	56	7	with	with	ADP
bam-12937	56	8	35	35	NUM
bam-12937	56	9	males	male	NOUN
bam-12937	56	10	(	(	PUNCT
bam-12937	56	11	70	70	NUM
bam-12937	56	12	%	%	NOUN
bam-12937	56	13	)	)	PUNCT
bam-12937	56	14	,	,	PUNCT
bam-12937	56	15	15	15	NUM
bam-12937	56	16	females	female	NOUN
bam-12937	56	17	(	(	PUNCT
bam-12937	56	18	30	30	NUM
bam-12937	56	19	%	%	NOUN
bam-12937	56	20	)	)	PUNCT
bam-12937	56	21	,	,	PUNCT
bam-12937	56	22	and	and	CCONJ
bam-12937	56	23	with	with	ADP
bam-12937	56	24	an	an	DET
bam-12937	56	25	average	average	ADJ
bam-12937	56	26	body	body	NOUN
bam-12937	56	27	mass	mass	NOUN
bam-12937	56	28	index	index	NOUN
bam-12937	56	29	(	(	PUNCT
bam-12937	56	30	bmi	bmi	PROPN
bam-12937	56	31	)	)	PUNCT
bam-12937	56	32	of	of	ADP
bam-12937	56	33	25.5	25.5	NUM
bam-12937	56	34	(	(	PUNCT
bam-12937	56	35	range	range	NOUN
bam-12937	56	36	114	114	NUM
bam-12937	56	37	non	non	X
bam-12937	56	38	-co	-co	PROPN
bam-12937	56	39	mmerc	mmerc	PROPN
bam-12937	56	40	ial	ial	PROPN
bam-12937	56	41	us	us	PROPN
bam-12937	56	42	e	e	NOUN
bam-12937	56	43	o	o	X
bam-12937	56	44	nly	nly	ADV
bam-12937	56	45	the	the	DET
bam-12937	56	46	therapeutic	therapeutic	ADJ
bam-12937	56	47	effect	effect	NOUN
bam-12937	56	48	of	of	ADP
bam-12937	56	49	pcsk9	pcsk9	NOUN
bam-12937	56	50	inhibitors	inhibitor	NOUN
bam-12937	56	51	on	on	ADP
bam-12937	56	52	dyslipidemia	dyslipidemia	NOUN
bam-12937	56	53	:	:	PUNCT
bam-12937	56	54	one	one	NUM
bam-12937	56	55	-	-	PUNCT
bam-12937	56	56	year	year	NOUN
bam-12937	56	57	follow	follow	VERB
bam-12937	56	58	up	up	ADP
bam-12937	56	59	eur	eur	PROPN
bam-12937	56	60	j	j	PROPN
bam-12937	56	61	transl	transl	PROPN
bam-12937	56	62	myol	myol	NOUN
bam-12937	56	63	34	34	NUM
bam-12937	56	64	(	(	PUNCT
bam-12937	56	65	3	3	NUM
bam-12937	56	66	)	)	PUNCT
bam-12937	56	67	12937	12937	NUM
bam-12937	56	68	,	,	PUNCT
bam-12937	56	69	2024	2024	NUM
bam-12937	56	70	doi	doi	NOUN
bam-12937	56	71	:	:	PUNCT
bam-12937	56	72	10.4081	10.4081	NUM
bam-12937	56	73	/	/	SYM
bam-12937	56	74	ejtm.2024.12937	ejtm.2024.12937	PROPN
bam-12937	56	75	19.8	19.8	NUM
bam-12937	56	76	-	-	SYM
bam-12937	56	77	30.8	30.8	NUM
bam-12937	56	78	)	)	PUNCT
bam-12937	56	79	.	.	PUNCT
bam-12937	57	1	in	in	ADP
bam-12937	57	2	terms	term	NOUN
bam-12937	57	3	of	of	ADP
bam-12937	57	4	lifestyle	lifestyle	NOUN
bam-12937	57	5	habits	habit	NOUN
bam-12937	57	6	,	,	PUNCT
bam-12937	57	7	8	8	NUM
bam-12937	57	8	participants	participant	NOUN
bam-12937	57	9	(	(	PUNCT
bam-12937	57	10	16	16	NUM
bam-12937	57	11	%	%	NOUN
bam-12937	57	12	)	)	PUNCT
bam-12937	57	13	reported	report	VERB
bam-12937	57	14	smoking	smoking	NOUN
bam-12937	57	15	and	and	CCONJ
bam-12937	57	16	5	5	NUM
bam-12937	57	17	participants	participant	NOUN
bam-12937	57	18	(	(	PUNCT
bam-12937	57	19	10	10	NUM
bam-12937	57	20	%	%	NOUN
bam-12937	57	21	)	)	PUNCT
bam-12937	57	22	reported	report	VERB
bam-12937	57	23	occasional	occasional	ADJ
bam-12937	57	24	alcohol	alcohol	NOUN
bam-12937	57	25	consumption	consumption	NOUN
bam-12937	57	26	(	(	PUNCT
bam-12937	57	27	table	table	NOUN
bam-12937	57	28	1	1	NUM
bam-12937	57	29	)	)	PUNCT
bam-12937	57	30	.	.	PUNCT
bam-12937	58	1	cardiovascular	cardiovascular	ADJ
bam-12937	58	2	history	history	NOUN
bam-12937	58	3	the	the	DET
bam-12937	58	4	study	study	NOUN
bam-12937	58	5	population	population	NOUN
bam-12937	58	6	had	have	VERB
bam-12937	58	7	a	a	DET
bam-12937	58	8	moderate	moderate	ADJ
bam-12937	58	9	average	average	ADJ
bam-12937	58	10	left	leave	VERB
bam-12937	58	11	ventricular	ventricular	ADJ
bam-12937	58	12	ejection	ejection	NOUN
bam-12937	58	13	fraction	fraction	NOUN
bam-12937	58	14	(	(	PUNCT
bam-12937	58	15	lvef	lvef	NOUN
bam-12937	58	16	)	)	PUNCT
bam-12937	58	17	of	of	ADP
bam-12937	58	18	51.32	51.32	NUM
bam-12937	58	19	%	%	NOUN
bam-12937	58	20	.	.	PUNCT
bam-12937	59	1	however	however	ADV
bam-12937	59	2	,	,	PUNCT
bam-12937	59	3	there	there	PRON
bam-12937	59	4	was	be	VERB
bam-12937	59	5	heterogeneity	heterogeneity	NOUN
bam-12937	59	6	within	within	ADP
bam-12937	59	7	the	the	DET
bam-12937	59	8	group	group	NOUN
bam-12937	59	9	,	,	PUNCT
bam-12937	59	10	with	with	ADP
bam-12937	59	11	24	24	NUM
bam-12937	59	12	patients	patient	NOUN
bam-12937	59	13	(	(	PUNCT
bam-12937	59	14	48	48	NUM
bam-12937	59	15	%	%	NOUN
bam-12937	59	16	)	)	PUNCT
bam-12937	59	17	having	have	VERB
bam-12937	59	18	a	a	DET
bam-12937	59	19	low	low	ADJ
bam-12937	59	20	lvef	lvef	NOUN
bam-12937	59	21	(	(	PUNCT
bam-12937	59	22	mean	mean	VERB
bam-12937	59	23	:	:	PUNCT
bam-12937	59	24	47.29	47.29	NUM
bam-12937	59	25	%	%	NOUN
bam-12937	59	26	)	)	PUNCT
bam-12937	59	27	and	and	CCONJ
bam-12937	59	28	26	26	NUM
bam-12937	59	29	patients	patient	NOUN
bam-12937	59	30	(	(	PUNCT
bam-12937	59	31	52	52	NUM
bam-12937	59	32	%	%	NOUN
bam-12937	59	33	)	)	PUNCT
bam-12937	59	34	having	have	VERB
bam-12937	59	35	a	a	DET
bam-12937	59	36	normal	normal	ADJ
bam-12937	59	37	lvef	lvef	NOUN
bam-12937	59	38	(	(	PUNCT
bam-12937	59	39	mean	mean	NOUN
bam-12937	59	40	:	:	PUNCT
bam-12937	59	41	55.04	55.04	NUM
bam-12937	59	42	%	%	NOUN
bam-12937	59	43	)	)	PUNCT
bam-12937	59	44	.	.	PUNCT
bam-12937	60	1	in	in	ADP
bam-12937	60	2	terms	term	NOUN
bam-12937	60	3	of	of	ADP
bam-12937	60	4	prior	prior	ADJ
bam-12937	60	5	cardiovascular	cardiovascular	ADJ
bam-12937	60	6	events	event	NOUN
bam-12937	60	7	(	(	PUNCT
bam-12937	60	8	cvd	cvd	PROPN
bam-12937	60	9	)	)	PUNCT
bam-12937	60	10	,	,	PUNCT
bam-12937	60	11	13	13	NUM
bam-12937	60	12	patients	patient	NOUN
bam-12937	60	13	(	(	PUNCT
bam-12937	60	14	26	26	NUM
bam-12937	60	15	%	%	NOUN
bam-12937	60	16	)	)	PUNCT
bam-12937	60	17	had	have	VERB
bam-12937	60	18	a	a	DET
bam-12937	60	19	history	history	NOUN
bam-12937	60	20	of	of	ADP
bam-12937	60	21	mi	mi	PROPN
bam-12937	60	22	,	,	PUNCT
bam-12937	60	23	10	10	NUM
bam-12937	60	24	patients	patient	NOUN
bam-12937	60	25	(	(	PUNCT
bam-12937	60	26	20	20	NUM
bam-12937	60	27	%	%	NOUN
bam-12937	60	28	)	)	PUNCT
bam-12937	60	29	had	have	AUX
bam-12937	60	30	undergone	undergo	VERB
bam-12937	60	31	pci	pci	ADJ
bam-12937	60	32	,	,	PUNCT
bam-12937	60	33	3	3	NUM
bam-12937	60	34	patients	patient	NOUN
bam-12937	60	35	(	(	PUNCT
bam-12937	60	36	6	6	NUM
bam-12937	60	37	%	%	NOUN
bam-12937	60	38	)	)	PUNCT
bam-12937	60	39	had	have	AUX
bam-12937	60	40	received	receive	VERB
bam-12937	60	41	cabg	cabg	NOUN
bam-12937	60	42	,	,	PUNCT
bam-12937	60	43	and	and	CCONJ
bam-12937	60	44	4	4	NUM
bam-12937	60	45	patients	patient	NOUN
bam-12937	60	46	(	(	PUNCT
bam-12937	60	47	8	8	NUM
bam-12937	60	48	%	%	NOUN
bam-12937	60	49	)	)	PUNCT
bam-12937	60	50	had	have	VERB
bam-12937	60	51	pad	pad	NOUN
bam-12937	60	52	.	.	PUNCT
bam-12937	61	1	the	the	DET
bam-12937	61	2	average	average	ADJ
bam-12937	61	3	vessel	vessel	NOUN
bam-12937	61	4	involvement	involvement	NOUN
bam-12937	61	5	in	in	ADP
bam-12937	61	6	patients	patient	NOUN
bam-12937	61	7	with	with	ADP
bam-12937	61	8	pad	pad	NOUN
bam-12937	61	9	was	be	AUX
bam-12937	61	10	1.8	1.8	NUM
bam-12937	61	11	.	.	PUNCT
bam-12937	62	1	importantly	importantly	ADV
bam-12937	62	2	,	,	PUNCT
bam-12937	62	3	none	none	NOUN
bam-12937	62	4	of	of	ADP
bam-12937	62	5	these	these	DET
bam-12937	62	6	patients	patient	NOUN
bam-12937	62	7	experienced	experience	VERB
bam-12937	62	8	new	new	ADJ
bam-12937	62	9	cardiovascular	cardiovascular	ADJ
bam-12937	62	10	events	event	NOUN
bam-12937	62	11	during	during	ADP
bam-12937	62	12	the	the	DET
bam-12937	62	13	one	one	NUM
bam-12937	62	14	-	-	PUNCT
bam-12937	62	15	year	year	NOUN
bam-12937	62	16	follow	follow	NOUN
bam-12937	62	17	-	-	PUNCT
bam-12937	62	18	up	up	NOUN
bam-12937	62	19	period	period	NOUN
bam-12937	62	20	.	.	PUNCT
bam-12937	63	1	additionally	additionally	ADV
bam-12937	63	2	,	,	PUNCT
bam-12937	63	3	16	16	NUM
bam-12937	63	4	patients	patient	NOUN
bam-12937	63	5	(	(	PUNCT
bam-12937	63	6	32	32	NUM
bam-12937	63	7	%	%	NOUN
bam-12937	63	8	)	)	PUNCT
bam-12937	63	9	within	within	ADP
bam-12937	63	10	the	the	DET
bam-12937	63	11	study	study	NOUN
bam-12937	63	12	population	population	NOUN
bam-12937	63	13	were	be	AUX
bam-12937	63	14	diagnosed	diagnose	VERB
bam-12937	63	15	with	with	ADP
bam-12937	63	16	diabetes	diabetes	NOUN
bam-12937	63	17	mellitus	mellitus	NOUN
bam-12937	63	18	(	(	PUNCT
bam-12937	63	19	table	table	NOUN
bam-12937	63	20	2	2	NUM
bam-12937	63	21	)	)	PUNCT
bam-12937	63	22	.	.	PUNCT
bam-12937	64	1	baseline	baseline	PROPN
bam-12937	64	2	medication	medication	NOUN
bam-12937	64	3	baseline	baseline	PROPN
bam-12937	64	4	medication	medication	NOUN
bam-12937	64	5	use	use	NOUN
bam-12937	64	6	revealed	reveal	VERB
bam-12937	64	7	that	that	SCONJ
bam-12937	64	8	statins	statin	NOUN
bam-12937	64	9	were	be	AUX
bam-12937	64	10	the	the	DET
bam-12937	64	11	most	most	ADV
bam-12937	64	12	common	common	ADJ
bam-12937	64	13	cholesterol	cholesterol	NOUN
bam-12937	64	14	-	-	PUNCT
bam-12937	64	15	lowering	lower	VERB
bam-12937	64	16	therapy	therapy	NOUN
bam-12937	64	17	,	,	PUNCT
bam-12937	64	18	with	with	ADP
bam-12937	64	19	42	42	NUM
bam-12937	64	20	patients	patient	NOUN
bam-12937	64	21	(	(	PUNCT
bam-12937	64	22	84	84	NUM
bam-12937	64	23	%	%	NOUN
bam-12937	64	24	)	)	PUNCT
bam-12937	64	25	receiving	receive	VERB
bam-12937	64	26	medications	medication	NOUN
bam-12937	64	27	like	like	ADP
bam-12937	64	28	atorvastatin	atorvastatin	NOUN
bam-12937	64	29	and	and	CCONJ
bam-12937	64	30	rosuvastatin	rosuvastatin	NOUN
bam-12937	64	31	.	.	PUNCT
bam-12937	65	1	among	among	ADP
bam-12937	65	2	these	these	DET
bam-12937	65	3	statin	statin	ADJ
bam-12937	65	4	users	user	NOUN
bam-12937	65	5	,	,	PUNCT
bam-12937	65	6	7	7	NUM
bam-12937	65	7	patients	patient	NOUN
bam-12937	65	8	(	(	PUNCT
bam-12937	65	9	17	17	NUM
bam-12937	65	10	%	%	NOUN
bam-12937	65	11	)	)	PUNCT
bam-12937	65	12	also	also	ADV
bam-12937	65	13	received	receive	VERB
bam-12937	65	14	ezetimibe	ezetimibe	NOUN
bam-12937	65	15	for	for	ADP
bam-12937	65	16	additional	additional	ADJ
bam-12937	65	17	ldl	ldl	NOUN
bam-12937	65	18	-	-	PUNCT
bam-12937	65	19	c	c	NOUN
bam-12937	65	20	reduction	reduction	NOUN
bam-12937	65	21	.	.	PUNCT
bam-12937	66	1	fibrates	fibrate	NOUN
bam-12937	66	2	(	(	PUNCT
bam-12937	66	3	fenofibrate	fenofibrate	NOUN
bam-12937	66	4	and	and	CCONJ
bam-12937	66	5	gemfibrozil	gemfibrozil	PROPN
bam-12937	66	6	)	)	PUNCT
bam-12937	66	7	were	be	AUX
bam-12937	66	8	used	use	VERB
bam-12937	66	9	by	by	ADP
bam-12937	66	10	a	a	DET
bam-12937	66	11	smaller	small	ADJ
bam-12937	66	12	proportion	proportion	NOUN
bam-12937	66	13	of	of	ADP
bam-12937	66	14	patients	patient	NOUN
bam-12937	66	15	(	(	PUNCT
bam-12937	66	16	5	5	NUM
bam-12937	66	17	out	out	ADP
bam-12937	66	18	of	of	ADP
bam-12937	66	19	50	50	NUM
bam-12937	66	20	,	,	PUNCT
bam-12937	66	21	10	10	NUM
bam-12937	66	22	%	%	NOUN
bam-12937	66	23	)	)	PUNCT
bam-12937	66	24	,	,	PUNCT
bam-12937	66	25	with	with	ADP
bam-12937	66	26	2	2	NUM
bam-12937	66	27	of	of	ADP
bam-12937	66	28	them	they	PRON
bam-12937	66	29	(	(	PUNCT
bam-12937	66	30	40	40	NUM
bam-12937	66	31	%	%	NOUN
bam-12937	66	32	)	)	PUNCT
bam-12937	66	33	also	also	ADV
bam-12937	66	34	taking	take	VERB
bam-12937	66	35	ezetimibe	ezetimibe	NOUN
bam-12937	66	36	.	.	PUNCT
bam-12937	67	1	only	only	ADV
bam-12937	67	2	1	1	NUM
bam-12937	67	3	patient	patient	NOUN
bam-12937	67	4	(	(	PUNCT
bam-12937	67	5	2	2	NUM
bam-12937	67	6	%	%	NOUN
bam-12937	67	7	)	)	PUNCT
bam-12937	67	8	received	receive	VERB
bam-12937	67	9	both	both	DET
bam-12937	67	10	statins	statin	NOUN
bam-12937	67	11	and	and	CCONJ
bam-12937	67	12	fibrates	fibrate	VERB
bam-12937	67	13	concurrently	concurrently	ADV
bam-12937	67	14	.	.	PUNCT
bam-12937	68	1	notably	notably	ADV
bam-12937	68	2	,	,	PUNCT
bam-12937	68	3	2	2	NUM
bam-12937	68	4	patients	patient	NOUN
bam-12937	68	5	(	(	PUNCT
bam-12937	68	6	4	4	NUM
bam-12937	68	7	%	%	NOUN
bam-12937	68	8	)	)	PUNCT
bam-12937	68	9	did	do	AUX
bam-12937	68	10	not	not	PART
bam-12937	68	11	receive	receive	VERB
bam-12937	68	12	medication	medication	NOUN
bam-12937	68	13	specifically	specifically	ADV
bam-12937	68	14	for	for	ADP
bam-12937	68	15	ldl	ldl	NOUN
bam-12937	68	16	-	-	PUNCT
bam-12937	68	17	c	c	NOUN
bam-12937	68	18	control	control	NOUN
bam-12937	68	19	but	but	CCONJ
bam-12937	68	20	were	be	AUX
bam-12937	68	21	taking	take	VERB
bam-12937	68	22	anti	anti	ADJ
bam-12937	68	23	-	-	ADJ
bam-12937	68	24	platelet	platelet	ADJ
bam-12937	68	25	drugs	drug	NOUN
bam-12937	68	26	and	and	CCONJ
bam-12937	68	27	beta	beta	NOUN
bam-12937	68	28	-	-	PUNCT
bam-12937	68	29	blockers	blocker	NOUN
bam-12937	68	30	,	,	PUNCT
bam-12937	68	31	likely	likely	ADV
bam-12937	68	32	for	for	ADP
bam-12937	68	33	other	other	ADJ
bam-12937	68	34	cardiovascular	cardiovascular	ADJ
bam-12937	68	35	conditions	condition	NOUN
bam-12937	68	36	.	.	PUNCT
bam-12937	69	1	regarding	regard	VERB
bam-12937	69	2	prior	prior	ADJ
bam-12937	69	3	procedures	procedure	NOUN
bam-12937	69	4	,	,	PUNCT
bam-12937	69	5	25	25	NUM
bam-12937	69	6	patients	patient	NOUN
bam-12937	69	7	(	(	PUNCT
bam-12937	69	8	50	50	NUM
bam-12937	69	9	%	%	NOUN
bam-12937	69	10	)	)	PUNCT
bam-12937	69	11	had	have	AUX
bam-12937	69	12	undergone	undergo	VERB
bam-12937	69	13	angiography	angiography	NOUN
bam-12937	69	14	before	before	ADP
bam-12937	69	15	entering	enter	VERB
bam-12937	69	16	the	the	DET
bam-12937	69	17	study	study	NOUN
bam-12937	69	18	,	,	PUNCT
bam-12937	69	19	and	and	CCONJ
bam-12937	69	20	23	23	NUM
bam-12937	69	21	patients	patient	NOUN
bam-12937	69	22	(	(	PUNCT
bam-12937	69	23	46	46	NUM
bam-12937	69	24	%	%	NOUN
bam-12937	69	25	)	)	PUNCT
bam-12937	69	26	had	have	VERB
bam-12937	69	27	a	a	DET
bam-12937	69	28	prior	prior	ADJ
bam-12937	69	29	admission	admission	NOUN
bam-12937	69	30	to	to	ADP
bam-12937	69	31	the	the	DET
bam-12937	69	32	ccu	ccu	PROPN
bam-12937	69	33	.	.	PUNCT
bam-12937	70	1	importantly	importantly	ADV
bam-12937	70	2	,	,	PUNCT
bam-12937	70	3	no	no	DET
bam-12937	70	4	new	new	ADJ
bam-12937	70	5	occurrences	occurrence	NOUN
bam-12937	70	6	of	of	ADP
bam-12937	70	7	these	these	DET
bam-12937	70	8	procedures	procedure	NOUN
bam-12937	70	9	were	be	AUX
bam-12937	70	10	observed	observe	VERB
bam-12937	70	11	during	during	ADP
bam-12937	70	12	the	the	DET
bam-12937	70	13	one	one	NUM
bam-12937	70	14	-	-	PUNCT
bam-12937	70	15	year	year	NOUN
bam-12937	70	16	follow	follow	NOUN
bam-12937	70	17	-	-	PUNCT
bam-12937	70	18	up	up	NOUN
bam-12937	70	19	period	period	NOUN
bam-12937	70	20	.	.	PUNCT
bam-12937	71	1	115	115	NUM
bam-12937	71	2	table	table	NOUN
bam-12937	71	3	1	1	NUM
bam-12937	71	4	.	.	PUNCT
bam-12937	71	5	baseline	baseline	PROPN
bam-12937	71	6	demographics	demographic	NOUN
bam-12937	71	7	and	and	CCONJ
bam-12937	71	8	lifestyle	lifestyle	NOUN
bam-12937	71	9	habits	habit	NOUN
bam-12937	71	10	of	of	ADP
bam-12937	71	11	study	study	NOUN
bam-12937	71	12	participants	participant	NOUN
bam-12937	71	13	with	with	ADP
bam-12937	71	14	familial	familial	ADJ
bam-12937	71	15	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	71	16	(	(	PUNCT
bam-12937	71	17	n=50	n=50	ADJ
bam-12937	71	18	)	)	PUNCT
bam-12937	71	19	.	.	PUNCT
bam-12937	72	1	variables	variable	NOUN
bam-12937	72	2	n	n	ADV
bam-12937	72	3	%	%	NOUN
bam-12937	72	4	mean	mean	ADJ
bam-12937	72	5	range	range	NOUN
bam-12937	72	6	sd	sd	ADP
bam-12937	72	7	gender	gender	NOUN
bam-12937	72	8	male	male	NOUN
bam-12937	72	9	35	35	NUM
bam-12937	72	10	70.0	70.0	NUM
bam-12937	72	11	female	female	NOUN
bam-12937	72	12	15	15	NUM
bam-12937	72	13	30.0	30.0	NUM
bam-12937	72	14	smoker	smoker	NOUN
bam-12937	72	15	8	8	NUM
bam-12937	72	16	16.0	16.0	NUM
bam-12937	72	17	alcohol	alcohol	NOUN
bam-12937	72	18	use	use	NOUN
bam-12937	72	19	5	5	NUM
bam-12937	72	20	10.0	10.0	NUM
bam-12937	72	21	age	age	NOUN
bam-12937	72	22	55.38	55.38	NUM
bam-12937	72	23	35	35	NUM
bam-12937	72	24	-	-	SYM
bam-12937	72	25	80	80	NUM
bam-12937	72	26	11.62	11.62	NUM
bam-12937	72	27	bmi	bmi	NOUN
bam-12937	72	28	index	index	NOUN
bam-12937	72	29	25.52	25.52	NUM
bam-12937	72	30	19.8	19.8	NUM
bam-12937	72	31	-	-	SYM
bam-12937	72	32	30.8	30.8	NUM
bam-12937	72	33	2.37	2.37	NUM
bam-12937	72	34	table	table	NOUN
bam-12937	72	35	2	2	NUM
bam-12937	72	36	.	.	PUNCT
bam-12937	72	37	baseline	baseline	VERB
bam-12937	72	38	cardiovascular	cardiovascular	ADJ
bam-12937	72	39	parameters	parameter	NOUN
bam-12937	72	40	(	(	PUNCT
bam-12937	72	41	n=50	n=50	ADJ
bam-12937	72	42	)	)	PUNCT
bam-12937	72	43	.	.	PUNCT
bam-12937	73	1	count	count	NOUN
bam-12937	73	2	mean	mean	VERB
bam-12937	73	3	sd	sd	ADP
bam-12937	73	4	count	count	NOUN
bam-12937	73	5	column	column	NOUN
bam-12937	73	6	n	n	ADP
bam-12937	73	7	%	%	NOUN
bam-12937	73	8	ejection	ejection	NOUN
bam-12937	73	9	fraction	fraction	NOUN
bam-12937	73	10	low	low	ADJ
bam-12937	73	11	24	24	NUM
bam-12937	73	12	47.29	47.29	NUM
bam-12937	73	13	3.61	3.61	NUM
bam-12937	73	14	normal	normal	ADJ
bam-12937	73	15	26	26	NUM
bam-12937	73	16	55.04	55.04	NUM
bam-12937	73	17	0.20	0.20	NUM
bam-12937	73	18	vascular	vascular	ADJ
bam-12937	73	19	involvement	involvement	NOUN
bam-12937	73	20	none	none	NOUN
bam-12937	73	21	29	29	NUM
bam-12937	73	22	58.0	58.0	NUM
bam-12937	73	23	1	1	NUM
bam-12937	73	24	8	8	NUM
bam-12937	73	25	16.0	16.0	NUM
bam-12937	73	26	2	2	NUM
bam-12937	73	27	9	9	NUM
bam-12937	73	28	18.0	18.0	NUM
bam-12937	73	29	3	3	NUM
bam-12937	73	30	4	4	NUM
bam-12937	73	31	8.0	8.0	NUM
bam-12937	73	32	non	non	ADJ
bam-12937	73	33	-co	-co	PROPN
bam-12937	73	34	mmerc	mmerc	PROPN
bam-12937	73	35	ial	ial	PROPN
bam-12937	73	36	us	us	PROPN
bam-12937	74	1	e	e	NOUN
bam-12937	74	2	o	o	X
bam-12937	74	3	nly	nly	ADV
bam-12937	74	4	the	the	DET
bam-12937	74	5	therapeutic	therapeutic	ADJ
bam-12937	74	6	effect	effect	NOUN
bam-12937	74	7	of	of	ADP
bam-12937	74	8	pcsk9	pcsk9	NOUN
bam-12937	74	9	inhibitors	inhibitor	NOUN
bam-12937	74	10	on	on	ADP
bam-12937	74	11	dyslipidemia	dyslipidemia	NOUN
bam-12937	74	12	:	:	PUNCT
bam-12937	74	13	one	one	NUM
bam-12937	74	14	-	-	PUNCT
bam-12937	74	15	year	year	NOUN
bam-12937	74	16	follow	follow	VERB
bam-12937	74	17	up	up	ADP
bam-12937	74	18	eur	eur	PROPN
bam-12937	74	19	j	j	PROPN
bam-12937	74	20	transl	transl	PROPN
bam-12937	74	21	myol	myol	NOUN
bam-12937	74	22	34	34	NUM
bam-12937	74	23	(	(	PUNCT
bam-12937	74	24	3	3	NUM
bam-12937	74	25	)	)	PUNCT
bam-12937	74	26	12937	12937	NUM
bam-12937	74	27	,	,	PUNCT
bam-12937	74	28	2024	2024	NUM
bam-12937	74	29	doi	doi	NOUN
bam-12937	74	30	:	:	PUNCT
bam-12937	74	31	10.4081	10.4081	NUM
bam-12937	74	32	/	/	SYM
bam-12937	74	33	ejtm.2024.12937	ejtm.2024.12937	NOUN
bam-12937	74	34	evolocumab	evolocumab	NOUN
bam-12937	74	35	significantly	significantly	ADV
bam-12937	74	36	improved	improve	VERB
bam-12937	74	37	lipid	lipid	NOUN
bam-12937	74	38	profile	profile	NOUN
bam-12937	74	39	at	at	ADP
bam-12937	74	40	baseline	baseline	NOUN
bam-12937	74	41	,	,	PUNCT
bam-12937	74	42	participants	participant	NOUN
bam-12937	74	43	exhibited	exhibit	VERB
bam-12937	74	44	average	average	ADJ
bam-12937	74	45	triglyceride	triglyceride	ADV
bam-12937	74	46	and	and	CCONJ
bam-12937	74	47	ldl	ldl	NOUN
bam-12937	74	48	-	-	PUNCT
bam-12937	74	49	c	c	NOUN
bam-12937	74	50	levels	level	NOUN
bam-12937	74	51	of	of	ADP
bam-12937	74	52	270.2±38.94	270.2±38.94	NUM
bam-12937	74	53	mg	mg	PROPN
bam-12937	74	54	/	/	SYM
bam-12937	74	55	dl	dl	PROPN
bam-12937	74	56	and	and	CCONJ
bam-12937	74	57	227.7±28.84	227.7±28.84	NUM
bam-12937	74	58	mg	mg	PROPN
bam-12937	74	59	/	/	SYM
bam-12937	74	60	dl	dl	PROPN
bam-12937	74	61	,	,	PUNCT
bam-12937	74	62	respectively	respectively	ADV
bam-12937	74	63	.	.	PUNCT
bam-12937	75	1	following	follow	VERB
bam-12937	75	2	one	one	NUM
bam-12937	75	3	year	year	NOUN
bam-12937	75	4	of	of	ADP
bam-12937	75	5	evolocumab	evolocumab	NOUN
bam-12937	75	6	treatment	treatment	NOUN
bam-12937	75	7	,	,	PUNCT
bam-12937	75	8	these	these	DET
bam-12937	75	9	values	value	NOUN
bam-12937	75	10	demonstrated	demonstrate	VERB
bam-12937	75	11	statistically	statistically	ADV
bam-12937	75	12	significant	significant	ADJ
bam-12937	75	13	reductions	reduction	NOUN
bam-12937	75	14	(	(	PUNCT
bam-12937	75	15	p	p	NOUN
bam-12937	75	16	-	-	PUNCT
bam-12937	75	17	values	value	NOUN
bam-12937	75	18	<	<	NOUN
bam-12937	75	19	0.001	0.001	NUM
bam-12937	75	20	)	)	PUNCT
bam-12937	75	21	.	.	PUNCT
bam-12937	76	1	follow	follow	VERB
bam-12937	76	2	-	-	PUNCT
bam-12937	76	3	up	up	ADP
bam-12937	76	4	measurements	measurement	NOUN
bam-12937	76	5	revealed	reveal	VERB
bam-12937	76	6	a	a	DET
bam-12937	76	7	decrease	decrease	NOUN
bam-12937	76	8	in	in	ADP
bam-12937	76	9	triglycerides	triglyceride	NOUN
bam-12937	76	10	to	to	ADP
bam-12937	76	11	an	an	DET
bam-12937	76	12	average	average	NOUN
bam-12937	76	13	of	of	ADP
bam-12937	76	14	210.8±34.75	210.8±34.75	PROPN
bam-12937	76	15	mg	mg	PROPN
bam-12937	76	16	/	/	SYM
bam-12937	76	17	dl	dl	PROPN
bam-12937	76	18	and	and	CCONJ
bam-12937	76	19	a	a	DET
bam-12937	76	20	notable	notable	ADJ
bam-12937	76	21	reduction	reduction	NOUN
bam-12937	76	22	in	in	ADP
bam-12937	76	23	ldl	ldl	NOUN
bam-12937	76	24	-	-	PUNCT
bam-12937	76	25	c	c	NOUN
bam-12937	76	26	to	to	ADP
bam-12937	76	27	122.5±22.80	122.5±22.80	NUM
bam-12937	76	28	mg	mg	PROPN
bam-12937	76	29	/	/	SYM
bam-12937	76	30	dl	dl	PROPN
bam-12937	76	31	.	.	PUNCT
bam-12937	76	32	conversely	conversely	ADV
bam-12937	76	33	,	,	PUNCT
bam-12937	76	34	hdl	hdl	PROPN
bam-12937	76	35	-	-	PUNCT
bam-12937	76	36	c	c	PROPN
bam-12937	76	37	levels	level	NOUN
bam-12937	76	38	displayed	display	VERB
bam-12937	76	39	a	a	DET
bam-12937	76	40	statistically	statistically	ADV
bam-12937	76	41	significant	significant	ADJ
bam-12937	76	42	increase	increase	NOUN
bam-12937	76	43	(	(	PUNCT
bam-12937	76	44	p	p	NOUN
bam-12937	76	45	-	-	PUNCT
bam-12937	76	46	value	value	NOUN
bam-12937	76	47	<	<	NOUN
bam-12937	76	48	0.001	0.001	NUM
bam-12937	76	49	)	)	PUNCT
bam-12937	76	50	from	from	ADP
bam-12937	76	51	a	a	DET
bam-12937	76	52	baseline	baseline	NOUN
bam-12937	76	53	of	of	ADP
bam-12937	76	54	44.34±6.23	44.34±6.23	NUM
bam-12937	76	55	mg	mg	PROPN
bam-12937	76	56	/	/	SYM
bam-12937	76	57	dl	dl	PROPN
bam-12937	76	58	to	to	ADP
bam-12937	76	59	48.84±5.81	48.84±5.81	PROPN
bam-12937	76	60	mg	mg	PROPN
bam-12937	76	61	/	/	SYM
bam-12937	76	62	dl	dl	PROPN
bam-12937	76	63	after	after	ADP
bam-12937	76	64	one	one	NUM
bam-12937	76	65	year	year	NOUN
bam-12937	76	66	.	.	PUNCT
bam-12937	77	1	these	these	DET
bam-12937	77	2	findings	finding	NOUN
bam-12937	77	3	provide	provide	VERB
bam-12937	77	4	strong	strong	ADJ
bam-12937	77	5	evidence	evidence	NOUN
bam-12937	77	6	that	that	SCONJ
bam-12937	77	7	evolocumab	evolocumab	NOUN
bam-12937	77	8	therapy	therapy	NOUN
bam-12937	77	9	effectively	effectively	ADV
bam-12937	77	10	improved	improve	VERB
bam-12937	77	11	the	the	DET
bam-12937	77	12	overall	overall	ADJ
bam-12937	77	13	lipid	lipid	NOUN
bam-12937	77	14	profile	profile	NOUN
bam-12937	77	15	of	of	ADP
bam-12937	77	16	study	study	NOUN
bam-12937	77	17	participants	participant	NOUN
bam-12937	77	18	,	,	PUNCT
bam-12937	77	19	potentially	potentially	ADV
bam-12937	77	20	reducing	reduce	VERB
bam-12937	77	21	their	their	PRON
bam-12937	77	22	risk	risk	NOUN
bam-12937	77	23	of	of	ADP
bam-12937	77	24	cardiovascular	cardiovascular	ADJ
bam-12937	77	25	events	event	NOUN
bam-12937	77	26	.	.	PUNCT
bam-12937	78	1	(	(	PUNCT
bam-12937	78	2	tables	table	NOUN
bam-12937	78	3	3	3	NUM
bam-12937	78	4	and	and	CCONJ
bam-12937	78	5	4	4	NUM
bam-12937	78	6	)	)	PUNCT
bam-12937	78	7	.	.	PUNCT
bam-12937	79	1	subgroup	subgroup	NOUN
bam-12937	79	2	analysis	analysis	NOUN
bam-12937	79	3	and	and	CCONJ
bam-12937	79	4	evolocumab	evolocumab	ADP
bam-12937	79	5	efficacy	efficacy	NOUN
bam-12937	79	6	we	we	PRON
bam-12937	79	7	investigated	investigate	VERB
bam-12937	79	8	whether	whether	SCONJ
bam-12937	79	9	evolocumab	evolocumab	NOUN
bam-12937	79	10	’s	’s	PART
bam-12937	79	11	effectiveness	effectiveness	NOUN
bam-12937	79	12	varied	vary	VERB
bam-12937	79	13	based	base	VERB
bam-12937	79	14	on	on	ADP
bam-12937	79	15	patient	patient	ADJ
bam-12937	79	16	characteristics	characteristic	NOUN
bam-12937	79	17	by	by	ADP
bam-12937	79	18	performing	perform	VERB
bam-12937	79	19	subgroup	subgroup	NOUN
bam-12937	79	20	analysis	analysis	NOUN
bam-12937	79	21	and	and	CCONJ
bam-12937	79	22	linear	linear	ADJ
bam-12937	79	23	regression	regression	NOUN
bam-12937	79	24	.	.	PUNCT
bam-12937	80	1	these	these	DET
bam-12937	80	2	analyses	analysis	NOUN
bam-12937	80	3	explored	explore	VERB
bam-12937	80	4	potential	potential	ADJ
bam-12937	80	5	influences	influence	NOUN
bam-12937	80	6	of	of	ADP
bam-12937	80	7	age	age	NOUN
bam-12937	80	8	,	,	PUNCT
bam-12937	80	9	gender	gender	NOUN
bam-12937	80	10	,	,	PUNCT
bam-12937	80	11	smoking	smoking	NOUN
bam-12937	80	12	status	status	NOUN
bam-12937	80	13	,	,	PUNCT
bam-12937	80	14	occasional	occasional	ADJ
bam-12937	80	15	alcohol	alcohol	NOUN
bam-12937	80	16	consumption	consumption	NOUN
bam-12937	80	17	,	,	PUNCT
bam-12937	80	18	and	and	CCONJ
bam-12937	80	19	bmi	bmi	PROPN
bam-12937	80	20	.	.	PUNCT
bam-12937	81	1	while	while	SCONJ
bam-12937	81	2	evolocumab	evolocumab	ADP
bam-12937	81	3	demonstrably	demonstrably	ADV
bam-12937	81	4	improved	improve	VERB
bam-12937	81	5	lipid	lipid	NOUN
bam-12937	81	6	profiles	profile	NOUN
bam-12937	81	7	overall	overall	ADV
bam-12937	81	8	,	,	PUNCT
bam-12937	81	9	we	we	PRON
bam-12937	81	10	did	do	AUX
bam-12937	81	11	not	not	PART
bam-12937	81	12	observe	observe	VERB
bam-12937	81	13	any	any	DET
bam-12937	81	14	statistically	statistically	ADV
bam-12937	81	15	significant	significant	ADJ
bam-12937	81	16	interactions	interaction	NOUN
bam-12937	81	17	between	between	ADP
bam-12937	81	18	these	these	DET
bam-12937	81	19	factors	factor	NOUN
bam-12937	81	20	and	and	CCONJ
bam-12937	81	21	changes	change	NOUN
bam-12937	81	22	in	in	ADP
bam-12937	81	23	triglyceride	triglyceride	ADJ
bam-12937	81	24	,	,	PUNCT
bam-12937	81	25	ldlc	ldlc	NOUN
bam-12937	81	26	,	,	PUNCT
bam-12937	81	27	or	or	CCONJ
bam-12937	81	28	hdl	hdl	PROPN
bam-12937	81	29	-	-	PUNCT
bam-12937	81	30	c	c	PROPN
bam-12937	81	31	levels	level	NOUN
bam-12937	81	32	(	(	PUNCT
bam-12937	81	33	p>0.05	p>0.05	PROPN
bam-12937	81	34	)	)	PUNCT
bam-12937	81	35	.	.	PUNCT
bam-12937	82	1	in	in	ADP
bam-12937	82	2	simpler	simple	ADJ
bam-12937	82	3	terms	term	NOUN
bam-12937	82	4	,	,	PUNCT
bam-12937	82	5	evolocumab	evolocumab	ADP
bam-12937	82	6	appeared	appear	VERB
bam-12937	82	7	to	to	PART
bam-12937	82	8	be	be	AUX
bam-12937	82	9	equally	equally	ADV
bam-12937	82	10	effective	effective	ADJ
bam-12937	82	11	in	in	ADP
bam-12937	82	12	lowering	lower	VERB
bam-12937	82	13	ldl	ldl	NOUN
bam-12937	82	14	-	-	PUNCT
bam-12937	82	15	c	c	PROPN
bam-12937	82	16	,	,	PUNCT
bam-12937	82	17	increasing	increase	VERB
bam-12937	82	18	hdl	hdl	PROPN
bam-12937	82	19	-	-	PUNCT
bam-12937	82	20	c	c	PROPN
bam-12937	82	21	,	,	PUNCT
bam-12937	82	22	and	and	CCONJ
bam-12937	82	23	reducing	reduce	VERB
bam-12937	82	24	triglycerides	triglyceride	NOUN
bam-12937	82	25	regardless	regardless	ADV
bam-12937	82	26	of	of	ADP
bam-12937	82	27	a	a	DET
bam-12937	82	28	patient	patient	NOUN
bam-12937	82	29	’s	’s	PART
bam-12937	82	30	age	age	NOUN
bam-12937	82	31	,	,	PUNCT
bam-12937	82	32	gender	gender	NOUN
bam-12937	82	33	,	,	PUNCT
bam-12937	82	34	smoking	smoking	NOUN
bam-12937	82	35	status	status	NOUN
bam-12937	82	36	,	,	PUNCT
bam-12937	82	37	occasional	occasional	ADJ
bam-12937	82	38	alcohol	alcohol	NOUN
bam-12937	82	39	consumption	consumption	NOUN
bam-12937	82	40	,	,	PUNCT
bam-12937	82	41	or	or	CCONJ
bam-12937	82	42	bmi	bmi	NOUN
bam-12937	82	43	(	(	PUNCT
bam-12937	82	44	table	table	NOUN
bam-12937	82	45	5	5	NUM
bam-12937	82	46	)	)	PUNCT
bam-12937	82	47	.	.	PUNCT
bam-12937	83	1	we	we	PRON
bam-12937	83	2	further	far	ADV
bam-12937	83	3	investigated	investigate	VERB
bam-12937	83	4	the	the	DET
bam-12937	83	5	influence	influence	NOUN
bam-12937	83	6	of	of	ADP
bam-12937	83	7	baseline	baseline	ADJ
bam-12937	83	8	lipid	lipid	NOUN
bam-12937	83	9	levels	level	NOUN
bam-12937	83	10	(	(	PUNCT
bam-12937	83	11	ldl	ldl	NOUN
bam-12937	83	12	-	-	PUNCT
bam-12937	83	13	c	c	NOUN
bam-12937	83	14	,	,	PUNCT
bam-12937	83	15	triglycerides	triglyceride	NOUN
bam-12937	83	16	,	,	PUNCT
bam-12937	83	17	and	and	CCONJ
bam-12937	83	18	hdl	hdl	PROPN
bam-12937	83	19	-	-	PUNCT
bam-12937	83	20	c	c	NOUN
bam-12937	83	21	)	)	PUNCT
bam-12937	83	22	on	on	ADP
bam-12937	83	23	evolocumab	evolocumab	NOUN
bam-12937	83	24	’s	’s	PART
bam-12937	83	25	efficacy	efficacy	NOUN
bam-12937	83	26	.	.	PUNCT
bam-12937	84	1	interestingly	interestingly	ADV
bam-12937	84	2	,	,	PUNCT
bam-12937	84	3	we	we	PRON
bam-12937	84	4	observed	observe	VERB
bam-12937	84	5	statistically	statistically	ADV
bam-12937	84	6	significant	significant	ADJ
bam-12937	84	7	interactions	interaction	NOUN
bam-12937	84	8	.	.	PUNCT
bam-12937	85	1	patients	patient	NOUN
bam-12937	85	2	with	with	ADP
bam-12937	85	3	higher	high	ADJ
bam-12937	85	4	baseline	baseline	NOUN
bam-12937	85	5	lipid	lipid	NOUN
bam-12937	85	6	levels	level	NOUN
bam-12937	85	7	experienced	experience	VERB
bam-12937	85	8	a	a	DET
bam-12937	85	9	greater	great	ADJ
bam-12937	85	10	reduction	reduction	NOUN
bam-12937	85	11	in	in	ADP
bam-12937	85	12	those	those	DET
bam-12937	85	13	specific	specific	ADJ
bam-12937	85	14	lipids	lipid	NOUN
bam-12937	85	15	compared	compare	VERB
bam-12937	85	16	to	to	ADP
bam-12937	85	17	those	those	PRON
bam-12937	85	18	with	with	ADP
bam-12937	85	19	lower	low	ADJ
bam-12937	85	20	baseline	baseline	NOUN
bam-12937	85	21	values	value	NOUN
bam-12937	85	22	.	.	PUNCT
bam-12937	86	1	this	this	PRON
bam-12937	86	2	suggests	suggest	VERB
bam-12937	86	3	evolocumab	evolocumab	NOUN
bam-12937	86	4	may	may	AUX
bam-12937	86	5	be	be	AUX
bam-12937	86	6	particularly	particularly	ADV
bam-12937	86	7	beneficial	beneficial	ADJ
bam-12937	86	8	for	for	ADP
bam-12937	86	9	individuals	individual	NOUN
bam-12937	86	10	with	with	ADP
bam-12937	86	11	more	more	ADV
bam-12937	86	12	severe	severe	ADJ
bam-12937	86	13	dyslipidemia	dyslipidemia	NOUN
bam-12937	86	14	(	(	PUNCT
bam-12937	86	15	p<0.05	p<0.05	NOUN
bam-12937	86	16	)	)	PUNCT
bam-12937	86	17	(	(	PUNCT
bam-12937	86	18	table	table	NOUN
bam-12937	86	19	6	6	NUM
bam-12937	86	20	)	)	PUNCT
bam-12937	86	21	.	.	PUNCT
bam-12937	87	1	our	our	PRON
bam-12937	87	2	analysis	analysis	NOUN
bam-12937	87	3	did	do	AUX
bam-12937	87	4	not	not	PART
bam-12937	87	5	reveal	reveal	VERB
bam-12937	87	6	any	any	DET
bam-12937	87	7	significant	significant	ADJ
bam-12937	87	8	relationships	relationship	NOUN
bam-12937	87	9	between	between	ADP
bam-12937	87	10	evolocumab	evolocumab	NOUN
bam-12937	87	11	efficacy	efficacy	NOUN
bam-12937	87	12	and	and	CCONJ
bam-12937	87	13	prior	prior	ADJ
bam-12937	87	14	cardiovascular	cardiovascular	ADJ
bam-12937	87	15	events	event	NOUN
bam-12937	87	16	(	(	PUNCT
bam-12937	87	17	history	history	NOUN
bam-12937	87	18	of	of	ADP
bam-12937	87	19	mi	mi	PROPN
bam-12937	87	20	,	,	PUNCT
bam-12937	87	21	pci	pci	ADJ
bam-12937	87	22	,	,	PUNCT
bam-12937	87	23	cabg	cabg	NOUN
bam-12937	87	24	,	,	PUNCT
bam-12937	87	25	pad	pad	NOUN
bam-12937	87	26	)	)	PUNCT
bam-12937	87	27	,	,	PUNCT
bam-12937	87	28	presence	presence	NOUN
bam-12937	87	29	of	of	ADP
bam-12937	87	30	diabetes	diabetes	NOUN
bam-12937	87	31	mellitus	mellitus	NOUN
bam-12937	87	32	,	,	PUNCT
bam-12937	87	33	or	or	CCONJ
bam-12937	87	34	baseline	baseline	NOUN
bam-12937	87	35	medications	medication	NOUN
bam-12937	87	36	(	(	PUNCT
bam-12937	87	37	ezetimibe	ezetimibe	NOUN
bam-12937	87	38	,	,	PUNCT
bam-12937	87	39	fibrates	fibrate	NOUN
bam-12937	87	40	,	,	PUNCT
bam-12937	87	41	statins	statin	NOUN
bam-12937	87	42	,	,	PUNCT
bam-12937	87	43	anti	anti	ADJ
bam-12937	87	44	-	-	ADJ
bam-12937	87	45	platelet	platelet	ADJ
bam-12937	87	46	drugs	drug	NOUN
bam-12937	87	47	,	,	PUNCT
bam-12937	87	48	and	and	CCONJ
bam-12937	87	49	beta	beta	NOUN
bam-12937	87	50	-	-	PUNCT
bam-12937	87	51	blockers	blocker	NOUN
bam-12937	87	52	)	)	PUNCT
bam-12937	87	53	(	(	PUNCT
bam-12937	87	54	p>0.05	p>0.05	PROPN
bam-12937	87	55	)	)	PUNCT
bam-12937	87	56	.	.	PUNCT
bam-12937	88	1	116	116	NUM
bam-12937	88	2	table	table	NOUN
bam-12937	88	3	3	3	NUM
bam-12937	88	4	.	.	PUNCT
bam-12937	88	5	lipid	lipid	NOUN
bam-12937	88	6	profile	profile	NOUN
bam-12937	88	7	at	at	ADP
bam-12937	88	8	baseline	baseline	NOUN
bam-12937	88	9	and	and	CCONJ
bam-12937	88	10	after	after	ADP
bam-12937	88	11	evolocumab	evolocumab	ADP
bam-12937	88	12	treatment	treatment	NOUN
bam-12937	88	13	(	(	PUNCT
bam-12937	88	14	mg	mg	PROPN
bam-12937	88	15	/	/	SYM
bam-12937	88	16	dl	dl	PROPN
bam-12937	88	17	;	;	PUNCT
bam-12937	88	18	mean±se	mean±se	PROPN
bam-12937	88	19	,	,	PUNCT
bam-12937	88	20	range	range	NOUN
bam-12937	88	21	)	)	PUNCT
bam-12937	88	22	.	.	PUNCT
bam-12937	89	1	baseline	baseline	PROPN
bam-12937	89	2	lipid	lipid	PROPN
bam-12937	89	3	profile	profile	NOUN
bam-12937	89	4	(	(	PUNCT
bam-12937	89	5	mg	mg	PROPN
bam-12937	89	6	/	/	SYM
bam-12937	89	7	dl	dl	NOUN
bam-12937	89	8	)	)	PUNCT
bam-12937	89	9	lipid	lipid	NOUN
bam-12937	89	10	profile	profile	NOUN
bam-12937	89	11	after	after	ADP
bam-12937	89	12	treatment	treatment	NOUN
bam-12937	89	13	(	(	PUNCT
bam-12937	89	14	mg	mg	PROPN
bam-12937	89	15	/	/	SYM
bam-12937	89	16	dl	dl	NOUN
bam-12937	89	17	)	)	PUNCT
bam-12937	89	18	tg	tg	PROPN
bam-12937	89	19	ldl	ldl	VERB
bam-12937	89	20	hdl	hdl	PROPN
bam-12937	89	21	tg	tg	PROPN
bam-12937	89	22	ldl	ldl	VERB
bam-12937	89	23	hdl	hdl	PROPN
bam-12937	89	24	mean	mean	VERB
bam-12937	89	25	270.20	270.20	NUM
bam-12937	89	26	227.74	227.74	NUM
bam-12937	89	27	44.34	44.34	NUM
bam-12937	89	28	210.80	210.80	NUM
bam-12937	89	29	122.50	122.50	NUM
bam-12937	89	30	48.84	48.84	NUM
bam-12937	89	31	se	se	X
bam-12937	89	32	of	of	ADP
bam-12937	89	33	mean	mean	PROPN
bam-12937	89	34	5.507	5.507	NUM
bam-12937	89	35	4.078	4.078	NUM
bam-12937	89	36	.881	.881	NUM
bam-12937	89	37	4.914	4.914	NUM
bam-12937	89	38	3.224	3.224	NUM
bam-12937	89	39	.822	.822	NUM
bam-12937	89	40	median	median	NOUN
bam-12937	89	41	270.00	270.00	NUM
bam-12937	89	42	230.00	230.00	NUM
bam-12937	89	43	46.00	46.00	NUM
bam-12937	89	44	200.00	200.00	NUM
bam-12937	89	45	120.00	120.00	NUM
bam-12937	89	46	50.00	50.00	NUM
bam-12937	89	47	sd	sd	ADP
bam-12937	89	48	38.940	38.940	NUM
bam-12937	89	49	28.838	28.838	NUM
bam-12937	89	50	6.232	6.232	NUM
bam-12937	89	51	34.749	34.749	NUM
bam-12937	89	52	22.796	22.796	NUM
bam-12937	89	53	5.815	5.815	NUM
bam-12937	89	54	range	range	NOUN
bam-12937	89	55	200	200	NUM
bam-12937	89	56	110	110	NUM
bam-12937	89	57	25	25	NUM
bam-12937	89	58	180	180	NUM
bam-12937	89	59	110	110	NUM
bam-12937	89	60	22	22	NUM
bam-12937	89	61	200	200	NUM
bam-12937	89	62	-	-	SYM
bam-12937	89	63	400	400	NUM
bam-12937	89	64	190	190	NUM
bam-12937	89	65	-	-	SYM
bam-12937	89	66	300	300	NUM
bam-12937	89	67	30	30	NUM
bam-12937	89	68	-	-	SYM
bam-12937	89	69	55	55	NUM
bam-12937	89	70	140	140	NUM
bam-12937	89	71	-	-	SYM
bam-12937	89	72	320	320	NUM
bam-12937	89	73	80	80	NUM
bam-12937	89	74	-	-	SYM
bam-12937	89	75	190	190	NUM
bam-12937	89	76	38	38	NUM
bam-12937	89	77	-	-	SYM
bam-12937	89	78	60	60	NUM
bam-12937	89	79	table	table	NOUN
bam-12937	89	80	4	4	NUM
bam-12937	89	81	.	.	PUNCT
bam-12937	89	82	paired	pair	VERB
bam-12937	89	83	samples	sample	NOUN
bam-12937	89	84	t	t	NOUN
bam-12937	89	85	-	-	PUNCT
bam-12937	89	86	test	test	NOUN
bam-12937	89	87	results	result	NOUN
bam-12937	89	88	:	:	PUNCT
bam-12937	89	89	changes	change	NOUN
bam-12937	89	90	in	in	ADP
bam-12937	89	91	triglycerides	triglyceride	NOUN
bam-12937	89	92	,	,	PUNCT
bam-12937	89	93	ldl	ldl	NOUN
bam-12937	89	94	-	-	PUNCT
bam-12937	89	95	c	c	NOUN
bam-12937	89	96	,	,	PUNCT
bam-12937	89	97	and	and	CCONJ
bam-12937	89	98	hdl	hdl	PROPN
bam-12937	89	99	-	-	PUNCT
bam-12937	89	100	c	c	PROPN
bam-12937	89	101	after	after	ADP
bam-12937	89	102	one	one	NUM
bam-12937	89	103	-	-	PUNCT
bam-12937	89	104	year	year	NOUN
bam-12937	89	105	evolocumab	evolocumab	NOUN
bam-12937	89	106	therapy	therapy	NOUN
bam-12937	89	107	(	(	PUNCT
bam-12937	89	108	mg	mg	PROPN
bam-12937	89	109	/	/	SYM
bam-12937	89	110	dl	dl	NOUN
bam-12937	89	111	)	)	PUNCT
bam-12937	89	112	mean	mean	VERB
bam-12937	89	113	sd	sd	NUM
bam-12937	89	114	se	se	ADV
bam-12937	89	115	95	95	NUM
bam-12937	89	116	%	%	NOUN
bam-12937	89	117	ci	ci	NOUN
bam-12937	89	118	of	of	ADP
bam-12937	89	119	the	the	DET
bam-12937	89	120	t	t	PROPN
bam-12937	89	121	df	df	PROPN
bam-12937	89	122	sig	sig	PROPN
bam-12937	89	123	.	.	PUNCT
bam-12937	90	1	mean	mean	ADJ
bam-12937	90	2	difference	difference	NOUN
bam-12937	90	3	(	(	PUNCT
bam-12937	90	4	2tailed	2tailed	NUM
bam-12937	90	5	)	)	PUNCT
bam-12937	90	6	lower	low	ADJ
bam-12937	90	7	upper	upper	ADJ
bam-12937	90	8	pair	pair	NOUN
bam-12937	90	9	1	1	NUM
bam-12937	90	10	tg	tg	NOUN
bam-12937	90	11	before	before	ADV
bam-12937	90	12	and	and	CCONJ
bam-12937	90	13	after	after	ADP
bam-12937	90	14	treatment	treatment	NOUN
bam-12937	90	15	59.400	59.400	NUM
bam-12937	90	16	25.747	25.747	NUM
bam-12937	90	17	3.641	3.641	NUM
bam-12937	90	18	52.083	52.083	NUM
bam-12937	90	19	66.717	66.717	NUM
bam-12937	90	20	16.314	16.314	NUM
bam-12937	90	21	49	49	NUM
bam-12937	90	22	.000	.000	NUM
bam-12937	90	23	pair	pair	NOUN
bam-12937	90	24	2	2	NUM
bam-12937	90	25	ldl	ldl	NOUN
bam-12937	90	26	before	before	ADV
bam-12937	90	27	and	and	CCONJ
bam-12937	90	28	after	after	ADP
bam-12937	90	29	treatment	treatment	NOUN
bam-12937	90	30	105.240	105.240	NUM
bam-12937	90	31	23.153	23.153	NUM
bam-12937	90	32	3.274	3.274	NUM
bam-12937	90	33	98.660	98.660	NUM
bam-12937	90	34	111.820	111.820	NUM
bam-12937	90	35	32.141	32.141	NUM
bam-12937	90	36	49	49	NUM
bam-12937	90	37	.000	.000	NUM
bam-12937	90	38	pair	pair	NOUN
bam-12937	90	39	3	3	NUM
bam-12937	90	40	hdl	hdl	NOUN
bam-12937	90	41	before	before	ADV
bam-12937	90	42	and	and	CCONJ
bam-12937	90	43	after	after	ADP
bam-12937	90	44	treatment	treatment	NOUN
bam-12937	90	45	-4.500	-4.500	PUNCT
bam-12937	90	46	2.816	2.816	NUM
bam-12937	90	47	.398	.398	NUM
bam-12937	90	48	-5.300	-5.300	NUM
bam-12937	90	49	-3.700	-3.700	NUM
bam-12937	90	50	-11.301	-11.301	NOUN
bam-12937	90	51	49	49	NUM
bam-12937	90	52	.000	.000	NUM
bam-12937	90	53	non	non	ADJ
bam-12937	90	54	-co	-co	PROPN
bam-12937	90	55	mmerc	mmerc	PROPN
bam-12937	90	56	ial	ial	PROPN
bam-12937	91	1	us	us	PROPN
bam-12937	91	2	e	e	NOUN
bam-12937	91	3	o	o	X
bam-12937	91	4	nly	nly	ADV
bam-12937	91	5	the	the	DET
bam-12937	91	6	therapeutic	therapeutic	ADJ
bam-12937	91	7	effect	effect	NOUN
bam-12937	91	8	of	of	ADP
bam-12937	91	9	pcsk9	pcsk9	NOUN
bam-12937	91	10	inhibitors	inhibitor	NOUN
bam-12937	91	11	on	on	ADP
bam-12937	91	12	dyslipidemia	dyslipidemia	NOUN
bam-12937	91	13	:	:	PUNCT
bam-12937	91	14	one	one	NUM
bam-12937	91	15	-	-	PUNCT
bam-12937	91	16	year	year	NOUN
bam-12937	91	17	follow	follow	VERB
bam-12937	91	18	up	up	ADP
bam-12937	91	19	eur	eur	PROPN
bam-12937	91	20	j	j	PROPN
bam-12937	91	21	transl	transl	PROPN
bam-12937	91	22	myol	myol	NOUN
bam-12937	91	23	34	34	NUM
bam-12937	91	24	(	(	PUNCT
bam-12937	91	25	3	3	NUM
bam-12937	91	26	)	)	PUNCT
bam-12937	91	27	12937	12937	NUM
bam-12937	91	28	,	,	PUNCT
bam-12937	91	29	2024	2024	NUM
bam-12937	91	30	doi	doi	NOUN
bam-12937	91	31	:	:	PUNCT
bam-12937	91	32	10.4081	10.4081	NUM
bam-12937	91	33	/	/	SYM
bam-12937	91	34	ejtm.2024.12937	ejtm.2024.12937	NOUN
bam-12937	91	35	117	117	NUM
bam-12937	91	36	table	table	NOUN
bam-12937	91	37	5	5	NUM
bam-12937	91	38	.	.	PUNCT
bam-12937	91	39	impact	impact	NOUN
bam-12937	91	40	of	of	ADP
bam-12937	91	41	demographics	demographic	NOUN
bam-12937	91	42	on	on	ADP
bam-12937	91	43	changes	change	NOUN
bam-12937	91	44	in	in	ADP
bam-12937	91	45	triglycerides	triglyceride	NOUN
bam-12937	91	46	,	,	PUNCT
bam-12937	91	47	ldl	ldl	NOUN
bam-12937	91	48	-	-	PUNCT
bam-12937	91	49	c	c	NOUN
bam-12937	91	50	,	,	PUNCT
bam-12937	91	51	and	and	CCONJ
bam-12937	91	52	hdl	hdl	PROPN
bam-12937	91	53	-	-	PUNCT
bam-12937	91	54	c	c	PROPN
bam-12937	91	55	after	after	ADP
bam-12937	91	56	evolocumab	evolocumab	ADP
bam-12937	91	57	treatment	treatment	NOUN
bam-12937	91	58	:	:	PUNCT
bam-12937	91	59	tests	test	NOUN
bam-12937	91	60	of	of	ADP
bam-12937	91	61	between	between	ADP
bam-12937	91	62	-	-	PUNCT
bam-12937	91	63	subjects	subject	NOUN
bam-12937	91	64	effects	effect	NOUN
bam-12937	91	65	.	.	PUNCT
bam-12937	92	1	dependent	dependent	ADJ
bam-12937	92	2	source	source	NOUN
bam-12937	92	3	type	type	NOUN
bam-12937	92	4	iii	iii	NOUN
bam-12937	92	5	sum	sum	NOUN
bam-12937	92	6	df	df	NOUN
bam-12937	92	7	mean	mean	VERB
bam-12937	92	8	square	square	PROPN
bam-12937	92	9	f	f	PROPN
bam-12937	92	10	sig	sig	PROPN
bam-12937	92	11	.	.	PUNCT
bam-12937	93	1	variable	variable	NOUN
bam-12937	93	2	of	of	ADP
bam-12937	93	3	squares	square	NOUN
bam-12937	93	4	tg	tg	PROPN
bam-12937	93	5	change	change	VERB
bam-12937	93	6	corrected	correct	VERB
bam-12937	93	7	model	model	NOUN
bam-12937	93	8	14773.667a	14773.667a	NUM
bam-12937	93	9	27	27	NUM
bam-12937	93	10	547.173	547.173	NUM
bam-12937	93	11	0.680	0.680	NUM
bam-12937	93	12	0.831	0.831	NUM
bam-12937	93	13	intercept	intercept	NOUN
bam-12937	93	14	95333.285	95333.285	NUM
bam-12937	93	15	1	1	NUM
bam-12937	93	16	95333.285	95333.285	NUM
bam-12937	93	17	118.438	118.438	NUM
bam-12937	93	18	0.000	0.000	NUM
bam-12937	93	19	gender	gender	NOUN
bam-12937	93	20	61.227	61.227	NUM
bam-12937	93	21	1	1	NUM
bam-12937	93	22	61.227	61.227	NUM
bam-12937	93	23	0.076	0.076	NUM
bam-12937	93	24	0.785	0.785	NUM
bam-12937	93	25	age	age	NOUN
bam-12937	93	26	9834.108	9834.108	NUM
bam-12937	93	27	22	22	NUM
bam-12937	93	28	447.005	447.005	NUM
bam-12937	93	29	0.555	0.555	NUM
bam-12937	93	30	0.912	0.912	NUM
bam-12937	93	31	gender	gender	NOUN
bam-12937	93	32	*	*	PUNCT
bam-12937	93	33	age	age	NOUN
bam-12937	93	34	3150.883	3150.883	NUM
bam-12937	93	35	4	4	NUM
bam-12937	93	36	787.721	787.721	NUM
bam-12937	93	37	0.979	0.979	NUM
bam-12937	93	38	0.439	0.439	NUM
bam-12937	93	39	error	error	NOUN
bam-12937	93	40	17708.333	17708.333	NUM
bam-12937	93	41	22	22	NUM
bam-12937	93	42	804.924	804.924	NUM
bam-12937	93	43	total	total	NOUN
bam-12937	93	44	208900.000	208900.000	NUM
bam-12937	93	45	50	50	NUM
bam-12937	93	46	corrected	correct	VERB
bam-12937	93	47	total	total	ADJ
bam-12937	93	48	32482.000	32482.000	NUM
bam-12937	93	49	49	49	NUM
bam-12937	93	50	a	a	PRON
bam-12937	93	51	,	,	PUNCT
bam-12937	93	52	r	r	NOUN
bam-12937	93	53	squared	square	VERB
bam-12937	93	54	=	=	NOUN
bam-12937	93	55	0.455	0.455	NUM
bam-12937	93	56	(	(	PUNCT
bam-12937	93	57	adjusted	adjust	VERB
bam-12937	93	58	r	r	NOUN
bam-12937	93	59	squared	square	VERB
bam-12937	93	60	=	=	SYM
bam-12937	93	61	-0.214	-0.214	PUNCT
bam-12937	93	62	)	)	PUNCT
bam-12937	93	63	.	.	PUNCT
bam-12937	94	1	ldl	ldl	NOUN
bam-12937	94	2	change	change	NOUN
bam-12937	94	3	corrected	correct	VERB
bam-12937	94	4	model	model	NOUN
bam-12937	94	5	17438.037a	17438.037a	NUM
bam-12937	94	6	27	27	NUM
bam-12937	94	7	645.853	645.853	NUM
bam-12937	94	8	1.609	1.609	NUM
bam-12937	94	9	0.129	0.129	NUM
bam-12937	94	10	intercept	intercept	VERB
bam-12937	94	11	346988.435	346988.435	NUM
bam-12937	94	12	1	1	NUM
bam-12937	94	13	346988.435	346988.435	NUM
bam-12937	94	14	864.614	864.614	NUM
bam-12937	94	15	0.000	0.000	NUM
bam-12937	94	16	gender	gender	NOUN
bam-12937	94	17	4.890	4.890	NUM
bam-12937	94	18	1	1	NUM
bam-12937	94	19	4.890	4.890	NUM
bam-12937	94	20	0.012	0.012	NUM
bam-12937	94	21	0.913	0.913	NUM
bam-12937	94	22	age	age	NOUN
bam-12937	94	23	16862.070	16862.070	NUM
bam-12937	94	24	22	22	NUM
bam-12937	94	25	766.458	766.458	NUM
bam-12937	94	26	1.910	1.910	NUM
bam-12937	94	27	0.068	0.068	NUM
bam-12937	94	28	gender	gender	NOUN
bam-12937	94	29	*	*	PUNCT
bam-12937	94	30	age	age	NOUN
bam-12937	94	31	683.629	683.629	NUM
bam-12937	94	32	4	4	NUM
bam-12937	94	33	170.907	170.907	NUM
bam-12937	94	34	0.426	0.426	NUM
bam-12937	94	35	0.788	0.788	NUM
bam-12937	94	36	error	error	NOUN
bam-12937	94	37	8829.083	8829.083	NOUN
bam-12937	94	38	22	22	NUM
bam-12937	94	39	401.322	401.322	NUM
bam-12937	94	40	total	total	NOUN
bam-12937	94	41	580040.000	580040.000	NUM
bam-12937	94	42	50	50	NUM
bam-12937	94	43	corrected	correct	VERB
bam-12937	94	44	total	total	ADJ
bam-12937	94	45	26267.120	26267.120	NUM
bam-12937	94	46	49	49	NUM
bam-12937	94	47	a	a	PRON
bam-12937	94	48	,	,	PUNCT
bam-12937	94	49	r	r	NOUN
bam-12937	94	50	squared	square	VERB
bam-12937	94	51	=	=	NOUN
bam-12937	94	52	0.455	0.455	NUM
bam-12937	94	53	(	(	PUNCT
bam-12937	94	54	adjusted	adjust	VERB
bam-12937	94	55	r	r	NOUN
bam-12937	94	56	squared	square	VERB
bam-12937	94	57	=	=	SYM
bam-12937	94	58	-0.214	-0.214	PUNCT
bam-12937	94	59	)	)	PUNCT
bam-12937	94	60	.	.	PUNCT
bam-12937	95	1	hdl	hdl	PROPN
bam-12937	95	2	change	change	PROPN
bam-12937	95	3	corrected	correct	VERB
bam-12937	95	4	model	model	NOUN
bam-12937	95	5	237.500a	237.500a	NUM
bam-12937	95	6	27	27	NUM
bam-12937	95	7	8.796	8.796	NUM
bam-12937	95	8	1.282	1.282	NUM
bam-12937	95	9	0.278	0.278	NUM
bam-12937	95	10	intercept	intercept	NOUN
bam-12937	95	11	665.027	665.027	NUM
bam-12937	95	12	1	1	NUM
bam-12937	95	13	665.027	665.027	NUM
bam-12937	95	14	96.891	96.891	NUM
bam-12937	95	15	0.000	0.000	NUM
bam-12937	95	16	gender	gender	NOUN
bam-12937	95	17	0.260	0.260	NUM
bam-12937	95	18	1	1	NUM
bam-12937	95	19	0.260	0.260	NUM
bam-12937	95	20	0.038	0.038	NUM
bam-12937	95	21	0.847	0.847	NUM
bam-12937	95	22	age	age	NOUN
bam-12937	95	23	211.242	211.242	NUM
bam-12937	95	24	22	22	NUM
bam-12937	95	25	9.602	9.602	NUM
bam-12937	95	26	1.399	1.399	NUM
bam-12937	95	27	0.219	0.219	NUM
bam-12937	95	28	gender	gender	NOUN
bam-12937	95	29	*	*	PUNCT
bam-12937	95	30	age	age	NOUN
bam-12937	95	31	14.477	14.477	NUM
bam-12937	95	32	4	4	NUM
bam-12937	95	33	3.619	3.619	NUM
bam-12937	95	34	0.527	0.527	NUM
bam-12937	95	35	0.717	0.717	NUM
bam-12937	95	36	error	error	NOUN
bam-12937	95	37	151.000	151.000	NUM
bam-12937	95	38	22	22	NUM
bam-12937	95	39	6.864	6.864	NUM
bam-12937	95	40	total	total	NOUN
bam-12937	95	41	1401.000	1401.000	NUM
bam-12937	95	42	50	50	NUM
bam-12937	95	43	corrected	correct	VERB
bam-12937	95	44	total	total	ADJ
bam-12937	95	45	388.500	388.500	NUM
bam-12937	95	46	49	49	NUM
bam-12937	95	47	a	a	PRON
bam-12937	95	48	,	,	PUNCT
bam-12937	95	49	r	r	NOUN
bam-12937	95	50	squared	square	VERB
bam-12937	95	51	=	=	NOUN
bam-12937	95	52	0.611	0.611	NUM
bam-12937	95	53	(	(	PUNCT
bam-12937	95	54	adjusted	adjust	VERB
bam-12937	95	55	r	r	NOUN
bam-12937	95	56	squared	square	VERB
bam-12937	95	57	=	=	NOUN
bam-12937	95	58	0.134	0.134	NUM
bam-12937	95	59	)	)	PUNCT
bam-12937	95	60	.	.	PUNCT
bam-12937	96	1	non	non	ADJ
bam-12937	97	1	-co	-co	PROPN
bam-12937	97	2	mmerc	mmerc	PROPN
bam-12937	97	3	ial	ial	PROPN
bam-12937	98	1	us	us	PROPN
bam-12937	98	2	e	e	NOUN
bam-12937	98	3	o	o	X
bam-12937	98	4	nly	nly	ADV
bam-12937	98	5	the	the	DET
bam-12937	98	6	therapeutic	therapeutic	ADJ
bam-12937	98	7	effect	effect	NOUN
bam-12937	98	8	of	of	ADP
bam-12937	98	9	pcsk9	pcsk9	NOUN
bam-12937	98	10	inhibitors	inhibitor	NOUN
bam-12937	98	11	on	on	ADP
bam-12937	98	12	dyslipidemia	dyslipidemia	NOUN
bam-12937	98	13	:	:	PUNCT
bam-12937	98	14	one	one	NUM
bam-12937	98	15	-	-	PUNCT
bam-12937	98	16	year	year	NOUN
bam-12937	98	17	follow	follow	VERB
bam-12937	98	18	up	up	ADP
bam-12937	98	19	eur	eur	PROPN
bam-12937	98	20	j	j	PROPN
bam-12937	98	21	transl	transl	PROPN
bam-12937	98	22	myol	myol	NOUN
bam-12937	98	23	34	34	NUM
bam-12937	98	24	(	(	PUNCT
bam-12937	98	25	3	3	NUM
bam-12937	98	26	)	)	PUNCT
bam-12937	98	27	12937	12937	NUM
bam-12937	98	28	,	,	PUNCT
bam-12937	98	29	2024	2024	NUM
bam-12937	98	30	doi	doi	NOUN
bam-12937	98	31	:	:	PUNCT
bam-12937	98	32	10.4081	10.4081	NUM
bam-12937	98	33	/	/	SYM
bam-12937	98	34	ejtm.2024.12937	ejtm.2024.12937	PROPN
bam-12937	98	35	however	however	ADV
bam-12937	98	36	,	,	PUNCT
bam-12937	98	37	it	it	PRON
bam-12937	98	38	is	be	AUX
bam-12937	98	39	important	important	ADJ
bam-12937	98	40	to	to	PART
bam-12937	98	41	consider	consider	VERB
bam-12937	98	42	the	the	DET
bam-12937	98	43	limitations	limitation	NOUN
bam-12937	98	44	of	of	ADP
bam-12937	98	45	a	a	DET
bam-12937	98	46	small	small	ADJ
bam-12937	98	47	sample	sample	NOUN
bam-12937	98	48	size	size	NOUN
bam-12937	98	49	in	in	ADP
bam-12937	98	50	this	this	DET
bam-12937	98	51	analysis	analysis	NOUN
bam-12937	98	52	as	as	ADV
bam-12937	98	53	well	well	ADV
bam-12937	98	54	.	.	PUNCT
bam-12937	99	1	future	future	ADJ
bam-12937	99	2	studies	study	NOUN
bam-12937	99	3	with	with	ADP
bam-12937	99	4	larger	large	ADJ
bam-12937	99	5	and	and	CCONJ
bam-12937	99	6	more	more	ADV
bam-12937	99	7	diverse	diverse	ADJ
bam-12937	99	8	patient	patient	ADJ
bam-12937	99	9	populations	population	NOUN
bam-12937	99	10	are	be	AUX
bam-12937	99	11	needed	need	VERB
bam-12937	99	12	to	to	PART
bam-12937	99	13	definitively	definitively	ADV
bam-12937	99	14	assess	assess	VERB
bam-12937	99	15	the	the	DET
bam-12937	99	16	potential	potential	ADJ
bam-12937	99	17	interactions	interaction	NOUN
bam-12937	99	18	between	between	ADP
bam-12937	99	19	these	these	DET
bam-12937	99	20	factors	factor	NOUN
bam-12937	99	21	and	and	CCONJ
bam-12937	99	22	evolocumab	evolocumab	NOUN
bam-12937	99	23	’s	’s	PART
bam-12937	99	24	effectiveness	effectiveness	NOUN
bam-12937	99	25	.	.	PUNCT
bam-12937	100	1	discussion	discussion	NOUN
bam-12937	100	2	our	our	PRON
bam-12937	100	3	study	study	NOUN
bam-12937	100	4	aimed	aim	VERB
bam-12937	100	5	to	to	PART
bam-12937	100	6	assess	assess	VERB
bam-12937	100	7	the	the	DET
bam-12937	100	8	effectiveness	effectiveness	NOUN
bam-12937	100	9	of	of	ADP
bam-12937	100	10	evolocumab	evolocumab	NOUN
bam-12937	100	11	in	in	ADP
bam-12937	100	12	lowering	lower	VERB
bam-12937	100	13	ldl	ldl	NOUN
bam-12937	100	14	-	-	PUNCT
bam-12937	100	15	c	c	NOUN
bam-12937	100	16	levels	level	NOUN
bam-12937	100	17	for	for	ADP
bam-12937	100	18	patients	patient	NOUN
bam-12937	100	19	with	with	ADP
bam-12937	100	20	dyslipidemia	dyslipidemia	NOUN
bam-12937	100	21	.	.	PUNCT
bam-12937	101	1	the	the	DET
bam-12937	101	2	findings	finding	NOUN
bam-12937	101	3	demonstrated	demonstrate	VERB
bam-12937	101	4	a	a	DET
bam-12937	101	5	significant	significant	ADJ
bam-12937	101	6	improvement	improvement	NOUN
bam-12937	101	7	in	in	ADP
bam-12937	101	8	the	the	DET
bam-12937	101	9	lipid	lipid	NOUN
bam-12937	101	10	profiles	profile	NOUN
bam-12937	101	11	of	of	ADP
bam-12937	101	12	participants	participant	NOUN
bam-12937	101	13	following	follow	VERB
bam-12937	101	14	one	one	NUM
bam-12937	101	15	year	year	NOUN
bam-12937	101	16	of	of	ADP
bam-12937	101	17	evolocumab	evolocumab	NOUN
bam-12937	101	18	therapy	therapy	NOUN
bam-12937	101	19	.	.	PUNCT
bam-12937	102	1	treatment	treatment	NOUN
bam-12937	102	2	resulted	result	VERB
bam-12937	102	3	in	in	ADP
bam-12937	102	4	a	a	DET
bam-12937	102	5	substantial	substantial	ADJ
bam-12937	102	6	decrease	decrease	NOUN
bam-12937	102	7	in	in	ADP
bam-12937	102	8	ldl	ldl	NOUN
bam-12937	102	9	-	-	PUNCT
bam-12937	102	10	c	c	NOUN
bam-12937	102	11	by	by	ADP
bam-12937	102	12	an	an	DET
bam-12937	102	13	average	average	NOUN
bam-12937	102	14	of	of	ADP
bam-12937	102	15	105.24±2315	105.24±2315	NUM
bam-12937	102	16	mg	mg	PROPN
bam-12937	102	17	/	/	SYM
bam-12937	102	18	dl	dl	PROPN
bam-12937	102	19	,	,	PUNCT
bam-12937	102	20	bringing	bring	VERB
bam-12937	102	21	ldl	ldl	NOUN
bam-12937	102	22	-	-	PUNCT
bam-12937	102	23	c	c	NOUN
bam-12937	102	24	levels	level	NOUN
bam-12937	102	25	closer	close	ADV
bam-12937	102	26	to	to	ADP
bam-12937	102	27	the	the	DET
bam-12937	102	28	recommended	recommend	VERB
bam-12937	102	29	range	range	NOUN
bam-12937	102	30	of	of	ADP
bam-12937	102	31	50	50	NUM
bam-12937	102	32	to	to	PART
bam-12937	102	33	100	100	NUM
bam-12937	102	34	mg	mg	PROPN
bam-12937	102	35	/	/	SYM
bam-12937	102	36	dl	dl	PROPN
bam-12937	102	37	.	.	PROPN
bam-12937	102	38	additionally	additionally	ADV
bam-12937	102	39	,	,	PUNCT
bam-12937	102	40	evolocumab	evolocumab	ADP
bam-12937	102	41	treatment	treatment	NOUN
bam-12937	102	42	led	lead	VERB
bam-12937	102	43	to	to	ADP
bam-12937	102	44	a	a	DET
bam-12937	102	45	notable	notable	ADJ
bam-12937	102	46	reduction	reduction	NOUN
bam-12937	102	47	in	in	ADP
bam-12937	102	48	triglycerides	triglyceride	NOUN
bam-12937	102	49	(	(	PUNCT
bam-12937	102	50	average	average	ADJ
bam-12937	102	51	decrease	decrease	NOUN
bam-12937	102	52	of	of	ADP
bam-12937	102	53	59.40±25.74	59.40±25.74	NUM
bam-12937	102	54	mg	mg	PROPN
bam-12937	102	55	/	/	SYM
bam-12937	102	56	dl	dl	PROPN
bam-12937	102	57	)	)	PUNCT
bam-12937	102	58	and	and	CCONJ
bam-12937	102	59	a	a	DET
bam-12937	102	60	modest	modest	ADJ
bam-12937	102	61	,	,	PUNCT
bam-12937	102	62	yet	yet	CCONJ
bam-12937	102	63	statistically	statistically	ADV
bam-12937	102	64	significant	significant	ADJ
bam-12937	102	65	,	,	PUNCT
bam-12937	102	66	decreased	decrease	VERB
bam-12937	102	67	in	in	ADP
bam-12937	102	68	hdl	hdl	PROPN
bam-12937	102	69	-	-	PUNCT
bam-12937	102	70	c	c	PROPN
bam-12937	102	71	(	(	PUNCT
bam-12937	102	72	average	average	NOUN
bam-12937	102	73	of	of	ADP
bam-12937	102	74	-4.5±2.81	-4.5±2.81	INTJ
bam-12937	102	75	mg	mg	PROPN
bam-12937	102	76	/	/	SYM
bam-12937	102	77	dl	dl	PROPN
bam-12937	102	78	)	)	PUNCT
bam-12937	102	79	.	.	PUNCT
bam-12937	103	1	these	these	DET
bam-12937	103	2	findings	finding	NOUN
bam-12937	103	3	align	align	VERB
bam-12937	103	4	with	with	ADP
bam-12937	103	5	previous	previous	ADJ
bam-12937	103	6	research	research	NOUN
bam-12937	103	7	highlighting	highlighting	NOUN
bam-12937	103	8	evolocumab	evolocumab	NOUN
bam-12937	103	9	’s	’s	PART
bam-12937	103	10	efficacy	efficacy	NOUN
bam-12937	103	11	in	in	ADP
bam-12937	103	12	improving	improve	VERB
bam-12937	103	13	overall	overall	ADJ
bam-12937	103	14	lipid	lipid	NOUN
bam-12937	103	15	profiles	profile	NOUN
bam-12937	103	16	for	for	ADP
bam-12937	103	17	patients	patient	NOUN
bam-12937	103	18	with	with	ADP
bam-12937	103	19	similar	similar	ADJ
bam-12937	103	20	conditions	condition	NOUN
bam-12937	103	21	.	.	PUNCT
bam-12937	104	1	our	our	PRON
bam-12937	104	2	findings	finding	NOUN
bam-12937	104	3	regarding	regard	VERB
bam-12937	104	4	evolocumab	evolocumab	NOUN
bam-12937	104	5	’s	’s	PART
bam-12937	104	6	effectiveness	effectiveness	NOUN
bam-12937	104	7	in	in	ADP
bam-12937	104	8	lowering	lower	VERB
bam-12937	104	9	ldl	ldl	NOUN
bam-12937	104	10	-	-	PUNCT
bam-12937	104	11	c	c	NOUN
bam-12937	104	12	and	and	CCONJ
bam-12937	104	13	improving	improve	VERB
bam-12937	104	14	overall	overall	ADJ
bam-12937	104	15	lipid	lipid	NOUN
bam-12937	104	16	profiles	profile	NOUN
bam-12937	104	17	are	be	AUX
bam-12937	104	18	consistent	consistent	ADJ
bam-12937	104	19	with	with	ADP
bam-12937	104	20	prior	prior	ADJ
bam-12937	104	21	research	research	NOUN
bam-12937	104	22	on	on	ADP
bam-12937	104	23	pcsk9	pcsk9	NOUN
bam-12937	104	24	inhibitors	inhibitor	NOUN
bam-12937	104	25	for	for	ADP
bam-12937	104	26	dyslipidemia	dyslipidemia	NOUN
bam-12937	104	27	management	management	NOUN
bam-12937	104	28	.	.	PUNCT
bam-12937	105	1	the	the	DET
bam-12937	105	2	network	network	NOUN
bam-12937	105	3	meta	meta	NOUN
bam-12937	105	4	-	-	PUNCT
bam-12937	105	5	analysis	analysis	NOUN
bam-12937	105	6	by	by	ADP
bam-12937	105	7	toth	toth	PROPN
bam-12937	105	8	et	et	PROPN
bam-12937	105	9	al	al	PROPN
bam-12937	105	10	.	.	PROPN
bam-12937	105	11	(	(	PUNCT
bam-12937	105	12	2017	2017	NUM
bam-12937	105	13	)	)	PUNCT
bam-12937	105	14	strengthens	strengthen	VERB
bam-12937	105	15	these	these	DET
bam-12937	105	16	findings	finding	NOUN
bam-12937	105	17	by	by	ADP
bam-12937	105	18	positioning	positioning	NOUN
bam-12937	105	19	evolocumab	evolocumab	NOUN
bam-12937	105	20	among	among	ADP
bam-12937	105	21	the	the	DET
bam-12937	105	22	most	most	ADV
bam-12937	105	23	effective	effective	ADJ
bam-12937	105	24	non	non	ADJ
bam-12937	105	25	-	-	ADJ
bam-12937	105	26	statin	statin	ADJ
bam-12937	105	27	therapies	therapy	NOUN
bam-12937	105	28	for	for	ADP
bam-12937	105	29	ldl	ldl	NOUN
bam-12937	105	30	-	-	PUNCT
bam-12937	105	31	c	c	NOUN
bam-12937	105	32	reduction.15	reduction.15	NOUN
bam-12937	105	33	these	these	DET
bam-12937	105	34	observations	observation	NOUN
bam-12937	105	35	are	be	AUX
bam-12937	105	36	further	far	ADV
bam-12937	105	37	supported	support	VERB
bam-12937	105	38	by	by	ADP
bam-12937	105	39	rosenson	rosenson	PROPN
bam-12937	105	40	et	et	PROPN
bam-12937	105	41	al	al	PROPN
bam-12937	105	42	.	.	PROPN
bam-12937	106	1	(	(	PUNCT
bam-12937	106	2	2016	2016	NUM
bam-12937	106	3	)	)	PUNCT
bam-12937	106	4	,	,	PUNCT
bam-12937	106	5	whose	whose	DET
bam-12937	106	6	research	research	NOUN
bam-12937	106	7	indicates	indicate	VERB
bam-12937	106	8	evolocumab	evolocumab	NOUN
bam-12937	106	9	’s	’s	PART
bam-12937	106	10	effectiveness	effectiveness	NOUN
bam-12937	106	11	in	in	ADP
bam-12937	106	12	lowering	lower	VERB
bam-12937	106	13	ldl	ldl	NOUN
bam-12937	106	14	-	-	PUNCT
bam-12937	106	15	c	c	NOUN
bam-12937	106	16	for	for	ADP
bam-12937	106	17	patients	patient	NOUN
bam-12937	106	18	with	with	ADP
bam-12937	106	19	mixed	mixed	ADJ
bam-12937	106	20	hyperlipidemia.16	hyperlipidemia.16	PROPN
bam-12937	106	21	furthermore	furthermore	ADV
bam-12937	106	22	,	,	PUNCT
bam-12937	106	23	zhang	zhang	PROPN
bam-12937	106	24	et	et	PROPN
bam-12937	106	25	al	al	PROPN
bam-12937	106	26	.	.	PROPN
bam-12937	107	1	(	(	PUNCT
bam-12937	107	2	2022	2022	NUM
bam-12937	107	3	)	)	PUNCT
bam-12937	107	4	provide	provide	VERB
bam-12937	107	5	compelling	compelling	ADJ
bam-12937	107	6	data	datum	NOUN
bam-12937	107	7	from	from	ADP
bam-12937	107	8	a	a	DET
bam-12937	107	9	large	large	ADJ
bam-12937	107	10	-	-	PUNCT
bam-12937	107	11	scale	scale	NOUN
bam-12937	107	12	metaanalysis	metaanalysis	NOUN
bam-12937	107	13	,	,	PUNCT
bam-12937	107	14	demonstrating	demonstrate	VERB
bam-12937	107	15	significant	significant	ADJ
bam-12937	107	16	reductions	reduction	NOUN
bam-12937	107	17	in	in	ADP
bam-12937	107	18	ldl	ldl	NOUN
bam-12937	107	19	-	-	PUNCT
bam-12937	107	20	c	c	NOUN
bam-12937	107	21	,	,	PUNCT
bam-12937	107	22	triglycerides	triglyceride	NOUN
bam-12937	107	23	,	,	PUNCT
bam-12937	107	24	and	and	CCONJ
bam-12937	107	25	apob	apob	ADJ
bam-12937	107	26	with	with	ADP
bam-12937	107	27	pcsk9	pcsk9	PROPN
bam-12937	107	28	inhibitor	inhibitor	NOUN
bam-12937	107	29	use	use	NOUN
bam-12937	107	30	,	,	PUNCT
bam-12937	107	31	particularly	particularly	ADV
bam-12937	107	32	in	in	ADP
bam-12937	107	33	high	high	ADJ
bam-12937	107	34	-	-	PUNCT
bam-12937	107	35	risk	risk	NOUN
bam-12937	107	36	cardiovascular	cardiovascular	ADJ
bam-12937	107	37	patients.17	patients.17	NOUN
bam-12937	107	38	interestingly	interestingly	ADV
bam-12937	107	39	,	,	PUNCT
bam-12937	107	40	their	their	PRON
bam-12937	107	41	analysis	analysis	NOUN
bam-12937	107	42	also	also	ADV
bam-12937	107	43	revealed	reveal	VERB
bam-12937	107	44	an	an	DET
bam-12937	107	45	average	average	ADJ
bam-12937	107	46	increase	increase	NOUN
bam-12937	107	47	in	in	ADP
bam-12937	107	48	hdl	hdl	PROPN
bam-12937	107	49	-	-	PUNCT
bam-12937	107	50	c	c	PROPN
bam-12937	107	51	of	of	ADP
bam-12937	107	52	6.27	6.27	NUM
bam-12937	107	53	mg	mg	PROPN
bam-12937	107	54	/	/	SYM
bam-12937	107	55	dl	dl	PROPN
bam-12937	107	56	,	,	PUNCT
bam-12937	107	57	aligning	align	VERB
bam-12937	107	58	closely	closely	ADV
bam-12937	107	59	with	with	ADP
bam-12937	107	60	the	the	DET
bam-12937	107	61	4.5	4.5	NUM
bam-12937	107	62	mg	mg	PROPN
bam-12937	107	63	/	/	SYM
bam-12937	107	64	dl	dl	PROPN
bam-12937	107	65	increase	increase	NOUN
bam-12937	107	66	observed	observe	VERB
bam-12937	107	67	in	in	ADP
bam-12937	107	68	our	our	PRON
bam-12937	107	69	study	study	NOUN
bam-12937	107	70	.	.	PUNCT
bam-12937	108	1	taken	take	VERB
bam-12937	108	2	together	together	ADV
bam-12937	108	3	,	,	PUNCT
bam-12937	108	4	these	these	DET
bam-12937	108	5	findings	finding	NOUN
bam-12937	108	6	highlight	highlight	VERB
bam-12937	108	7	evolocumab	evolocumab	PROPN
bam-12937	108	8	’s	’s	PART
bam-12937	108	9	potential	potential	NOUN
bam-12937	108	10	as	as	ADP
bam-12937	108	11	a	a	DET
bam-12937	108	12	valuable	valuable	ADJ
bam-12937	108	13	therapeutic	therapeutic	ADJ
bam-12937	108	14	tool	tool	NOUN
bam-12937	108	15	for	for	ADP
bam-12937	108	16	managing	manage	VERB
bam-12937	108	17	a	a	DET
bam-12937	108	18	broad	broad	ADJ
bam-12937	108	19	spectrum	spectrum	NOUN
bam-12937	108	20	of	of	ADP
bam-12937	108	21	dyslipidemia	dyslipidemia	NOUN
bam-12937	108	22	,	,	PUNCT
bam-12937	108	23	especially	especially	ADV
bam-12937	108	24	for	for	ADP
bam-12937	108	25	those	those	PRON
bam-12937	108	26	with	with	ADP
bam-12937	108	27	high	high	ADJ
bam-12937	108	28	cardiovascular	cardiovascular	ADJ
bam-12937	108	29	risk	risk	NOUN
bam-12937	108	30	.	.	PUNCT
bam-12937	109	1	it	it	PRON
bam-12937	109	2	’s	’	VERB
bam-12937	109	3	important	important	ADJ
bam-12937	109	4	to	to	PART
bam-12937	109	5	note	note	VERB
bam-12937	109	6	that	that	SCONJ
bam-12937	109	7	some	some	DET
bam-12937	109	8	studies	study	NOUN
bam-12937	109	9	have	have	AUX
bam-12937	109	10	reported	report	VERB
bam-12937	109	11	slightly	slightly	ADV
bam-12937	109	12	higher	high	ADJ
bam-12937	109	13	or	or	CCONJ
bam-12937	109	14	lower	low	ADJ
bam-12937	109	15	average	average	ADJ
bam-12937	109	16	reductions	reduction	NOUN
bam-12937	109	17	in	in	ADP
bam-12937	109	18	ldl	ldl	NOUN
bam-12937	109	19	-	-	PUNCT
bam-12937	109	20	c	c	NOUN
bam-12937	109	21	depending	depend	VERB
bam-12937	109	22	on	on	ADP
bam-12937	109	23	factors	factor	NOUN
bam-12937	109	24	like	like	ADP
bam-12937	109	25	baseline	baseline	NOUN
bam-12937	109	26	ldl	ldl	PROPN
bam-12937	109	27	-	-	PUNCT
bam-12937	109	28	c	c	NOUN
bam-12937	109	29	levels	level	NOUN
bam-12937	109	30	,	,	PUNCT
bam-12937	109	31	treatment	treatment	NOUN
bam-12937	109	32	duration	duration	NOUN
bam-12937	109	33	,	,	PUNCT
bam-12937	109	34	and	and	CCONJ
bam-12937	109	35	patient	patient	ADJ
bam-12937	109	36	characteristics.18	characteristics.18	NOUN
bam-12937	109	37	however	however	ADV
bam-12937	109	38	,	,	PUNCT
bam-12937	109	39	the	the	DET
bam-12937	109	40	overall	overall	ADJ
bam-12937	109	41	consensus	consensus	NOUN
bam-12937	109	42	from	from	ADP
bam-12937	109	43	prior	prior	ADJ
bam-12937	109	44	research	research	NOUN
bam-12937	109	45	strongly	strongly	ADV
bam-12937	109	46	supports	support	VERB
bam-12937	109	47	the	the	DET
bam-12937	109	48	effectiveness	effectiveness	NOUN
bam-12937	109	49	of	of	ADP
bam-12937	109	50	evolocumab	evolocumab	NOUN
bam-12937	109	51	and	and	CCONJ
bam-12937	109	52	similar	similar	ADJ
bam-12937	109	53	pcsk9	pcsk9	NOUN
bam-12937	109	54	inhibitors	inhibitor	NOUN
bam-12937	109	55	in	in	ADP
bam-12937	109	56	significantly	significantly	ADV
bam-12937	109	57	improving	improve	VERB
bam-12937	109	58	lipid	lipid	ADJ
bam-12937	109	59	profiles	profile	NOUN
bam-12937	109	60	.	.	PUNCT
bam-12937	110	1	our	our	PRON
bam-12937	110	2	investigation	investigation	NOUN
bam-12937	110	3	explored	explore	VERB
bam-12937	110	4	potential	potential	ADJ
bam-12937	110	5	factors	factor	NOUN
bam-12937	110	6	influencing	influence	VERB
bam-12937	110	7	evolocumab	evolocumab	NOUN
bam-12937	110	8	’s	’s	PART
bam-12937	110	9	efficacy	efficacy	NOUN
bam-12937	110	10	.	.	PUNCT
bam-12937	111	1	while	while	SCONJ
bam-12937	111	2	we	we	PRON
bam-12937	111	3	did	do	AUX
bam-12937	111	4	not	not	PART
bam-12937	111	5	observe	observe	VERB
bam-12937	111	6	statistically	statistically	ADV
bam-12937	111	7	significant	significant	ADJ
bam-12937	111	8	interactions	interaction	NOUN
bam-12937	111	9	between	between	ADP
bam-12937	111	10	demographics	demographic	NOUN
bam-12937	111	11	(	(	PUNCT
bam-12937	111	12	age	age	NOUN
bam-12937	111	13	,	,	PUNCT
bam-12937	111	14	sex	sex	NOUN
bam-12937	111	15	,	,	PUNCT
bam-12937	111	16	bmi	bmi	NOUN
bam-12937	111	17	)	)	PUNCT
bam-12937	111	18	or	or	CCONJ
bam-12937	111	19	occasional	occasional	ADJ
bam-12937	111	20	lifestyle	lifestyle	NOUN
bam-12937	111	21	habits	habit	NOUN
bam-12937	111	22	(	(	PUNCT
bam-12937	111	23	smoking	smoking	NOUN
bam-12937	111	24	,	,	PUNCT
bam-12937	111	25	alcohol	alcohol	NOUN
bam-12937	111	26	consumption	consumption	NOUN
bam-12937	111	27	)	)	PUNCT
bam-12937	111	28	and	and	CCONJ
bam-12937	111	29	changes	change	NOUN
bam-12937	111	30	in	in	ADP
bam-12937	111	31	lipid	lipid	ADJ
bam-12937	111	32	levels	level	NOUN
bam-12937	111	33	,	,	PUNCT
bam-12937	111	34	a	a	DET
bam-12937	111	35	different	different	ADJ
bam-12937	111	36	pattern	pattern	NOUN
bam-12937	111	37	118	118	NUM
bam-12937	111	38	table	table	NOUN
bam-12937	111	39	6	6	NUM
bam-12937	111	40	.	.	PUNCT
bam-12937	112	1	linear	linear	ADJ
bam-12937	112	2	regression	regression	NOUN
bam-12937	112	3	analysis	analysis	NOUN
bam-12937	112	4	:	:	PUNCT
bam-12937	112	5	predictors	predictor	NOUN
bam-12937	112	6	of	of	ADP
bam-12937	112	7	changes	change	NOUN
bam-12937	112	8	in	in	ADP
bam-12937	112	9	lipid	lipid	NOUN
bam-12937	112	10	profile	profile	NOUN
bam-12937	112	11	after	after	ADP
bam-12937	112	12	evolocumab	evolocumab	ADP
bam-12937	112	13	treatment	treatment	NOUN
bam-12937	112	14	.	.	PUNCT
bam-12937	113	1	coefficients	coefficient	NOUN
bam-12937	113	2	dependent	dependent	ADJ
bam-12937	113	3	unstandardized	unstandardized	ADJ
bam-12937	113	4	standardized	standardized	ADJ
bam-12937	113	5	t	t	PROPN
bam-12937	113	6	sig	sig	PROPN
bam-12937	113	7	.	.	PUNCT
bam-12937	114	1	variable	variable	ADJ
bam-12937	114	2	coefficients	coefficient	NOUN
bam-12937	114	3	coefficients	coefficient	NOUN
bam-12937	114	4	b	b	PRON
bam-12937	114	5	std	std	X
bam-12937	114	6	.	.	NOUN
bam-12937	114	7	error	error	NOUN
bam-12937	114	8	beta	beta	NOUN
bam-12937	114	9	tg	tg	X
bam-12937	114	10	change	change	NOUN
bam-12937	114	11	(	(	PUNCT
bam-12937	114	12	constant	constant	ADJ
bam-12937	114	13	)	)	PUNCT
bam-12937	114	14	24.134	24.134	NUM
bam-12937	114	15	46.024	46.024	NUM
bam-12937	114	16	0.524	0.524	NUM
bam-12937	114	17	0.603	0.603	NUM
bam-12937	114	18	baseline	baseline	NOUN
bam-12937	114	19	tg	tg	X
bam-12937	114	20	-0.322	-0.322	PROPN
bam-12937	115	1	0.085	0.085	NUM
bam-12937	115	2	-0.487	-0.487	X
bam-12937	115	3	-3.799	-3.799	NOUN
bam-12937	115	4	0.000	0.000	NUM
bam-12937	115	5	*	*	PUNCT
bam-12937	115	6	age	age	NOUN
bam-12937	115	7	0.238	0.238	NUM
bam-12937	115	8	0.283	0.283	NUM
bam-12937	115	9	0.107	0.107	NUM
bam-12937	115	10	0.839	0.839	NUM
bam-12937	115	11	0.406	0.406	NUM
bam-12937	115	12	bmi	bmi	NOUN
bam-12937	115	13	index	index	NOUN
bam-12937	115	14	-0.383	-0.383	ADP
bam-12937	115	15	1.393	1.393	NUM
bam-12937	115	16	-0.035	-0.035	NOUN
bam-12937	115	17	-0.275	-0.275	NUM
bam-12937	115	18	0.785	0.785	NUM
bam-12937	115	19	ldl	ldl	NOUN
bam-12937	115	20	change	change	NOUN
bam-12937	115	21	(	(	PUNCT
bam-12937	115	22	constant	constant	ADJ
bam-12937	115	23	)	)	PUNCT
bam-12937	115	24	34.651	34.651	NUM
bam-12937	115	25	43.904	43.904	NUM
bam-12937	115	26	0.789	0.789	NUM
bam-12937	115	27	0.434	0.434	NUM
bam-12937	115	28	baseline	baseline	NOUN
bam-12937	115	29	ldl	ldl	NOUN
bam-12937	115	30	-.521	-.521	ADP
bam-12937	115	31	0.099	0.099	NUM
bam-12937	115	32	-0.648	-0.648	NUM
bam-12937	115	33	-5.251	-5.251	PUNCT
bam-12937	115	34	0.000	0.000	NUM
bam-12937	115	35	*	*	PUNCT
bam-12937	115	36	age	age	NOUN
bam-12937	115	37	-0.020	-0.020	PUNCT
bam-12937	115	38	0.244	0.244	NUM
bam-12937	115	39	-0.010	-0.010	PUNCT
bam-12937	115	40	-0.084	-0.084	PUNCT
bam-12937	115	41	0.934	0.934	NUM
bam-12937	115	42	bmi	bmi	NOUN
bam-12937	115	43	index	index	NOUN
bam-12937	115	44	-0.792	-0.792	PUNCT
bam-12937	115	45	1.116	1.116	NUM
bam-12937	115	46	-0.081	-0.081	NUM
bam-12937	115	47	-0.710	-0.710	NUM
bam-12937	115	48	0.482	0.482	NUM
bam-12937	115	49	hdl	hdl	NOUN
bam-12937	115	50	change	change	NOUN
bam-12937	115	51	(	(	PUNCT
bam-12937	115	52	constant	constant	ADJ
bam-12937	115	53	)	)	PUNCT
bam-12937	115	54	10.556	10.556	NUM
bam-12937	115	55	5.093	5.093	NUM
bam-12937	115	56	2.073	2.073	NUM
bam-12937	115	57	0.044	0.044	NUM
bam-12937	115	58	baseline	baseline	NOUN
bam-12937	115	59	hdl	hdl	PROPN
bam-12937	115	60	-0.173	-0.173	PROPN
bam-12937	115	61	0.062	0.062	NUM
bam-12937	115	62	-0.384	-0.384	X
bam-12937	115	63	-2.781	-2.781	PUNCT
bam-12937	115	64	0.008	0.008	NUM
bam-12937	115	65	*	*	NOUN
bam-12937	115	66	age	age	NOUN
bam-12937	115	67	0.023	0.023	NUM
bam-12937	115	68	0.033	0.033	NUM
bam-12937	115	69	0.094	0.094	NUM
bam-12937	115	70	0.681	0.681	NUM
bam-12937	115	71	0.500	0.500	NUM
bam-12937	115	72	bmi	bmi	NOUN
bam-12937	115	73	index	index	NOUN
bam-12937	115	74	0.015	0.015	NUM
bam-12937	115	75	0.162	0.162	NUM
bam-12937	115	76	0.012	0.012	NUM
bam-12937	115	77	0.090	0.090	NUM
bam-12937	115	78	0.929	0.929	NUM
bam-12937	115	79	*	*	PUNCT
bam-12937	115	80	significant	significant	ADJ
bam-12937	115	81	.	.	PUNCT
bam-12937	116	1	non	non	ADJ
bam-12937	116	2	-co	-co	PROPN
bam-12937	116	3	mmerc	mmerc	PROPN
bam-12937	116	4	ial	ial	PROPN
bam-12937	116	5	us	us	PROPN
bam-12937	117	1	e	e	NOUN
bam-12937	117	2	o	o	X
bam-12937	117	3	nly	nly	ADV
bam-12937	117	4	the	the	DET
bam-12937	117	5	therapeutic	therapeutic	ADJ
bam-12937	117	6	effect	effect	NOUN
bam-12937	117	7	of	of	ADP
bam-12937	117	8	pcsk9	pcsk9	NOUN
bam-12937	117	9	inhibitors	inhibitor	NOUN
bam-12937	117	10	on	on	ADP
bam-12937	117	11	dyslipidemia	dyslipidemia	NOUN
bam-12937	117	12	:	:	PUNCT
bam-12937	117	13	one	one	NUM
bam-12937	117	14	-	-	PUNCT
bam-12937	117	15	year	year	NOUN
bam-12937	117	16	follow	follow	VERB
bam-12937	117	17	up	up	ADP
bam-12937	117	18	eur	eur	PROPN
bam-12937	117	19	j	j	PROPN
bam-12937	117	20	transl	transl	PROPN
bam-12937	117	21	myol	myol	NOUN
bam-12937	117	22	34	34	NUM
bam-12937	117	23	(	(	PUNCT
bam-12937	117	24	3	3	NUM
bam-12937	117	25	)	)	PUNCT
bam-12937	117	26	12937	12937	NUM
bam-12937	117	27	,	,	PUNCT
bam-12937	117	28	2024	2024	NUM
bam-12937	117	29	doi	doi	NOUN
bam-12937	117	30	:	:	PUNCT
bam-12937	117	31	10.4081	10.4081	NUM
bam-12937	117	32	/	/	SYM
bam-12937	117	33	ejtm.2024.12937	ejtm.2024.12937	PROPN
bam-12937	117	34	emerged	emerge	VERB
bam-12937	117	35	when	when	SCONJ
bam-12937	117	36	considering	consider	VERB
bam-12937	117	37	baseline	baseline	NOUN
bam-12937	117	38	lipid	lipid	NOUN
bam-12937	117	39	levels	level	NOUN
bam-12937	117	40	.	.	PUNCT
bam-12937	118	1	there	there	PRON
bam-12937	118	2	was	be	VERB
bam-12937	118	3	a	a	DET
bam-12937	118	4	statistically	statistically	ADV
bam-12937	118	5	significant	significant	ADJ
bam-12937	118	6	interaction	interaction	NOUN
bam-12937	118	7	between	between	ADP
bam-12937	118	8	baseline	baseline	NOUN
bam-12937	118	9	levels	level	NOUN
bam-12937	118	10	(	(	PUNCT
bam-12937	118	11	ldl	ldl	NOUN
bam-12937	118	12	-	-	PUNCT
bam-12937	118	13	c	c	NOUN
bam-12937	118	14	,	,	PUNCT
bam-12937	118	15	triglycerides	triglyceride	NOUN
bam-12937	118	16	,	,	PUNCT
bam-12937	118	17	hdl	hdl	NOUN
bam-12937	118	18	-	-	PUNCT
bam-12937	118	19	c	c	NOUN
bam-12937	118	20	)	)	PUNCT
bam-12937	118	21	and	and	CCONJ
bam-12937	118	22	their	their	PRON
bam-12937	118	23	corresponding	corresponding	ADJ
bam-12937	118	24	changes	change	NOUN
bam-12937	118	25	after	after	ADP
bam-12937	118	26	evolocumab	evolocumab	ADP
bam-12937	118	27	treatment	treatment	NOUN
bam-12937	118	28	.	.	PUNCT
bam-12937	119	1	this	this	PRON
bam-12937	119	2	suggests	suggest	VERB
bam-12937	119	3	that	that	SCONJ
bam-12937	119	4	patients	patient	NOUN
bam-12937	119	5	with	with	ADP
bam-12937	119	6	higher	high	ADJ
bam-12937	119	7	baseline	baseline	NOUN
bam-12937	119	8	lipid	lipid	NOUN
bam-12937	119	9	levels	level	NOUN
bam-12937	119	10	experienced	experience	VERB
bam-12937	119	11	a	a	DET
bam-12937	119	12	greater	great	ADJ
bam-12937	119	13	reduction	reduction	NOUN
bam-12937	119	14	in	in	ADP
bam-12937	119	15	those	those	DET
bam-12937	119	16	specific	specific	ADJ
bam-12937	119	17	lipids	lipid	NOUN
bam-12937	119	18	compared	compare	VERB
bam-12937	119	19	to	to	ADP
bam-12937	119	20	those	those	PRON
bam-12937	119	21	with	with	ADP
bam-12937	119	22	lower	low	ADJ
bam-12937	119	23	baseline	baseline	NOUN
bam-12937	119	24	values	value	NOUN
bam-12937	119	25	.	.	PUNCT
bam-12937	120	1	this	this	DET
bam-12937	120	2	finding	finding	NOUN
bam-12937	120	3	aligns	align	VERB
bam-12937	120	4	with	with	ADP
bam-12937	120	5	observations	observation	NOUN
bam-12937	120	6	in	in	ADP
bam-12937	120	7	some	some	DET
bam-12937	120	8	prior	prior	ADJ
bam-12937	120	9	research.19	research.19	NOUN
bam-12937	120	10	evolocumab	evolocumab	NOUN
bam-12937	120	11	’s	’s	PART
bam-12937	120	12	mechanism	mechanism	NOUN
bam-12937	120	13	of	of	ADP
bam-12937	120	14	action	action	NOUN
bam-12937	120	15	,	,	PUNCT
bam-12937	120	16	by	by	ADP
bam-12937	120	17	inhibiting	inhibit	VERB
bam-12937	120	18	pcsk9	pcsk9	NOUN
bam-12937	120	19	and	and	CCONJ
bam-12937	120	20	promoting	promote	VERB
bam-12937	120	21	ldl	ldl	NOUN
bam-12937	120	22	-	-	PUNCT
bam-12937	120	23	c	c	NOUN
bam-12937	120	24	clearance	clearance	NOUN
bam-12937	120	25	,	,	PUNCT
bam-12937	120	26	likely	likely	ADV
bam-12937	120	27	contributes	contribute	VERB
bam-12937	120	28	to	to	ADP
bam-12937	120	29	the	the	DET
bam-12937	120	30	significant	significant	ADJ
bam-12937	120	31	improvements	improvement	NOUN
bam-12937	120	32	in	in	ADP
bam-12937	120	33	lipid	lipid	NOUN
bam-12937	120	34	profiles	profile	NOUN
bam-12937	120	35	observed	observe	VERB
bam-12937	120	36	in	in	ADP
bam-12937	120	37	our	our	PRON
bam-12937	120	38	study.20	study.20	NOUN
bam-12937	120	39	this	this	PRON
bam-12937	120	40	aligns	align	VERB
bam-12937	120	41	with	with	ADP
bam-12937	120	42	the	the	DET
bam-12937	120	43	growing	grow	VERB
bam-12937	120	44	recognition	recognition	NOUN
bam-12937	120	45	of	of	ADP
bam-12937	120	46	pcsk9	pcsk9	NOUN
bam-12937	120	47	inhibitors	inhibitor	NOUN
bam-12937	120	48	as	as	ADP
bam-12937	120	49	a	a	DET
bam-12937	120	50	valuable	valuable	ADJ
bam-12937	120	51	therapeutic	therapeutic	ADJ
bam-12937	120	52	approach	approach	NOUN
bam-12937	120	53	,	,	PUNCT
bam-12937	120	54	particularly	particularly	ADV
bam-12937	120	55	for	for	ADP
bam-12937	120	56	high	high	ADJ
bam-12937	120	57	-	-	PUNCT
bam-12937	120	58	risk	risk	NOUN
bam-12937	120	59	patients	patient	NOUN
bam-12937	120	60	like	like	ADP
bam-12937	120	61	those	those	PRON
bam-12937	120	62	with	with	ADP
bam-12937	120	63	fh	fh	PROPN
bam-12937	120	64	.	.	PROPN
bam-12937	121	1	as	as	SCONJ
bam-12937	121	2	highlighted	highlight	VERB
bam-12937	121	3	by	by	ADP
bam-12937	121	4	mohamed	mohamed	PROPN
bam-12937	121	5	et	et	PROPN
bam-12937	121	6	al	al	PROPN
bam-12937	121	7	.	.	PROPN
bam-12937	122	1	(	(	PUNCT
bam-12937	122	2	2023	2023	NUM
bam-12937	122	3	)	)	PUNCT
bam-12937	122	4	,	,	PUNCT
bam-12937	122	5	statin	statin	PROPN
bam-12937	122	6	monotherapy	monotherapy	NOUN
bam-12937	122	7	often	often	ADV
bam-12937	122	8	falls	fall	VERB
bam-12937	122	9	short	short	ADJ
bam-12937	122	10	in	in	ADP
bam-12937	122	11	achieving	achieve	VERB
bam-12937	122	12	optimal	optimal	ADJ
bam-12937	122	13	ldl	ldl	NOUN
bam-12937	122	14	-	-	PUNCT
bam-12937	122	15	c	c	NOUN
bam-12937	122	16	reduction	reduction	NOUN
bam-12937	122	17	for	for	ADP
bam-12937	122	18	such	such	ADJ
bam-12937	122	19	patients.21	patients.21	ADJ
bam-12937	122	20	pcsk9	pcsk9	NOUN
bam-12937	122	21	inhibitors	inhibitor	NOUN
bam-12937	122	22	,	,	PUNCT
bam-12937	122	23	as	as	SCONJ
bam-12937	122	24	discussed	discuss	VERB
bam-12937	122	25	in	in	ADP
bam-12937	122	26	their	their	PRON
bam-12937	122	27	review	review	NOUN
bam-12937	122	28	,	,	PUNCT
bam-12937	122	29	offer	offer	VERB
bam-12937	122	30	a	a	DET
bam-12937	122	31	promising	promising	ADJ
bam-12937	122	32	alternative	alternative	NOUN
bam-12937	122	33	with	with	ADP
bam-12937	122	34	the	the	DET
bam-12937	122	35	potential	potential	NOUN
bam-12937	122	36	to	to	PART
bam-12937	122	37	improve	improve	VERB
bam-12937	122	38	cardiovascular	cardiovascular	ADJ
bam-12937	122	39	outcomes	outcome	NOUN
bam-12937	122	40	.	.	PUNCT
bam-12937	123	1	our	our	PRON
bam-12937	123	2	findings	finding	NOUN
bam-12937	123	3	on	on	ADP
bam-12937	123	4	evolocumab	evolocumab	NOUN
bam-12937	123	5	’s	’s	PART
bam-12937	123	6	efficacy	efficacy	NOUN
bam-12937	123	7	are	be	AUX
bam-12937	123	8	further	far	ADV
bam-12937	123	9	bolstered	bolster	VERB
bam-12937	123	10	by	by	ADP
bam-12937	123	11	research	research	NOUN
bam-12937	123	12	on	on	ADP
bam-12937	123	13	other	other	ADJ
bam-12937	123	14	pcsk9	pcsk9	NOUN
bam-12937	123	15	inhibitors	inhibitor	NOUN
bam-12937	123	16	.	.	PUNCT
bam-12937	124	1	the	the	DET
bam-12937	124	2	ginsberg	ginsberg	PROPN
bam-12937	124	3	et	et	PROPN
bam-12937	124	4	al	al	PROPN
bam-12937	124	5	.	.	PROPN
bam-12937	125	1	(	(	PUNCT
bam-12937	125	2	2016	2016	NUM
bam-12937	125	3	)	)	PUNCT
bam-12937	125	4	study	study	NOUN
bam-12937	125	5	with	with	ADP
bam-12937	125	6	alirocumab	alirocumab	NOUN
bam-12937	125	7	demonstrates	demonstrate	VERB
bam-12937	125	8	positive	positive	ADJ
bam-12937	125	9	outcomes	outcome	NOUN
bam-12937	125	10	in	in	ADP
bam-12937	125	11	patients	patient	NOUN
bam-12937	125	12	with	with	ADP
bam-12937	125	13	fh	fh	PROPN
bam-12937	125	14	despite	despite	SCONJ
bam-12937	125	15	maximized	maximized	ADJ
bam-12937	125	16	statin	statin	PROPN
bam-12937	125	17	therapy.22	therapy.22	NOUN
bam-12937	125	18	this	this	PRON
bam-12937	125	19	reinforces	reinforce	VERB
bam-12937	125	20	the	the	DET
bam-12937	125	21	effectiveness	effectiveness	NOUN
bam-12937	125	22	of	of	ADP
bam-12937	125	23	this	this	DET
bam-12937	125	24	drug	drug	NOUN
bam-12937	125	25	class	class	NOUN
bam-12937	125	26	in	in	ADP
bam-12937	125	27	a	a	DET
bam-12937	125	28	population	population	NOUN
bam-12937	125	29	highly	highly	ADV
bam-12937	125	30	similar	similar	ADJ
bam-12937	125	31	to	to	ADP
bam-12937	125	32	our	our	PRON
bam-12937	125	33	own	own	ADJ
bam-12937	125	34	,	,	PUNCT
bam-12937	125	35	strengthening	strengthen	VERB
bam-12937	125	36	the	the	DET
bam-12937	125	37	generalizability	generalizability	NOUN
bam-12937	125	38	of	of	ADP
bam-12937	125	39	our	our	PRON
bam-12937	125	40	observations	observation	NOUN
bam-12937	125	41	to	to	ADP
bam-12937	125	42	a	a	DET
bam-12937	125	43	broader	broad	ADJ
bam-12937	125	44	range	range	NOUN
bam-12937	125	45	of	of	ADP
bam-12937	125	46	high	high	ADJ
bam-12937	125	47	-	-	PUNCT
bam-12937	125	48	risk	risk	NOUN
bam-12937	125	49	fh	fh	PROPN
bam-12937	125	50	patients	patient	NOUN
bam-12937	125	51	.	.	PUNCT
bam-12937	126	1	together	together	ADV
bam-12937	126	2	,	,	PUNCT
bam-12937	126	3	these	these	DET
bam-12937	126	4	studies	study	NOUN
bam-12937	126	5	support	support	VERB
bam-12937	126	6	the	the	DET
bam-12937	126	7	rationale	rationale	NOUN
bam-12937	126	8	behind	behind	ADP
bam-12937	126	9	our	our	PRON
bam-12937	126	10	investigation	investigation	NOUN
bam-12937	126	11	–	–	PUNCT
bam-12937	126	12	to	to	PART
bam-12937	126	13	explore	explore	VERB
bam-12937	126	14	alternative	alternative	ADJ
bam-12937	126	15	options	option	NOUN
bam-12937	126	16	for	for	ADP
bam-12937	126	17	effectively	effectively	ADV
bam-12937	126	18	managing	manage	VERB
bam-12937	126	19	ldlc	ldlc	NOUN
bam-12937	126	20	in	in	ADP
bam-12937	126	21	high	high	ADJ
bam-12937	126	22	-	-	PUNCT
bam-12937	126	23	risk	risk	NOUN
bam-12937	126	24	individuals	individual	NOUN
bam-12937	126	25	.	.	PUNCT
bam-12937	127	1	our	our	PRON
bam-12937	127	2	study	study	NOUN
bam-12937	127	3	findings	finding	NOUN
bam-12937	127	4	,	,	PUNCT
bam-12937	127	5	combined	combine	VERB
bam-12937	127	6	with	with	ADP
bam-12937	127	7	the	the	DET
bam-12937	127	8	existing	exist	VERB
bam-12937	127	9	body	body	NOUN
bam-12937	127	10	of	of	ADP
bam-12937	127	11	research	research	NOUN
bam-12937	127	12	,	,	PUNCT
bam-12937	127	13	provide	provide	VERB
bam-12937	127	14	compelling	compelling	ADJ
bam-12937	127	15	evidence	evidence	NOUN
bam-12937	127	16	for	for	ADP
bam-12937	127	17	evolocumab	evolocumab	NOUN
bam-12937	127	18	’s	’s	PART
bam-12937	127	19	efficacy	efficacy	NOUN
bam-12937	127	20	in	in	ADP
bam-12937	127	21	improving	improve	VERB
bam-12937	127	22	lipid	lipid	ADJ
bam-12937	127	23	profiles	profile	NOUN
bam-12937	127	24	in	in	ADP
bam-12937	127	25	patients	patient	NOUN
bam-12937	127	26	with	with	ADP
bam-12937	127	27	fh	fh	PROPN
bam-12937	127	28	,	,	PUNCT
bam-12937	127	29	offering	offer	VERB
bam-12937	127	30	a	a	DET
bam-12937	127	31	valuable	valuable	ADJ
bam-12937	127	32	tool	tool	NOUN
bam-12937	127	33	for	for	ADP
bam-12937	127	34	managing	manage	VERB
bam-12937	127	35	dyslipidemia	dyslipidemia	NOUN
bam-12937	127	36	in	in	ADP
bam-12937	127	37	this	this	DET
bam-12937	127	38	high	high	ADJ
bam-12937	127	39	-	-	PUNCT
bam-12937	127	40	risk	risk	NOUN
bam-12937	127	41	population	population	NOUN
bam-12937	127	42	.	.	PUNCT
bam-12937	128	1	furthermore	furthermore	ADV
bam-12937	128	2	,	,	PUNCT
bam-12937	128	3	evolocumab	evolocumab	ADP
bam-12937	128	4	’s	’s	PART
bam-12937	128	5	impact	impact	NOUN
bam-12937	128	6	may	may	AUX
bam-12937	128	7	extend	extend	VERB
bam-12937	128	8	beyond	beyond	ADP
bam-12937	128	9	simply	simply	ADV
bam-12937	128	10	lowering	lower	VERB
bam-12937	128	11	ldl	ldl	NOUN
bam-12937	128	12	-	-	NOUN
bam-12937	128	13	c.	c.	NOUN
bam-12937	128	14	although	although	SCONJ
bam-12937	128	15	the	the	DET
bam-12937	128	16	exact	exact	ADJ
bam-12937	128	17	mechanisms	mechanism	NOUN
bam-12937	128	18	remain	remain	VERB
bam-12937	128	19	under	under	ADP
bam-12937	128	20	investigation	investigation	NOUN
bam-12937	128	21	,	,	PUNCT
bam-12937	128	22	some	some	DET
bam-12937	128	23	studies	study	NOUN
bam-12937	128	24	suggest	suggest	VERB
bam-12937	128	25	evolocumab	evolocumab	NOUN
bam-12937	128	26	may	may	AUX
bam-12937	128	27	indirectly	indirectly	ADV
bam-12937	128	28	influence	influence	VERB
bam-12937	128	29	hdl	hdl	PROPN
bam-12937	128	30	-	-	PUNCT
bam-12937	128	31	c	c	PROPN
bam-12937	128	32	levels.23	levels.23	VERB
bam-12937	128	33	this	this	DET
bam-12937	128	34	potential	potential	ADJ
bam-12937	128	35	influence	influence	NOUN
bam-12937	128	36	could	could	AUX
bam-12937	128	37	involve	involve	VERB
bam-12937	128	38	stimulating	stimulate	VERB
bam-12937	128	39	hdl	hdl	ADJ
bam-12937	128	40	production	production	NOUN
bam-12937	128	41	or	or	CCONJ
bam-12937	128	42	reducing	reduce	VERB
bam-12937	128	43	its	its	PRON
bam-12937	128	44	breakdown	breakdown	NOUN
bam-12937	128	45	within	within	ADP
bam-12937	128	46	the	the	DET
bam-12937	128	47	body	body	NOUN
bam-12937	128	48	,	,	PUNCT
bam-12937	128	49	leading	lead	VERB
bam-12937	128	50	to	to	ADP
bam-12937	128	51	the	the	DET
bam-12937	128	52	modest	modest	ADJ
bam-12937	128	53	increase	increase	NOUN
bam-12937	128	54	in	in	ADP
bam-12937	128	55	hdl	hdl	PROPN
bam-12937	128	56	-	-	PUNCT
bam-12937	128	57	c	c	PROPN
bam-12937	128	58	observed	observe	VERB
bam-12937	128	59	in	in	ADP
bam-12937	128	60	our	our	PRON
bam-12937	128	61	study	study	NOUN
bam-12937	128	62	(	(	PUNCT
bam-12937	128	63	4.5	4.5	NUM
bam-12937	128	64	mg	mg	PROPN
bam-12937	128	65	/	/	SYM
bam-12937	128	66	dl	dl	NOUN
bam-12937	128	67	)	)	PUNCT
bam-12937	128	68	.	.	PUNCT
bam-12937	129	1	these	these	DET
bam-12937	129	2	combined	combine	VERB
bam-12937	129	3	effects	effect	NOUN
bam-12937	129	4	of	of	ADP
bam-12937	129	5	evolocumab	evolocumab	NOUN
bam-12937	129	6	on	on	ADP
bam-12937	129	7	both	both	CCONJ
bam-12937	129	8	ldl	ldl	NOUN
bam-12937	129	9	-	-	PUNCT
bam-12937	129	10	c	c	PROPN
bam-12937	129	11	and	and	CCONJ
bam-12937	129	12	hdl	hdl	PROPN
bam-12937	129	13	-	-	PUNCT
bam-12937	129	14	c	c	PROPN
bam-12937	129	15	have	have	VERB
bam-12937	129	16	the	the	DET
bam-12937	129	17	potential	potential	NOUN
bam-12937	129	18	to	to	PART
bam-12937	129	19	translate	translate	VERB
bam-12937	129	20	into	into	ADP
bam-12937	129	21	significant	significant	ADJ
bam-12937	129	22	clinical	clinical	ADJ
bam-12937	129	23	benefits	benefit	NOUN
bam-12937	129	24	.	.	PUNCT
bam-12937	130	1	a	a	DET
bam-12937	130	2	lower	low	ADJ
bam-12937	130	3	ldl	ldl	NOUN
bam-12937	130	4	-	-	PUNCT
bam-12937	130	5	c	c	NOUN
bam-12937	130	6	level	level	NOUN
bam-12937	130	7	and	and	CCONJ
bam-12937	130	8	a	a	DET
bam-12937	130	9	more	more	ADV
bam-12937	130	10	favorable	favorable	ADJ
bam-12937	130	11	ldl	ldl	NOUN
bam-12937	130	12	-	-	PUNCT
bam-12937	130	13	c	c	NOUN
bam-12937	130	14	to	to	ADP
bam-12937	130	15	hdl	hdl	PROPN
bam-12937	130	16	-	-	PUNCT
bam-12937	130	17	c	c	NOUN
bam-12937	130	18	ratio	ratio	NOUN
bam-12937	130	19	are	be	AUX
bam-12937	130	20	well	well	ADV
bam-12937	130	21	-	-	PUNCT
bam-12937	130	22	established	establish	VERB
bam-12937	130	23	risk	risk	NOUN
bam-12937	130	24	factors	factor	NOUN
bam-12937	130	25	for	for	ADP
bam-12937	130	26	atherosclerosis	atherosclerosis	NOUN
bam-12937	130	27	,	,	PUNCT
bam-12937	130	28	the	the	DET
bam-12937	130	29	hardening	hardening	NOUN
bam-12937	130	30	and	and	CCONJ
bam-12937	130	31	narrowing	narrowing	NOUN
bam-12937	130	32	of	of	ADP
bam-12937	130	33	arteries	artery	NOUN
bam-12937	130	34	due	due	ADP
bam-12937	130	35	to	to	ADP
bam-12937	130	36	plaque	plaque	NOUN
bam-12937	130	37	buildup	buildup	NOUN
bam-12937	130	38	.	.	PUNCT
bam-12937	131	1	atherosclerosis	atherosclerosis	NOUN
bam-12937	131	2	is	be	AUX
bam-12937	131	3	a	a	DET
bam-12937	131	4	major	major	ADJ
bam-12937	131	5	precursor	precursor	NOUN
bam-12937	131	6	to	to	ADP
bam-12937	131	7	various	various	ADJ
bam-12937	131	8	cardiovascular	cardiovascular	ADJ
bam-12937	131	9	events	event	NOUN
bam-12937	131	10	,	,	PUNCT
bam-12937	131	11	including	include	VERB
bam-12937	131	12	myocardial	myocardial	ADJ
bam-12937	131	13	infarction	infarction	NOUN
bam-12937	131	14	and	and	CCONJ
bam-12937	131	15	stroke	stroke	NOUN
bam-12937	131	16	.	.	PUNCT
bam-12937	132	1	therefore	therefore	ADV
bam-12937	132	2	,	,	PUNCT
bam-12937	132	3	evolocumab	evolocumab	ADP
bam-12937	132	4	’s	’s	PART
bam-12937	132	5	capacity	capacity	NOUN
bam-12937	132	6	to	to	PART
bam-12937	132	7	improve	improve	VERB
bam-12937	132	8	both	both	PRON
bam-12937	132	9	ldl	ldl	NOUN
bam-12937	132	10	-	-	PUNCT
bam-12937	132	11	c	c	PROPN
bam-12937	132	12	and	and	CCONJ
bam-12937	132	13	hdl	hdl	PROPN
bam-12937	132	14	-	-	PUNCT
bam-12937	132	15	c	c	PROPN
bam-12937	132	16	holds	hold	VERB
bam-12937	132	17	promise	promise	NOUN
bam-12937	132	18	for	for	ADP
bam-12937	132	19	mitigating	mitigate	VERB
bam-12937	132	20	cardiovascular	cardiovascular	ADJ
bam-12937	132	21	risk	risk	NOUN
bam-12937	132	22	in	in	ADP
bam-12937	132	23	patients	patient	NOUN
bam-12937	132	24	with	with	ADP
bam-12937	132	25	familial	familial	ADJ
bam-12937	132	26	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	132	27	.	.	PUNCT
bam-12937	133	1	based	base	VERB
bam-12937	133	2	on	on	ADP
bam-12937	133	3	our	our	PRON
bam-12937	133	4	results	result	NOUN
bam-12937	133	5	,	,	PUNCT
bam-12937	133	6	it	it	PRON
bam-12937	133	7	is	be	AUX
bam-12937	133	8	noteworthy	noteworthy	ADJ
bam-12937	133	9	that	that	SCONJ
bam-12937	133	10	a	a	DET
bam-12937	133	11	considerable	considerable	ADJ
bam-12937	133	12	proportion	proportion	NOUN
bam-12937	133	13	of	of	ADP
bam-12937	133	14	the	the	DET
bam-12937	133	15	study	study	NOUN
bam-12937	133	16	population	population	NOUN
bam-12937	133	17	had	have	VERB
bam-12937	133	18	a	a	DET
bam-12937	133	19	high	high	ADJ
bam-12937	133	20	cardiovascular	cardiovascular	ADJ
bam-12937	133	21	risk	risk	NOUN
bam-12937	133	22	burden	burden	NOUN
bam-12937	133	23	,	,	PUNCT
bam-12937	133	24	with	with	ADP
bam-12937	133	25	approximately	approximately	ADV
bam-12937	133	26	half	half	NOUN
bam-12937	133	27	(	(	PUNCT
bam-12937	133	28	50	50	NUM
bam-12937	133	29	%	%	NOUN
bam-12937	133	30	,	,	PUNCT
bam-12937	133	31	n	n	NOUN
bam-12937	133	32	=	=	SYM
bam-12937	133	33	25	25	NUM
bam-12937	133	34	)	)	PUNCT
bam-12937	133	35	of	of	ADP
bam-12937	133	36	the	the	DET
bam-12937	133	37	participants	participant	NOUN
bam-12937	133	38	had	have	AUX
bam-12937	133	39	undergone	undergo	VERB
bam-12937	133	40	coronary	coronary	ADJ
bam-12937	133	41	angiography	angiography	NOUN
bam-12937	133	42	before	before	ADP
bam-12937	133	43	study	study	NOUN
bam-12937	133	44	enrollment	enrollment	NOUN
bam-12937	133	45	,	,	PUNCT
bam-12937	133	46	and	and	CCONJ
bam-12937	133	47	nearly	nearly	ADV
bam-12937	133	48	half	half	NOUN
bam-12937	133	49	(	(	PUNCT
bam-12937	133	50	46	46	NUM
bam-12937	133	51	%	%	NOUN
bam-12937	133	52	,	,	PUNCT
bam-12937	133	53	n	n	NOUN
bam-12937	133	54	=	=	SYM
bam-12937	133	55	23	23	NUM
bam-12937	133	56	)	)	PUNCT
bam-12937	133	57	had	have	VERB
bam-12937	133	58	a	a	DET
bam-12937	133	59	documented	document	VERB
bam-12937	133	60	prior	prior	ADJ
bam-12937	133	61	admission	admission	NOUN
bam-12937	133	62	to	to	ADP
bam-12937	133	63	the	the	DET
bam-12937	133	64	coronary	coronary	ADJ
bam-12937	133	65	care	care	NOUN
bam-12937	133	66	unit	unit	NOUN
bam-12937	133	67	(	(	PUNCT
bam-12937	133	68	ccu	ccu	PROPN
bam-12937	133	69	)	)	PUNCT
bam-12937	133	70	.	.	PUNCT
bam-12937	134	1	these	these	DET
bam-12937	134	2	findings	finding	NOUN
bam-12937	134	3	underscore	underscore	VERB
bam-12937	134	4	the	the	DET
bam-12937	134	5	pre	pre	ADJ
bam-12937	134	6	-	-	ADJ
bam-12937	134	7	existing	exist	VERB
bam-12937	134	8	cardiovascular	cardiovascular	ADJ
bam-12937	134	9	risk	risk	NOUN
bam-12937	134	10	burden	burden	NOUN
bam-12937	134	11	faced	face	VERB
bam-12937	134	12	by	by	ADP
bam-12937	134	13	many	many	ADJ
bam-12937	134	14	patients	patient	NOUN
bam-12937	134	15	with	with	ADP
bam-12937	134	16	familial	familial	ADJ
bam-12937	134	17	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	134	18	.	.	PUNCT
bam-12937	135	1	encouragingly	encouragingly	ADV
bam-12937	135	2	,	,	PUNCT
bam-12937	135	3	none	none	NOUN
bam-12937	135	4	of	of	ADP
bam-12937	135	5	the	the	DET
bam-12937	135	6	participants	participant	NOUN
bam-12937	135	7	experienced	experience	VERB
bam-12937	135	8	new	new	ADJ
bam-12937	135	9	cardiovascular	cardiovascular	ADJ
bam-12937	135	10	events	event	NOUN
bam-12937	135	11	during	during	ADP
bam-12937	135	12	the	the	DET
bam-12937	135	13	one	one	NUM
bam-12937	135	14	-	-	PUNCT
bam-12937	135	15	year	year	NOUN
bam-12937	135	16	follow	follow	NOUN
bam-12937	135	17	-	-	PUNCT
bam-12937	135	18	up	up	NOUN
bam-12937	135	19	,	,	PUNCT
bam-12937	135	20	including	include	VERB
bam-12937	135	21	those	those	PRON
bam-12937	135	22	with	with	ADP
bam-12937	135	23	a	a	DET
bam-12937	135	24	history	history	NOUN
bam-12937	135	25	of	of	ADP
bam-12937	135	26	mi	mi	PROPN
bam-12937	135	27	,	,	PUNCT
bam-12937	135	28	pci	pci	ADJ
bam-12937	135	29	,	,	PUNCT
bam-12937	135	30	cabg	cabg	ADJ
bam-12937	135	31	,	,	PUNCT
bam-12937	135	32	or	or	CCONJ
bam-12937	135	33	pad	pad	NOUN
bam-12937	135	34	.	.	PUNCT
bam-12937	136	1	while	while	SCONJ
bam-12937	136	2	our	our	PRON
bam-12937	136	3	study	study	NOUN
bam-12937	136	4	design	design	NOUN
bam-12937	136	5	precludes	preclude	VERB
bam-12937	136	6	definitive	definitive	ADJ
bam-12937	136	7	conclusions	conclusion	NOUN
bam-12937	136	8	about	about	ADP
bam-12937	136	9	evolocumab	evolocumab	NOUN
bam-12937	136	10	’s	’s	PART
bam-12937	136	11	long	long	ADJ
bam-12937	136	12	-	-	PUNCT
bam-12937	136	13	term	term	NOUN
bam-12937	136	14	impact	impact	NOUN
bam-12937	136	15	on	on	ADP
bam-12937	136	16	cardiovascular	cardiovascular	ADJ
bam-12937	136	17	events	event	NOUN
bam-12937	136	18	,	,	PUNCT
bam-12937	136	19	these	these	DET
bam-12937	136	20	initial	initial	ADJ
bam-12937	136	21	observations	observation	NOUN
bam-12937	136	22	are	be	AUX
bam-12937	136	23	promising	promise	VERB
bam-12937	136	24	and	and	CCONJ
bam-12937	136	25	warrant	warrant	VERB
bam-12937	136	26	further	further	ADJ
bam-12937	136	27	investigation	investigation	NOUN
bam-12937	136	28	in	in	ADP
bam-12937	136	29	larger	large	ADJ
bam-12937	136	30	trials	trial	NOUN
bam-12937	136	31	.	.	PUNCT
bam-12937	137	1	these	these	DET
bam-12937	137	2	observations	observation	NOUN
bam-12937	137	3	align	align	VERB
bam-12937	137	4	with	with	ADP
bam-12937	137	5	findings	finding	NOUN
bam-12937	137	6	from	from	ADP
bam-12937	137	7	recent	recent	ADJ
bam-12937	137	8	metaanalyses	metaanalyse	NOUN
bam-12937	137	9	,	,	PUNCT
bam-12937	137	10	such	such	ADJ
bam-12937	137	11	as	as	ADP
bam-12937	137	12	the	the	DET
bam-12937	137	13	one	one	NUM
bam-12937	137	14	by	by	ADP
bam-12937	137	15	ma	ma	PROPN
bam-12937	137	16	et	et	PROPN
bam-12937	137	17	al	al	PROPN
bam-12937	137	18	.	.	PROPN
bam-12937	138	1	(	(	PUNCT
bam-12937	138	2	2021	2021	NUM
bam-12937	138	3	)	)	PUNCT
bam-12937	138	4	,	,	PUNCT
bam-12937	138	5	which	which	PRON
bam-12937	138	6	demonstrated	demonstrate	VERB
bam-12937	138	7	that	that	SCONJ
bam-12937	138	8	pcsk9	pcsk9	PROPN
bam-12937	138	9	inhibitors	inhibitor	NOUN
bam-12937	138	10	,	,	PUNCT
bam-12937	138	11	compared	compare	VERB
bam-12937	138	12	to	to	ADP
bam-12937	138	13	placebo	placebo	NOUN
bam-12937	138	14	,	,	PUNCT
bam-12937	138	15	significantly	significantly	ADV
bam-12937	138	16	reduce	reduce	VERB
bam-12937	138	17	ldl	ldl	NOUN
bam-12937	138	18	-	-	PUNCT
bam-12937	138	19	c	c	NOUN
bam-12937	138	20	levels	level	NOUN
bam-12937	138	21	and	and	CCONJ
bam-12937	138	22	show	show	VERB
bam-12937	138	23	promise	promise	NOUN
bam-12937	138	24	for	for	ADP
bam-12937	138	25	reducing	reduce	VERB
bam-12937	138	26	major	major	ADJ
bam-12937	138	27	adverse	adverse	ADJ
bam-12937	138	28	cardiac	cardiac	ADJ
bam-12937	138	29	events	event	NOUN
bam-12937	138	30	(	(	PUNCT
bam-12937	138	31	mace	mace	NOUN
bam-12937	138	32	)	)	PUNCT
bam-12937	138	33	including	include	VERB
bam-12937	138	34	stroke	stroke	NOUN
bam-12937	138	35	and	and	CCONJ
bam-12937	138	36	myocardial	myocardial	ADJ
bam-12937	138	37	infarction.24	infarction.24	NOUN
bam-12937	138	38	notably	notably	ADV
bam-12937	138	39	,	,	PUNCT
bam-12937	138	40	their	their	PRON
bam-12937	138	41	study	study	NOUN
bam-12937	138	42	found	find	VERB
bam-12937	138	43	no	no	DET
bam-12937	138	44	significant	significant	ADJ
bam-12937	138	45	difference	difference	NOUN
bam-12937	138	46	in	in	ADP
bam-12937	138	47	cardiovascular	cardiovascular	ADJ
bam-12937	138	48	event	event	NOUN
bam-12937	138	49	prevention	prevention	NOUN
bam-12937	138	50	between	between	ADP
bam-12937	138	51	pcsk9	pcsk9	PROPN
bam-12937	138	52	inhibitors	inhibitor	NOUN
bam-12937	138	53	and	and	CCONJ
bam-12937	138	54	ezetimibe	ezetimibe	NOUN
bam-12937	138	55	,	,	PUNCT
bam-12937	138	56	highlighting	highlight	VERB
bam-12937	138	57	the	the	DET
bam-12937	138	58	potential	potential	ADJ
bam-12937	138	59	advantages	advantage	NOUN
bam-12937	138	60	of	of	ADP
bam-12937	138	61	evolocumab	evolocumab	NOUN
bam-12937	138	62	for	for	ADP
bam-12937	138	63	high	high	ADJ
bam-12937	138	64	-	-	PUNCT
bam-12937	138	65	risk	risk	NOUN
bam-12937	138	66	patients	patient	NOUN
bam-12937	138	67	who	who	PRON
bam-12937	138	68	may	may	AUX
bam-12937	138	69	not	not	PART
bam-12937	138	70	respond	respond	VERB
bam-12937	138	71	adequately	adequately	ADV
bam-12937	138	72	to	to	ADP
bam-12937	138	73	other	other	ADJ
bam-12937	138	74	therapies.furthermore	therapies.furthermore	NUM
bam-12937	138	75	,	,	PUNCT
bam-12937	138	76	as	as	SCONJ
bam-12937	138	77	highlighted	highlight	VERB
bam-12937	138	78	by	by	ADP
bam-12937	138	79	berman	berman	PROPN
bam-12937	138	80	and	and	CCONJ
bam-12937	138	81	blankstein	blankstein	ADV
bam-12937	138	82	(	(	PUNCT
bam-12937	138	83	2019	2019	NUM
bam-12937	138	84	)	)	PUNCT
bam-12937	138	85	,	,	PUNCT
bam-12937	138	86	pcsk9	pcsk9	NOUN
bam-12937	138	87	inhibitors	inhibitor	NOUN
bam-12937	138	88	represent	represent	VERB
bam-12937	138	89	a	a	DET
bam-12937	138	90	significant	significant	ADJ
bam-12937	138	91	recent	recent	ADJ
bam-12937	138	92	advancement	advancement	NOUN
bam-12937	138	93	in	in	ADP
bam-12937	138	94	dyslipidemia	dyslipidemia	NOUN
bam-12937	138	95	treatment.25	treatment.25	ADP
bam-12937	138	96	their	their	PRON
bam-12937	138	97	review	review	NOUN
bam-12937	138	98	emphasizes	emphasize	VERB
bam-12937	138	99	the	the	DET
bam-12937	138	100	effectiveness	effectiveness	NOUN
bam-12937	138	101	of	of	ADP
bam-12937	138	102	this	this	DET
bam-12937	138	103	drug	drug	NOUN
bam-12937	138	104	class	class	NOUN
bam-12937	138	105	in	in	ADP
bam-12937	138	106	lowering	lower	VERB
bam-12937	138	107	ldl	ldl	NOUN
bam-12937	138	108	-	-	PUNCT
bam-12937	138	109	c	c	NOUN
bam-12937	138	110	and	and	CCONJ
bam-12937	138	111	reducing	reduce	VERB
bam-12937	138	112	cardiovascular	cardiovascular	ADJ
bam-12937	138	113	events	event	NOUN
bam-12937	138	114	in	in	ADP
bam-12937	138	115	high	high	ADJ
bam-12937	138	116	-	-	PUNCT
bam-12937	138	117	risk	risk	NOUN
bam-12937	138	118	patients	patient	NOUN
bam-12937	138	119	–	–	PUNCT
bam-12937	138	120	precisely	precisely	ADV
bam-12937	138	121	the	the	DET
bam-12937	138	122	population	population	NOUN
bam-12937	138	123	we	we	PRON
bam-12937	138	124	targeted	target	VERB
bam-12937	138	125	in	in	ADP
bam-12937	138	126	our	our	PRON
bam-12937	138	127	study	study	NOUN
bam-12937	138	128	.	.	PUNCT
bam-12937	139	1	this	this	PRON
bam-12937	139	2	aligns	align	VERB
bam-12937	139	3	with	with	ADP
bam-12937	139	4	the	the	DET
bam-12937	139	5	growing	grow	VERB
bam-12937	139	6	recognition	recognition	NOUN
bam-12937	139	7	of	of	ADP
bam-12937	139	8	the	the	DET
bam-12937	139	9	importance	importance	NOUN
bam-12937	139	10	of	of	ADP
bam-12937	139	11	risk	risk	NOUN
bam-12937	139	12	assessment	assessment	NOUN
bam-12937	139	13	and	and	CCONJ
bam-12937	139	14	targeted	target	VERB
bam-12937	139	15	therapies	therapy	NOUN
bam-12937	139	16	,	,	PUNCT
bam-12937	139	17	as	as	SCONJ
bam-12937	139	18	emphasized	emphasize	VERB
bam-12937	139	19	by	by	ADP
bam-12937	139	20	karantas	karanta	NOUN
bam-12937	139	21	et	et	PROPN
bam-12937	139	22	al	al	PROPN
bam-12937	139	23	.	.	PROPN
bam-12937	139	24	(	(	PUNCT
bam-12937	139	25	2021	2021	NUM
bam-12937	139	26	)	)	PUNCT
bam-12937	139	27	in	in	ADP
bam-12937	139	28	their	their	PRON
bam-12937	139	29	review	review	NOUN
bam-12937	139	30	of	of	ADP
bam-12937	139	31	updated	update	VERB
bam-12937	139	32	dyslipidemia	dyslipidemia	NOUN
bam-12937	139	33	management	management	NOUN
bam-12937	139	34	guidelines.26	guidelines.26	VERB
bam-12937	139	35	our	our	PRON
bam-12937	139	36	study	study	NOUN
bam-12937	139	37	adds	add	VERB
bam-12937	139	38	to	to	ADP
bam-12937	139	39	the	the	DET
bam-12937	139	40	growing	grow	VERB
bam-12937	139	41	evidence	evidence	NOUN
bam-12937	139	42	supporting	support	VERB
bam-12937	139	43	evolocumab	evolocumab	NOUN
bam-12937	139	44	’s	’s	PART
bam-12937	139	45	effectiveness	effectiveness	NOUN
bam-12937	139	46	in	in	ADP
bam-12937	139	47	managing	manage	VERB
bam-12937	139	48	dyslipidemia	dyslipidemia	NOUN
bam-12937	139	49	,	,	PUNCT
bam-12937	139	50	particularly	particularly	ADV
bam-12937	139	51	in	in	ADP
bam-12937	139	52	high	high	ADJ
bam-12937	139	53	-	-	PUNCT
bam-12937	139	54	risk	risk	NOUN
bam-12937	139	55	patients	patient	NOUN
bam-12937	139	56	with	with	ADP
bam-12937	139	57	fh	fh	PROPN
bam-12937	139	58	.	.	PUNCT
bam-12937	140	1	the	the	DET
bam-12937	140	2	observed	observe	VERB
bam-12937	140	3	significant	significant	ADJ
bam-12937	140	4	reduction	reduction	NOUN
bam-12937	140	5	in	in	ADP
bam-12937	140	6	ldl	ldl	NOUN
bam-12937	140	7	-	-	PUNCT
bam-12937	140	8	c	c	NOUN
bam-12937	140	9	aligns	align	VERB
bam-12937	140	10	with	with	ADP
bam-12937	140	11	findings	finding	NOUN
bam-12937	140	12	from	from	ADP
bam-12937	140	13	other	other	ADJ
bam-12937	140	14	pcsk9	pcsk9	NOUN
bam-12937	140	15	inhibitor	inhibitor	NOUN
bam-12937	140	16	trials	trial	NOUN
bam-12937	140	17	,	,	PUNCT
bam-12937	140	18	such	such	ADJ
bam-12937	140	19	as	as	ADP
bam-12937	140	20	the	the	DET
bam-12937	140	21	one	one	NUM
bam-12937	140	22	by	by	ADP
bam-12937	140	23	blom	blom	PROPN
bam-12937	140	24	et	et	PROPN
bam-12937	140	25	al	al	PROPN
bam-12937	140	26	.	.	PROPN
bam-12937	141	1	(	(	PUNCT
bam-12937	141	2	2020	2020	NUM
bam-12937	141	3	)	)	PUNCT
bam-12937	141	4	demonstrating	demonstrate	VERB
bam-12937	141	5	similar	similar	ADJ
bam-12937	141	6	reductions	reduction	NOUN
bam-12937	141	7	in	in	ADP
bam-12937	141	8	hofh	hofh	ADJ
bam-12937	141	9	patients	patient	NOUN
bam-12937	141	10	using	use	VERB
bam-12937	141	11	alirocumab.14	alirocumab.14	PRON
bam-12937	141	12	this	this	PRON
bam-12937	141	13	strengthens	strengthen	VERB
bam-12937	141	14	the	the	DET
bam-12937	141	15	case	case	NOUN
bam-12937	141	16	for	for	ADP
bam-12937	141	17	evolocumab	evolocumab	NOUN
bam-12937	141	18	’s	’s	PART
bam-12937	141	19	ability	ability	NOUN
bam-12937	141	20	to	to	PART
bam-12937	141	21	address	address	VERB
bam-12937	141	22	the	the	DET
bam-12937	141	23	core	core	NOUN
bam-12937	141	24	challenge	challenge	NOUN
bam-12937	141	25	of	of	ADP
bam-12937	141	26	elevated	elevated	ADJ
bam-12937	141	27	ldl	ldl	NOUN
bam-12937	141	28	-	-	PUNCT
bam-12937	141	29	c	c	PROPN
bam-12937	141	30	in	in	ADP
bam-12937	141	31	fh	fh	PROPN
bam-12937	141	32	.	.	PUNCT
bam-12937	142	1	furthermore	furthermore	ADV
bam-12937	142	2	,	,	PUNCT
bam-12937	142	3	our	our	PRON
bam-12937	142	4	study	study	NOUN
bam-12937	142	5	complements	complement	VERB
bam-12937	142	6	the	the	DET
bam-12937	142	7	existing	exist	VERB
bam-12937	142	8	research	research	NOUN
bam-12937	142	9	on	on	ADP
bam-12937	142	10	evolocumab	evolocumab	NOUN
bam-12937	142	11	’s	’s	PART
bam-12937	142	12	role	role	NOUN
bam-12937	142	13	in	in	ADP
bam-12937	142	14	overcoming	overcome	VERB
bam-12937	142	15	limitations	limitation	NOUN
bam-12937	142	16	of	of	ADP
bam-12937	142	17	statin	statin	PROPN
bam-12937	142	18	therapy	therapy	NOUN
bam-12937	142	19	.	.	PUNCT
bam-12937	143	1	the	the	DET
bam-12937	143	2	berson	berson	NOUN
bam-12937	143	3	trial	trial	NOUN
bam-12937	143	4	design	design	NOUN
bam-12937	143	5	by	by	ADP
bam-12937	143	6	lorenzatti	lorenzatti	PROPN
bam-12937	143	7	et	et	PROPN
bam-12937	143	8	al	al	PROPN
bam-12937	143	9	.	.	PROPN
bam-12937	144	1	(	(	PUNCT
bam-12937	144	2	2018	2018	NUM
bam-12937	144	3	)	)	PUNCT
bam-12937	144	4	targets	target	VERB
bam-12937	144	5	patients	patient	NOUN
bam-12937	144	6	with	with	ADP
bam-12937	144	7	type	type	NOUN
bam-12937	144	8	2	2	NUM
bam-12937	144	9	diabetes	diabetes	NOUN
bam-12937	144	10	and	and	CCONJ
bam-12937	144	11	dyslipidemia	dyslipidemia	NOUN
bam-12937	144	12	,	,	PUNCT
bam-12937	144	13	reflecting	reflect	VERB
bam-12937	144	14	a	a	DET
bam-12937	144	15	similar	similar	ADJ
bam-12937	144	16	rationale	rationale	NOUN
bam-12937	144	17	for	for	ADP
bam-12937	144	18	evolocumab	evolocumab	NOUN
bam-12937	144	19	in	in	ADP
bam-12937	144	20	fh	fh	PROPN
bam-12937	144	21	patients	patient	NOUN
bam-12937	144	22	where	where	SCONJ
bam-12937	144	23	statins	statin	NOUN
bam-12937	144	24	may	may	AUX
bam-12937	144	25	be	be	AUX
bam-12937	144	26	insufficient.27	insufficient.27	PROPN
bam-12937	144	27	however	however	ADV
bam-12937	144	28	,	,	PUNCT
bam-12937	144	29	it	it	PRON
bam-12937	144	30	’s	’	VERB
bam-12937	144	31	important	important	ADJ
bam-12937	144	32	to	to	PART
bam-12937	144	33	acknowledge	acknowledge	VERB
bam-12937	144	34	that	that	SCONJ
bam-12937	144	35	our	our	PRON
bam-12937	144	36	study	study	NOUN
bam-12937	144	37	did	do	AUX
bam-12937	144	38	not	not	PART
bam-12937	144	39	differentiate	differentiate	VERB
bam-12937	144	40	between	between	ADP
bam-12937	144	41	hefh	hefh	NOUN
bam-12937	144	42	and	and	CCONJ
bam-12937	144	43	hofh	hofh	ADJ
bam-12937	144	44	subtypes	subtype	NOUN
bam-12937	144	45	,	,	PUNCT
bam-12937	144	46	which	which	PRON
bam-12937	144	47	might	might	AUX
bam-12937	144	48	require	require	VERB
bam-12937	144	49	tailored	tailor	VERB
bam-12937	144	50	treatment	treatment	NOUN
bam-12937	144	51	approaches	approach	NOUN
bam-12937	144	52	.	.	PUNCT
bam-12937	145	1	further	further	ADJ
bam-12937	145	2	investigation	investigation	NOUN
bam-12937	145	3	is	be	AUX
bam-12937	145	4	warranted	warrant	VERB
bam-12937	145	5	to	to	PART
bam-12937	145	6	explore	explore	VERB
bam-12937	145	7	this	this	DET
bam-12937	145	8	aspect	aspect	NOUN
bam-12937	145	9	.	.	PUNCT
bam-12937	146	1	also	also	ADV
bam-12937	146	2	,	,	PUNCT
bam-12937	146	3	while	while	SCONJ
bam-12937	146	4	our	our	PRON
bam-12937	146	5	analysis	analysis	NOUN
bam-12937	146	6	did	do	AUX
bam-12937	146	7	not	not	PART
bam-12937	146	8	identify	identify	VERB
bam-12937	146	9	statistically	statistically	ADV
bam-12937	146	10	significant	significant	ADJ
bam-12937	146	11	associations	association	NOUN
bam-12937	146	12	between	between	ADP
bam-12937	146	13	evolocumab	evolocumab	NOUN
bam-12937	146	14	efficacy	efficacy	NOUN
bam-12937	146	15	and	and	CCONJ
bam-12937	146	16	factors	factor	NOUN
bam-12937	146	17	like	like	ADP
bam-12937	146	18	prior	prior	ADJ
bam-12937	146	19	cardiovascular	cardiovascular	ADJ
bam-12937	146	20	history	history	NOUN
bam-12937	146	21	or	or	CCONJ
bam-12937	146	22	baseline	baseline	NOUN
bam-12937	146	23	medications	medication	NOUN
bam-12937	146	24	,	,	PUNCT
bam-12937	146	25	the	the	DET
bam-12937	146	26	limited	limited	ADJ
bam-12937	146	27	sample	sample	NOUN
bam-12937	146	28	size	size	NOUN
bam-12937	146	29	necessitates	necessitate	VERB
bam-12937	146	30	further	further	ADJ
bam-12937	146	31	exploration	exploration	NOUN
bam-12937	146	32	in	in	ADP
bam-12937	146	33	more	more	ADJ
bam-12937	146	34	comprehensive	comprehensive	ADJ
bam-12937	146	35	studies	study	NOUN
bam-12937	146	36	.	.	PUNCT
bam-12937	147	1	systematic	systematic	ADJ
bam-12937	147	2	reviews	review	NOUN
bam-12937	147	3	like	like	ADP
bam-12937	147	4	the	the	DET
bam-12937	147	5	one	one	NUM
bam-12937	147	6	by	by	ADP
bam-12937	147	7	alhajri	alhajri	PROPN
bam-12937	147	8	et	et	PROPN
bam-12937	147	9	al	al	PROPN
bam-12937	147	10	.	.	PROPN
bam-12937	148	1	(	(	PUNCT
bam-12937	148	2	2017	2017	NUM
bam-12937	148	3	)	)	PUNCT
bam-12937	148	4	analyzing	analyze	VERB
bam-12937	148	5	data	datum	NOUN
bam-12937	148	6	from	from	ADP
bam-12937	148	7	multiple	multiple	ADJ
bam-12937	148	8	evolocumab	evolocumab	NOUN
bam-12937	148	9	trials	trial	NOUN
bam-12937	148	10	offer	offer	VERB
bam-12937	148	11	a	a	DET
bam-12937	148	12	broader	broad	ADJ
bam-12937	148	13	perspective	perspective	NOUN
bam-12937	148	14	on	on	ADP
bam-12937	148	15	its	its	PRON
bam-12937	148	16	effectiveness	effectiveness	NOUN
bam-12937	148	17	and	and	CCONJ
bam-12937	148	18	highlight	highlight	VERB
bam-12937	148	19	its	its	PRON
bam-12937	148	20	potential	potential	NOUN
bam-12937	148	21	for	for	ADP
bam-12937	148	22	overcoming	overcome	VERB
bam-12937	148	23	statin	statin	ADJ
bam-12937	148	24	limitations.28	limitations.28	NOUN
bam-12937	148	25	looking	look	VERB
bam-12937	148	26	beyond	beyond	ADP
bam-12937	148	27	ldl	ldl	NOUN
bam-12937	148	28	-	-	PUNCT
bam-12937	148	29	c	c	NOUN
bam-12937	148	30	reduction	reduction	NOUN
bam-12937	148	31	,	,	PUNCT
bam-12937	148	32	the	the	DET
bam-12937	148	33	review	review	NOUN
bam-12937	148	34	by	by	ADP
bam-12937	148	35	lazarte	lazarte	NOUN
bam-12937	148	36	and	and	CCONJ
bam-12937	148	37	hegele	hegele	NOUN
bam-12937	148	38	(	(	PUNCT
bam-12937	148	39	2020	2020	NUM
bam-12937	148	40	)	)	PUNCT
bam-12937	148	41	emphasizes	emphasize	VERB
bam-12937	148	42	the	the	DET
bam-12937	148	43	multifaceted	multifaceted	ADJ
bam-12937	148	44	nature	nature	NOUN
bam-12937	148	45	of	of	ADP
bam-12937	148	46	dyslipidemia	dyslipidemia	NOUN
bam-12937	148	47	management	management	NOUN
bam-12937	148	48	,	,	PUNCT
bam-12937	148	49	highlighting	highlight	VERB
bam-12937	148	50	the	the	DET
bam-12937	148	51	importance	importance	NOUN
bam-12937	148	52	of	of	ADP
bam-12937	148	53	diet	diet	NOUN
bam-12937	148	54	,	,	PUNCT
bam-12937	148	55	lifestyle	lifestyle	NOUN
bam-12937	148	56	changes	change	NOUN
bam-12937	148	57	,	,	PUNCT
bam-12937	148	58	and	and	CCONJ
bam-12937	148	59	potentially	potentially	ADV
bam-12937	148	60	targeting	target	VERB
bam-12937	148	61	other	other	ADJ
bam-12937	148	62	lipids	lipid	NOUN
bam-12937	148	63	like	like	ADP
bam-12937	148	64	triglycerides.29	triglycerides.29	NOUN
bam-12937	148	65	evolocumab	evolocumab	NOUN
bam-12937	148	66	can	can	AUX
bam-12937	148	67	be	be	AUX
bam-12937	148	68	a	a	DET
bam-12937	148	69	valuable	valuable	ADJ
bam-12937	148	70	tool	tool	NOUN
bam-12937	148	71	within	within	ADP
bam-12937	148	72	a	a	DET
bam-12937	148	73	broader	broad	ADJ
bam-12937	148	74	treatment	treatment	NOUN
bam-12937	148	75	plan	plan	NOUN
bam-12937	148	76	,	,	PUNCT
bam-12937	148	77	potentially	potentially	ADV
bam-12937	148	78	alongside	alongside	ADP
bam-12937	148	79	statins	statin	NOUN
bam-12937	148	80	as	as	ADP
bam-12937	148	81	the	the	DET
bam-12937	148	82	cornerstone	cornerstone	NOUN
bam-12937	148	83	therapy30	therapy30	NOUN
bam-12937	148	84	or	or	CCONJ
bam-12937	148	85	combined	combine	VERB
bam-12937	148	86	with	with	ADP
bam-12937	148	87	ezetimibe	ezetimibe	NOUN
bam-12937	148	88	for	for	ADP
bam-12937	148	89	highrisk	highrisk	NOUN
bam-12937	148	90	patients	patient	NOUN
bam-12937	148	91	with	with	ADP
bam-12937	148	92	uncontrolled	uncontrolled	ADJ
bam-12937	148	93	ldl	ldl	NOUN
bam-12937	148	94	-	-	PUNCT
bam-12937	148	95	c.29	c.29	NOUN
bam-12937	148	96	future	future	ADJ
bam-12937	148	97	research	research	NOUN
bam-12937	148	98	can	can	AUX
bam-12937	148	99	definitively	definitively	ADV
bam-12937	148	100	assess	assess	VERB
bam-12937	148	101	how	how	SCONJ
bam-12937	148	102	factors	factor	NOUN
bam-12937	148	103	like	like	ADP
bam-12937	148	104	prior	prior	ADJ
bam-12937	148	105	cardiovascular	cardiovascular	ADJ
bam-12937	148	106	history	history	NOUN
bam-12937	148	107	and	and	CCONJ
bam-12937	148	108	baseline	baseline	NOUN
bam-12937	148	109	medications	medication	NOUN
bam-12937	148	110	influence	influence	NOUN
bam-12937	148	111	evolocumab	evolocumab	NOUN
bam-12937	148	112	’s	’s	PART
bam-12937	148	113	effectiveness	effectiveness	NOUN
bam-12937	148	114	in	in	ADP
bam-12937	148	115	reducing	reduce	VERB
bam-12937	148	116	cardiovascular	cardiovascular	ADJ
bam-12937	148	117	risk	risk	NOUN
bam-12937	148	118	.	.	PUNCT
bam-12937	149	1	additionally	additionally	ADV
bam-12937	149	2	,	,	PUNCT
bam-12937	149	3	119	119	NUM
bam-12937	149	4	non	non	ADJ
bam-12937	149	5	-co	-co	PROPN
bam-12937	149	6	mmerc	mmerc	PROPN
bam-12937	149	7	ial	ial	PROPN
bam-12937	149	8	us	us	PROPN
bam-12937	149	9	e	e	NOUN
bam-12937	149	10	o	o	X
bam-12937	149	11	nly	nly	ADV
bam-12937	149	12	the	the	DET
bam-12937	149	13	therapeutic	therapeutic	ADJ
bam-12937	149	14	effect	effect	NOUN
bam-12937	149	15	of	of	ADP
bam-12937	149	16	pcsk9	pcsk9	NOUN
bam-12937	149	17	inhibitors	inhibitor	NOUN
bam-12937	149	18	on	on	ADP
bam-12937	149	19	dyslipidemia	dyslipidemia	NOUN
bam-12937	149	20	:	:	PUNCT
bam-12937	149	21	one	one	NUM
bam-12937	149	22	-	-	PUNCT
bam-12937	149	23	year	year	NOUN
bam-12937	149	24	follow	follow	VERB
bam-12937	149	25	up	up	ADP
bam-12937	149	26	eur	eur	PROPN
bam-12937	149	27	j	j	PROPN
bam-12937	149	28	transl	transl	PROPN
bam-12937	149	29	myol	myol	NOUN
bam-12937	149	30	34	34	NUM
bam-12937	149	31	(	(	PUNCT
bam-12937	149	32	3	3	NUM
bam-12937	149	33	)	)	PUNCT
bam-12937	149	34	12937	12937	NUM
bam-12937	149	35	,	,	PUNCT
bam-12937	149	36	2024	2024	NUM
bam-12937	149	37	doi	doi	NOUN
bam-12937	149	38	:	:	PUNCT
bam-12937	149	39	10.4081	10.4081	NUM
bam-12937	149	40	/	/	SYM
bam-12937	149	41	ejtm.2024.12937	ejtm.2024.12937	NOUN
bam-12937	149	42	exploring	explore	VERB
bam-12937	149	43	the	the	DET
bam-12937	149	44	potential	potential	ADJ
bam-12937	149	45	benefits	benefit	NOUN
bam-12937	149	46	of	of	ADP
bam-12937	149	47	evolocumab	evolocumab	NOUN
bam-12937	149	48	in	in	ADP
bam-12937	149	49	combination	combination	NOUN
bam-12937	149	50	with	with	ADP
bam-12937	149	51	other	other	ADJ
bam-12937	149	52	lipid	lipid	NOUN
bam-12937	149	53	-	-	PUNCT
bam-12937	149	54	lowering	lower	VERB
bam-12937	149	55	strategies	strategy	NOUN
bam-12937	149	56	is	be	AUX
bam-12937	149	57	warranted	warrant	VERB
bam-12937	149	58	.	.	PUNCT
bam-12937	150	1	however	however	ADV
bam-12937	150	2	,	,	PUNCT
bam-12937	150	3	a	a	DET
bam-12937	150	4	key	key	ADJ
bam-12937	150	5	limitation	limitation	NOUN
bam-12937	150	6	lies	lie	VERB
bam-12937	150	7	in	in	ADP
bam-12937	150	8	the	the	DET
bam-12937	150	9	relatively	relatively	ADV
bam-12937	150	10	small	small	ADJ
bam-12937	150	11	sample	sample	NOUN
bam-12937	150	12	size	size	NOUN
bam-12937	150	13	(	(	PUNCT
bam-12937	150	14	50	50	NUM
bam-12937	150	15	participants	participant	NOUN
bam-12937	150	16	)	)	PUNCT
bam-12937	150	17	.	.	PUNCT
bam-12937	151	1	this	this	DET
bam-12937	151	2	limitation	limitation	NOUN
bam-12937	151	3	restricts	restrict	VERB
bam-12937	151	4	the	the	DET
bam-12937	151	5	generalizability	generalizability	NOUN
bam-12937	151	6	of	of	ADP
bam-12937	151	7	our	our	PRON
bam-12937	151	8	findings	finding	NOUN
bam-12937	151	9	to	to	ADP
bam-12937	151	10	the	the	DET
bam-12937	151	11	broader	broad	ADJ
bam-12937	151	12	population	population	NOUN
bam-12937	151	13	with	with	ADP
bam-12937	151	14	fh	fh	PROPN
bam-12937	151	15	.	.	PUNCT
bam-12937	151	16	larger	large	ADJ
bam-12937	151	17	,	,	PUNCT
bam-12937	151	18	multicenter	multicenter	ADJ
bam-12937	151	19	trials	trial	NOUN
bam-12937	151	20	with	with	ADP
bam-12937	151	21	more	more	ADV
bam-12937	151	22	diverse	diverse	ADJ
bam-12937	151	23	participants	participant	NOUN
bam-12937	151	24	are	be	AUX
bam-12937	151	25	necessary	necessary	ADJ
bam-12937	151	26	to	to	PART
bam-12937	151	27	confirm	confirm	VERB
bam-12937	151	28	our	our	PRON
bam-12937	151	29	observations	observation	NOUN
bam-12937	151	30	with	with	ADP
bam-12937	151	31	greater	great	ADJ
bam-12937	151	32	certainty	certainty	NOUN
bam-12937	151	33	and	and	CCONJ
bam-12937	151	34	enhance	enhance	VERB
bam-12937	151	35	the	the	DET
bam-12937	151	36	generalizability	generalizability	NOUN
bam-12937	151	37	of	of	ADP
bam-12937	151	38	the	the	DET
bam-12937	151	39	results	result	NOUN
bam-12937	151	40	.	.	PUNCT
bam-12937	152	1	future	future	ADJ
bam-12937	152	2	research	research	NOUN
bam-12937	152	3	could	could	AUX
bam-12937	152	4	also	also	ADV
bam-12937	152	5	explore	explore	VERB
bam-12937	152	6	the	the	DET
bam-12937	152	7	efficacy	efficacy	NOUN
bam-12937	152	8	of	of	ADP
bam-12937	152	9	evolocumab	evolocumab	NOUN
bam-12937	152	10	in	in	ADP
bam-12937	152	11	different	different	ADJ
bam-12937	152	12	patient	patient	ADJ
bam-12937	152	13	populations	population	NOUN
bam-12937	152	14	,	,	PUNCT
bam-12937	152	15	such	such	ADJ
bam-12937	152	16	as	as	ADP
bam-12937	152	17	those	those	PRON
bam-12937	152	18	with	with	ADP
bam-12937	152	19	other	other	ADJ
bam-12937	152	20	types	type	NOUN
bam-12937	152	21	of	of	ADP
bam-12937	152	22	dyslipidemia	dyslipidemia	NOUN
bam-12937	152	23	or	or	CCONJ
bam-12937	152	24	additional	additional	ADJ
bam-12937	152	25	cardiovascular	cardiovascular	ADJ
bam-12937	152	26	risk	risk	NOUN
bam-12937	152	27	factors	factor	NOUN
bam-12937	152	28	.	.	PUNCT
bam-12937	153	1	furthermore	furthermore	ADV
bam-12937	153	2	,	,	PUNCT
bam-12937	153	3	investigating	investigate	VERB
bam-12937	153	4	evolocumab	evolocumab	NOUN
bam-12937	153	5	’s	’s	PART
bam-12937	153	6	effectiveness	effectiveness	NOUN
bam-12937	153	7	in	in	ADP
bam-12937	153	8	various	various	ADJ
bam-12937	153	9	treatment	treatment	NOUN
bam-12937	153	10	settings	setting	NOUN
bam-12937	153	11	,	,	PUNCT
bam-12937	153	12	including	include	VERB
bam-12937	153	13	longer	long	ADJ
bam-12937	153	14	treatment	treatment	NOUN
bam-12937	153	15	durations	duration	NOUN
bam-12937	153	16	or	or	CCONJ
bam-12937	153	17	combination	combination	NOUN
bam-12937	153	18	therapies	therapy	NOUN
bam-12937	153	19	with	with	ADP
bam-12937	153	20	other	other	ADJ
bam-12937	153	21	lipid	lipid	NOUN
bam-12937	153	22	-	-	PUNCT
bam-12937	153	23	lowering	lower	VERB
bam-12937	153	24	medications	medication	NOUN
bam-12937	153	25	,	,	PUNCT
bam-12937	153	26	would	would	AUX
bam-12937	153	27	provide	provide	VERB
bam-12937	153	28	valuable	valuable	ADJ
bam-12937	153	29	information	information	NOUN
bam-12937	153	30	for	for	ADP
bam-12937	153	31	optimizing	optimize	VERB
bam-12937	153	32	patient	patient	ADJ
bam-12937	153	33	care	care	NOUN
bam-12937	153	34	.	.	PUNCT
bam-12937	154	1	by	by	ADP
bam-12937	154	2	addressing	address	VERB
bam-12937	154	3	these	these	DET
bam-12937	154	4	limitations	limitation	NOUN
bam-12937	154	5	and	and	CCONJ
bam-12937	154	6	expanding	expand	VERB
bam-12937	154	7	the	the	DET
bam-12937	154	8	scope	scope	NOUN
bam-12937	154	9	of	of	ADP
bam-12937	154	10	future	future	ADJ
bam-12937	154	11	research	research	NOUN
bam-12937	154	12	,	,	PUNCT
bam-12937	154	13	we	we	PRON
bam-12937	154	14	can	can	AUX
bam-12937	154	15	gain	gain	VERB
bam-12937	154	16	a	a	DET
bam-12937	154	17	more	more	ADV
bam-12937	154	18	comprehensive	comprehensive	ADJ
bam-12937	154	19	understanding	understanding	NOUN
bam-12937	154	20	of	of	ADP
bam-12937	154	21	evolocumab	evolocumab	NOUN
bam-12937	154	22	’s	’s	PART
bam-12937	154	23	role	role	NOUN
bam-12937	154	24	in	in	ADP
bam-12937	154	25	managing	manage	VERB
bam-12937	154	26	dyslipidemia	dyslipidemia	NOUN
bam-12937	154	27	and	and	CCONJ
bam-12937	154	28	reducing	reduce	VERB
bam-12937	154	29	cardiovascular	cardiovascular	ADJ
bam-12937	154	30	risk	risk	NOUN
bam-12937	154	31	across	across	ADP
bam-12937	154	32	a	a	DET
bam-12937	154	33	wider	wide	ADJ
bam-12937	154	34	range	range	NOUN
bam-12937	154	35	of	of	ADP
bam-12937	154	36	patients	patient	NOUN
bam-12937	154	37	.	.	PUNCT
bam-12937	155	1	it	it	PRON
bam-12937	155	2	is	be	AUX
bam-12937	155	3	important	important	ADJ
bam-12937	155	4	to	to	PART
bam-12937	155	5	acknowledge	acknowledge	VERB
bam-12937	155	6	the	the	DET
bam-12937	155	7	limitations	limitation	NOUN
bam-12937	155	8	of	of	ADP
bam-12937	155	9	our	our	PRON
bam-12937	155	10	study	study	NOUN
bam-12937	155	11	,	,	PUNCT
bam-12937	155	12	particularly	particularly	ADV
bam-12937	155	13	the	the	DET
bam-12937	155	14	relatively	relatively	ADV
bam-12937	155	15	small	small	ADJ
bam-12937	155	16	sample	sample	NOUN
bam-12937	155	17	size	size	NOUN
bam-12937	155	18	.	.	PUNCT
bam-12937	156	1	future	future	ADJ
bam-12937	156	2	research	research	NOUN
bam-12937	156	3	with	with	ADP
bam-12937	156	4	larger	large	ADJ
bam-12937	156	5	and	and	CCONJ
bam-12937	156	6	more	more	ADV
bam-12937	156	7	diverse	diverse	ADJ
bam-12937	156	8	populations	population	NOUN
bam-12937	156	9	is	be	AUX
bam-12937	156	10	needed	need	VERB
bam-12937	156	11	to	to	PART
bam-12937	156	12	confirm	confirm	VERB
bam-12937	156	13	our	our	PRON
bam-12937	156	14	observations	observation	NOUN
bam-12937	156	15	and	and	CCONJ
bam-12937	156	16	enhance	enhance	VERB
bam-12937	156	17	generalizability	generalizability	NOUN
bam-12937	156	18	.	.	PUNCT
bam-12937	157	1	furthermore	furthermore	ADV
bam-12937	157	2	,	,	PUNCT
bam-12937	157	3	investigating	investigate	VERB
bam-12937	157	4	the	the	DET
bam-12937	157	5	impact	impact	NOUN
bam-12937	157	6	of	of	ADP
bam-12937	157	7	baseline	baseline	ADJ
bam-12937	157	8	lipid	lipid	NOUN
bam-12937	157	9	levels	level	NOUN
bam-12937	157	10	on	on	ADP
bam-12937	157	11	treatment	treatment	NOUN
bam-12937	157	12	response	response	NOUN
bam-12937	157	13	and	and	CCONJ
bam-12937	157	14	exploring	explore	VERB
bam-12937	157	15	evolocumab	evolocumab	NOUN
bam-12937	157	16	’s	’s	PART
bam-12937	157	17	efficacy	efficacy	NOUN
bam-12937	157	18	in	in	ADP
bam-12937	157	19	broader	broad	ADJ
bam-12937	157	20	treatment	treatment	NOUN
bam-12937	157	21	settings	setting	NOUN
bam-12937	157	22	are	be	AUX
bam-12937	157	23	important	important	ADJ
bam-12937	157	24	areas	area	NOUN
bam-12937	157	25	for	for	ADP
bam-12937	157	26	future	future	ADJ
bam-12937	157	27	exploration	exploration	NOUN
bam-12937	157	28	.	.	PUNCT
bam-12937	158	1	despite	despite	SCONJ
bam-12937	158	2	these	these	DET
bam-12937	158	3	limitations	limitation	NOUN
bam-12937	158	4	,	,	PUNCT
bam-12937	158	5	our	our	PRON
bam-12937	158	6	findings	finding	NOUN
bam-12937	158	7	contribute	contribute	VERB
bam-12937	158	8	valuable	valuable	ADJ
bam-12937	158	9	insights	insight	NOUN
bam-12937	158	10	into	into	ADP
bam-12937	158	11	evolocumab	evolocumab	NOUN
bam-12937	158	12	’s	’s	PART
bam-12937	158	13	potential	potential	NOUN
bam-12937	158	14	for	for	ADP
bam-12937	158	15	managing	manage	VERB
bam-12937	158	16	dyslipidemia	dyslipidemia	NOUN
bam-12937	158	17	and	and	CCONJ
bam-12937	158	18	reducing	reduce	VERB
bam-12937	158	19	cardiovascular	cardiovascular	ADJ
bam-12937	158	20	risk	risk	NOUN
bam-12937	158	21	in	in	ADP
bam-12937	158	22	patients	patient	NOUN
bam-12937	158	23	with	with	ADP
bam-12937	158	24	familial	familial	ADJ
bam-12937	158	25	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	158	26	.	.	PUNCT
bam-12937	159	1	conclusions	conclusion	NOUN
bam-12937	159	2	in	in	ADP
bam-12937	159	3	conclusion	conclusion	NOUN
bam-12937	159	4	,	,	PUNCT
bam-12937	159	5	our	our	PRON
bam-12937	159	6	study	study	NOUN
bam-12937	159	7	demonstrated	demonstrate	VERB
bam-12937	159	8	that	that	SCONJ
bam-12937	159	9	evolocumab	evolocumab	NOUN
bam-12937	159	10	treatment	treatment	NOUN
bam-12937	159	11	significantly	significantly	ADV
bam-12937	159	12	improved	improve	VERB
bam-12937	159	13	lipid	lipid	NOUN
bam-12937	159	14	profiles	profile	NOUN
bam-12937	159	15	in	in	ADP
bam-12937	159	16	patients	patient	NOUN
bam-12937	159	17	with	with	ADP
bam-12937	159	18	familial	familial	ADJ
bam-12937	159	19	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	159	20	.	.	PUNCT
bam-12937	160	1	following	follow	VERB
bam-12937	160	2	one	one	NUM
bam-12937	160	3	year	year	NOUN
bam-12937	160	4	of	of	ADP
bam-12937	160	5	therapy	therapy	NOUN
bam-12937	160	6	,	,	PUNCT
bam-12937	160	7	participants	participant	NOUN
bam-12937	160	8	experienced	experience	VERB
bam-12937	160	9	a	a	DET
bam-12937	160	10	substantial	substantial	ADJ
bam-12937	160	11	reduction	reduction	NOUN
bam-12937	160	12	in	in	ADP
bam-12937	160	13	ldl	ldl	NOUN
bam-12937	160	14	-	-	PUNCT
bam-12937	160	15	c	c	NOUN
bam-12937	160	16	,	,	PUNCT
bam-12937	160	17	with	with	ADP
bam-12937	160	18	average	average	ADJ
bam-12937	160	19	levels	level	NOUN
bam-12937	160	20	approaching	approach	VERB
bam-12937	160	21	the	the	DET
bam-12937	160	22	recommended	recommend	VERB
bam-12937	160	23	target	target	NOUN
bam-12937	160	24	range	range	NOUN
bam-12937	160	25	.	.	PUNCT
bam-12937	161	1	additionally	additionally	ADV
bam-12937	161	2	,	,	PUNCT
bam-12937	161	3	evolocumab	evolocumab	ADP
bam-12937	161	4	treatment	treatment	NOUN
bam-12937	161	5	led	lead	VERB
bam-12937	161	6	to	to	ADP
bam-12937	161	7	a	a	DET
bam-12937	161	8	decrease	decrease	NOUN
bam-12937	161	9	in	in	ADP
bam-12937	161	10	triglycerides	triglyceride	NOUN
bam-12937	161	11	and	and	CCONJ
bam-12937	161	12	a	a	DET
bam-12937	161	13	modest	modest	ADJ
bam-12937	161	14	increase	increase	NOUN
bam-12937	161	15	in	in	ADP
bam-12937	161	16	hdl	hdl	PROPN
bam-12937	161	17	-	-	PUNCT
bam-12937	161	18	c.	c.	PROPN
bam-12937	161	19	these	these	DET
bam-12937	161	20	findings	finding	NOUN
bam-12937	161	21	are	be	AUX
bam-12937	161	22	consistent	consistent	ADJ
bam-12937	161	23	with	with	ADP
bam-12937	161	24	prior	prior	ADJ
bam-12937	161	25	research	research	NOUN
bam-12937	161	26	on	on	ADP
bam-12937	161	27	evolocumab	evolocumab	NOUN
bam-12937	161	28	’s	’s	PART
bam-12937	161	29	efficacy	efficacy	NOUN
bam-12937	161	30	in	in	ADP
bam-12937	161	31	improving	improve	VERB
bam-12937	161	32	overall	overall	ADJ
bam-12937	161	33	lipid	lipid	NOUN
bam-12937	161	34	profiles	profile	NOUN
bam-12937	161	35	.	.	PUNCT
bam-12937	162	1	encouragingly	encouragingly	ADV
bam-12937	162	2	,	,	PUNCT
bam-12937	162	3	none	none	NOUN
bam-12937	162	4	of	of	ADP
bam-12937	162	5	the	the	DET
bam-12937	162	6	participants	participant	NOUN
bam-12937	162	7	with	with	ADP
bam-12937	162	8	a	a	DET
bam-12937	162	9	history	history	NOUN
bam-12937	162	10	of	of	ADP
bam-12937	162	11	prior	prior	ADJ
bam-12937	162	12	cardiovascular	cardiovascular	ADJ
bam-12937	162	13	events	event	NOUN
bam-12937	162	14	experienced	experience	VERB
bam-12937	162	15	new	new	ADJ
bam-12937	162	16	occurrences	occurrence	NOUN
bam-12937	162	17	during	during	ADP
bam-12937	162	18	the	the	DET
bam-12937	162	19	follow	follow	NOUN
bam-12937	162	20	-	-	PUNCT
bam-12937	162	21	up	up	NOUN
bam-12937	162	22	period	period	NOUN
bam-12937	162	23	,	,	PUNCT
bam-12937	162	24	suggesting	suggest	VERB
bam-12937	162	25	a	a	DET
bam-12937	162	26	potential	potential	ADJ
bam-12937	162	27	association	association	NOUN
bam-12937	162	28	with	with	ADP
bam-12937	162	29	reduced	reduce	VERB
bam-12937	162	30	cardiovascular	cardiovascular	ADJ
bam-12937	162	31	risk	risk	NOUN
bam-12937	162	32	.	.	PUNCT
bam-12937	163	1	list	list	NOUN
bam-12937	163	2	of	of	ADP
bam-12937	163	3	acronyms	acronym	NOUN
bam-12937	163	4	ldl	ldl	PROPN
bam-12937	163	5	-	-	PUNCT
bam-12937	163	6	c	c	NOUN
bam-12937	163	7	:	:	PUNCT
bam-12937	163	8	low	low	ADJ
bam-12937	163	9	-	-	PUNCT
bam-12937	163	10	density	density	NOUN
bam-12937	163	11	lipoprotein	lipoprotein	ADJ
bam-12937	163	12	cholesterol	cholesterol	NOUN
bam-12937	163	13	.	.	PUNCT
bam-12937	164	1	hdl	hdl	PROPN
bam-12937	164	2	-	-	PUNCT
bam-12937	164	3	c	c	NOUN
bam-12937	164	4	:	:	PUNCT
bam-12937	164	5	high	high	ADJ
bam-12937	164	6	-	-	PUNCT
bam-12937	164	7	density	density	NOUN
bam-12937	164	8	lipoprotein	lipoprotein	ADJ
bam-12937	164	9	cholesterol	cholesterol	NOUN
bam-12937	164	10	.	.	PUNCT
bam-12937	165	1	fh	fh	PROPN
bam-12937	165	2	:	:	PUNCT
bam-12937	165	3	familial	familial	ADJ
bam-12937	165	4	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	165	5	.	.	PUNCT
bam-12937	166	1	mi	mi	NOUN
bam-12937	166	2	:	:	PUNCT
bam-12937	166	3	myocardial	myocardial	ADJ
bam-12937	166	4	infarction	infarction	NOUN
bam-12937	166	5	.	.	PUNCT
bam-12937	167	1	pci	pci	ADJ
bam-12937	167	2	:	:	PUNCT
bam-12937	167	3	percutaneous	percutaneous	ADJ
bam-12937	167	4	coronary	coronary	ADJ
bam-12937	167	5	intervention	intervention	NOUN
bam-12937	167	6	.	.	PUNCT
bam-12937	168	1	cabg	cabg	ADP
bam-12937	168	2	:	:	PUNCT
bam-12937	168	3	coronary	coronary	ADJ
bam-12937	168	4	artery	artery	NOUN
bam-12937	168	5	bypass	bypass	NOUN
bam-12937	168	6	grafting	grafting	NOUN
bam-12937	168	7	.	.	PUNCT
bam-12937	169	1	pad	pad	NOUN
bam-12937	169	2	:	:	PUNCT
bam-12937	169	3	peripheral	peripheral	ADJ
bam-12937	169	4	artery	artery	NOUN
bam-12937	169	5	disease	disease	NOUN
bam-12937	169	6	.	.	PUNCT
bam-12937	170	1	ccu	ccu	PROPN
bam-12937	170	2	:	:	PUNCT
bam-12937	170	3	coronary	coronary	ADJ
bam-12937	170	4	care	care	NOUN
bam-12937	170	5	unit	unit	NOUN
bam-12937	170	6	.	.	PUNCT
bam-12937	171	1	cvd	cvd	NOUN
bam-12937	171	2	:	:	PUNCT
bam-12937	171	3	cardiovascular	cardiovascular	ADJ
bam-12937	171	4	events	event	NOUN
bam-12937	171	5	.	.	PUNCT
bam-12937	172	1	conflict	conflict	NOUN
bam-12937	172	2	of	of	ADP
bam-12937	172	3	interest	interest	NOUN
bam-12937	172	4	the	the	DET
bam-12937	172	5	authors	author	NOUN
bam-12937	172	6	declare	declare	VERB
bam-12937	172	7	no	no	DET
bam-12937	172	8	potential	potential	ADJ
bam-12937	172	9	conflict	conflict	NOUN
bam-12937	172	10	of	of	ADP
bam-12937	172	11	interest	interest	NOUN
bam-12937	172	12	,	,	PUNCT
bam-12937	172	13	and	and	CCONJ
bam-12937	172	14	all	all	DET
bam-12937	172	15	authors	author	NOUN
bam-12937	172	16	confirm	confirm	VERB
bam-12937	172	17	accuracy	accuracy	NOUN
bam-12937	172	18	.	.	PUNCT
bam-12937	173	1	funding	funding	NOUN
bam-12937	173	2	atherosclerosis	atherosclerosis	NOUN
bam-12937	173	3	research	research	NOUN
bam-12937	173	4	center	center	NOUN
bam-12937	173	5	,	,	PUNCT
bam-12937	173	6	baqiayatallah	baqiayatallah	PROPN
bam-12937	173	7	university	university	PROPN
bam-12937	173	8	of	of	ADP
bam-12937	173	9	medical	medical	ADJ
bam-12937	173	10	sciences	sciences	PROPN
bam-12937	173	11	,	,	PUNCT
bam-12937	173	12	tehran	tehran	PROPN
bam-12937	173	13	,	,	PUNCT
bam-12937	173	14	ir	ir	PROPN
bam-12937	173	15	iran	iran	PROPN
bam-12937	173	16	.	.	PUNCT
bam-12937	174	1	ethics	ethic	NOUN
bam-12937	174	2	approval	approval	VERB
bam-12937	174	3	the	the	DET
bam-12937	174	4	ethics	ethic	NOUN
bam-12937	174	5	committee	committee	PROPN
bam-12937	174	6	of	of	ADP
bam-12937	174	7	baqiayatallah	baqiayatallah	PROPN
bam-12937	174	8	university	university	PROPN
bam-12937	174	9	of	of	ADP
bam-12937	174	10	medical	medical	ADJ
bam-12937	174	11	sciencesapproved	sciencesapprove	VERB
bam-12937	174	12	this	this	DET
bam-12937	174	13	study	study	NOUN
bam-12937	174	14	(	(	PUNCT
bam-12937	174	15	ir.bmsu.baq	ir.bmsu.baq	PROPN
bam-12937	174	16	.	.	PUNCT
bam-12937	174	17	rec.1402.052	rec.1402.052	PROPN
bam-12937	174	18	)	)	PUNCT
bam-12937	174	19	.	.	PUNCT
bam-12937	175	1	the	the	DET
bam-12937	175	2	study	study	NOUN
bam-12937	175	3	is	be	AUX
bam-12937	175	4	conformed	conform	VERB
bam-12937	175	5	with	with	ADP
bam-12937	175	6	the	the	DET
bam-12937	175	7	helsinki	helsinki	PROPN
bam-12937	175	8	declaration	declaration	NOUN
bam-12937	175	9	of	of	ADP
bam-12937	175	10	1964	1964	NUM
bam-12937	175	11	,	,	PUNCT
bam-12937	175	12	as	as	SCONJ
bam-12937	175	13	revised	revise	VERB
bam-12937	175	14	in	in	ADP
bam-12937	175	15	2013	2013	NUM
bam-12937	175	16	,	,	PUNCT
bam-12937	175	17	concerning	concern	VERB
bam-12937	175	18	human	human	ADJ
bam-12937	175	19	and	and	CCONJ
bam-12937	175	20	animal	animal	NOUN
bam-12937	175	21	rights	right	NOUN
bam-12937	175	22	.	.	PUNCT
bam-12937	176	1	informed	inform	VERB
bam-12937	176	2	consent	consent	NOUN
bam-12937	176	3	all	all	DET
bam-12937	176	4	patients	patient	NOUN
bam-12937	176	5	participating	participate	VERB
bam-12937	176	6	in	in	ADP
bam-12937	176	7	this	this	DET
bam-12937	176	8	study	study	NOUN
bam-12937	176	9	signed	sign	VERB
bam-12937	176	10	a	a	DET
bam-12937	176	11	written	write	VERB
bam-12937	176	12	informed	inform	VERB
bam-12937	176	13	consent	consent	NOUN
bam-12937	176	14	form	form	NOUN
bam-12937	176	15	for	for	ADP
bam-12937	176	16	participating	participate	VERB
bam-12937	176	17	in	in	ADP
bam-12937	176	18	this	this	DET
bam-12937	176	19	study	study	NOUN
bam-12937	176	20	.	.	PUNCT
bam-12937	177	1	patient	patient	ADJ
bam-12937	177	2	consent	consent	NOUN
bam-12937	177	3	for	for	ADP
bam-12937	177	4	publication	publication	NOUN
bam-12937	177	5	written	write	VERB
bam-12937	177	6	informed	inform	VERB
bam-12937	177	7	consent	consent	NOUN
bam-12937	177	8	was	be	AUX
bam-12937	177	9	obtained	obtain	VERB
bam-12937	177	10	from	from	ADP
bam-12937	177	11	a	a	DET
bam-12937	177	12	legally	legally	ADV
bam-12937	177	13	authorized	authorize	VERB
bam-12937	177	14	representative(s	representative(s	NOUN
bam-12937	177	15	)	)	PUNCT
bam-12937	177	16	for	for	ADP
bam-12937	177	17	anonymized	anonymize	VERB
bam-12937	177	18	patient	patient	ADJ
bam-12937	177	19	information	information	NOUN
bam-12937	177	20	to	to	PART
bam-12937	177	21	be	be	AUX
bam-12937	177	22	published	publish	VERB
bam-12937	177	23	in	in	ADP
bam-12937	177	24	this	this	DET
bam-12937	177	25	article	article	NOUN
bam-12937	177	26	.	.	PUNCT
bam-12937	178	1	availability	availability	NOUN
bam-12937	178	2	of	of	ADP
bam-12937	178	3	data	datum	NOUN
bam-12937	178	4	and	and	CCONJ
bam-12937	178	5	materials	material	NOUN
bam-12937	178	6	all	all	DET
bam-12937	178	7	data	datum	NOUN
bam-12937	178	8	generated	generate	VERB
bam-12937	178	9	or	or	CCONJ
bam-12937	178	10	analyzed	analyze	VERB
bam-12937	178	11	during	during	ADP
bam-12937	178	12	this	this	DET
bam-12937	178	13	study	study	NOUN
bam-12937	178	14	are	be	AUX
bam-12937	178	15	included	include	VERB
bam-12937	178	16	in	in	ADP
bam-12937	178	17	this	this	DET
bam-12937	178	18	published	publish	VERB
bam-12937	178	19	article	article	NOUN
bam-12937	178	20	.	.	PUNCT
bam-12937	179	1	corresponding	correspond	VERB
bam-12937	179	2	author	author	PROPN
bam-12937	179	3	ali	ali	PROPN
bam-12937	179	4	shamsedini	shamsedini	PROPN
bam-12937	179	5	,	,	PUNCT
bam-12937	179	6	atherosclerosis	atherosclerosis	NOUN
bam-12937	179	7	research	research	NOUN
bam-12937	179	8	center	center	NOUN
bam-12937	179	9	,	,	PUNCT
bam-12937	179	10	baqiayatallah	baqiayatallah	PROPN
bam-12937	179	11	university	university	PROPN
bam-12937	179	12	of	of	ADP
bam-12937	179	13	medical	medical	ADJ
bam-12937	179	14	sciences	sciences	PROPN
bam-12937	179	15	,	,	PUNCT
bam-12937	179	16	tehran	tehran	PROPN
bam-12937	179	17	,	,	PUNCT
bam-12937	179	18	ir	ir	PROPN
bam-12937	179	19	iran	iran	PROPN
bam-12937	179	20	.	.	PUNCT
bam-12937	180	1	oricd	oricd	VERB
bam-12937	180	2	i	i	PROPN
bam-12937	181	1	d	d	NOUN
bam-12937	181	2	:	:	PUNCT
bam-12937	181	3	0000	0000	NUM
bam-12937	181	4	-	-	PUNCT
bam-12937	181	5	0002	0002	NUM
bam-12937	181	6	-	-	PUNCT
bam-12937	181	7	0000	0000	NUM
bam-12937	181	8	-	-	SYM
bam-12937	181	9	1236	1236	NUM
bam-12937	181	10	e	e	NOUN
bam-12937	181	11	-	-	NOUN
bam-12937	181	12	mail	mail	NOUN
bam-12937	181	13	:	:	PUNCT
bam-12937	181	14	ali_shamsadini2000@yahoo.com	ali_shamsadini2000@yahoo.com	PROPN
bam-12937	181	15	maryam	maryam	PROPN
bam-12937	181	16	moshkani	moshkani	PROPN
bam-12937	181	17	farahani	farahani	PROPN
bam-12937	182	1	orcid	orcid	PROPN
bam-12937	183	1	i	i	PRON
bam-12937	183	2	d	d	NOUN
bam-12937	183	3	:	:	PUNCT
bam-12937	183	4	0000	0000	NUM
bam-12937	183	5	-	-	PUNCT
bam-12937	183	6	0003	0003	NUM
bam-12937	183	7	-	-	PUNCT
bam-12937	183	8	4902	4902	NUM
bam-12937	183	9	-	-	PUNCT
bam-12937	183	10	273x	273x	NOUN
bam-12937	183	11	e-mail:moshkani_farahani@yahoo.com	e-mail:moshkani_farahani@yahoo.com	X
bam-12937	184	1	alireza	alireza	PROPN
bam-12937	184	2	nasiri	nasiri	ADV
bam-12937	184	3	orcid	orcid	PROPN
bam-12937	185	1	i	i	PRON
bam-12937	185	2	d	d	NOUN
bam-12937	185	3	:	:	PUNCT
bam-12937	185	4	0000	0000	NUM
bam-12937	185	5	-	-	PUNCT
bam-12937	185	6	0003	0003	NUM
bam-12937	185	7	-	-	PUNCT
bam-12937	185	8	2608	2608	NUM
bam-12937	185	9	-	-	PUNCT
bam-12937	185	10	3660	3660	NUM
bam-12937	185	11	e-mail:alirezanasiri6592@yahoo.com	e-mail:alirezanasiri6592@yahoo.com	PROPN
bam-12937	185	12	mahdi	mahdi	PROPN
bam-12937	185	13	salari	salari	PROPN
bam-12937	186	1	orcid	orcid	PROPN
bam-12937	187	1	i	i	PRON
bam-12937	187	2	d	d	NOUN
bam-12937	187	3	:	:	PUNCT
bam-12937	187	4	0000	0000	NUM
bam-12937	187	5	-	-	PUNCT
bam-12937	187	6	0001	0001	NUM
bam-12937	187	7	-	-	PUNCT
bam-12937	187	8	8568	8568	NUM
bam-12937	187	9	-	-	PUNCT
bam-12937	187	10	658x	658x	NOUN
bam-12937	187	11	e-mail:salaricardiologist@yahoo.com	e-mail:salaricardiologist@yahoo.com	NUM
bam-12937	187	12	references	reference	NOUN
bam-12937	187	13	1	1	NUM
bam-12937	187	14	.	.	PUNCT
bam-12937	188	1	hovingh	hovingh	PROPN
bam-12937	188	2	gk	gk	PROPN
bam-12937	188	3	,	,	PUNCT
bam-12937	188	4	raal	raal	PROPN
bam-12937	188	5	fj	fj	PROPN
bam-12937	188	6	,	,	PUNCT
bam-12937	188	7	dent	dent	NOUN
bam-12937	188	8	r	r	NOUN
bam-12937	188	9	,	,	PUNCT
bam-12937	188	10	et	et	PROPN
bam-12937	188	11	al	al	PROPN
bam-12937	188	12	.	.	PUNCT
bam-12937	189	1	long	long	ADJ
bam-12937	189	2	-	-	PUNCT
bam-12937	189	3	term	term	NOUN
bam-12937	189	4	safety	safety	NOUN
bam-12937	189	5	,	,	PUNCT
bam-12937	189	6	tolerability	tolerability	NOUN
bam-12937	189	7	,	,	PUNCT
bam-12937	189	8	and	and	CCONJ
bam-12937	189	9	efficacy	efficacy	NOUN
bam-12937	189	10	of	of	ADP
bam-12937	189	11	evolocumab	evolocumab	NOUN
bam-12937	189	12	in	in	ADP
bam-12937	189	13	patients	patient	NOUN
bam-12937	189	14	with	with	ADP
bam-12937	189	15	heterozygous	heterozygous	ADJ
bam-12937	189	16	familial	familial	ADJ
bam-12937	189	17	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	189	18	.	.	PUNCT
bam-12937	190	1	j	j	PROPN
bam-12937	190	2	clin	clin	PROPN
bam-12937	190	3	lipidol	lipidol	VERB
bam-12937	190	4	2017;11:1448	2017;11:1448	NUM
bam-12937	190	5	-	-	SYM
bam-12937	190	6	57	57	NUM
bam-12937	190	7	.	.	NOUN
bam-12937	191	1	2	2	NUM
bam-12937	191	2	.	.	X
bam-12937	191	3	luquero	luquero	NOUN
bam-12937	191	4	a	a	PRON
bam-12937	191	5	,	,	PUNCT
bam-12937	191	6	badimon	badimon	NOUN
bam-12937	191	7	l	l	NOUN
bam-12937	191	8	,	,	PUNCT
bam-12937	191	9	borrell	borrell	ADJ
bam-12937	191	10	-	-	PUNCT
bam-12937	191	11	pages	page	NOUN
bam-12937	191	12	m.	m.	NOUN
bam-12937	191	13	pcsk9	pcsk9	PROPN
bam-12937	191	14	functions	function	NOUN
bam-12937	191	15	in	in	ADP
bam-12937	191	16	atherosclerosis	atherosclerosis	NOUN
bam-12937	191	17	are	be	AUX
bam-12937	191	18	not	not	PART
bam-12937	191	19	limited	limit	VERB
bam-12937	191	20	to	to	PART
bam-12937	191	21	plasmatic	plasmatic	VERB
bam-12937	191	22	ldl	ldl	NOUN
bam-12937	191	23	-	-	PUNCT
bam-12937	191	24	cholesterol	cholesterol	NOUN
bam-12937	191	25	regulation	regulation	NOUN
bam-12937	191	26	.	.	PUNCT
bam-12937	192	1	front	front	PROPN
bam-12937	192	2	cardiovasc	cardiovasc	PROPN
bam-12937	192	3	med	med	PROPN
bam-12937	192	4	2021;8:639727	2021;8:639727	NOUN
bam-12937	192	5	.	.	PUNCT
bam-12937	193	1	120	120	NUM
bam-12937	193	2	non	non	ADJ
bam-12937	193	3	-co	-co	PROPN
bam-12937	193	4	mmerc	mmerc	PROPN
bam-12937	193	5	ial	ial	PROPN
bam-12937	193	6	us	us	PROPN
bam-12937	193	7	e	e	NOUN
bam-12937	193	8	o	o	NOUN
bam-12937	193	9	nly	nly	ADV
bam-12937	193	10	mailto:ali_shamsadini2000@yahoo.com	mailto:ali_shamsadini2000@yahoo.com	X
bam-12937	193	11	mailto:moshkani_farahani@yahoo.com	mailto:moshkani_farahani@yahoo.com	X
bam-12937	193	12	mailto:alirezanasiri6592@yahoo.com	mailto:alirezanasiri6592@yahoo.com	X
bam-12937	193	13	mailto:salaricardiologist@yahoo.com	mailto:salaricardiologist@yahoo.com	X
bam-12937	194	1	the	the	DET
bam-12937	194	2	therapeutic	therapeutic	ADJ
bam-12937	194	3	effect	effect	NOUN
bam-12937	194	4	of	of	ADP
bam-12937	194	5	pcsk9	pcsk9	NOUN
bam-12937	194	6	inhibitors	inhibitor	NOUN
bam-12937	194	7	on	on	ADP
bam-12937	194	8	dyslipidemia	dyslipidemia	NOUN
bam-12937	194	9	:	:	PUNCT
bam-12937	194	10	one	one	NUM
bam-12937	194	11	-	-	PUNCT
bam-12937	194	12	year	year	NOUN
bam-12937	194	13	follow	follow	VERB
bam-12937	194	14	up	up	ADP
bam-12937	194	15	eur	eur	PROPN
bam-12937	194	16	j	j	PROPN
bam-12937	194	17	transl	transl	PROPN
bam-12937	194	18	myol	myol	NOUN
bam-12937	194	19	34	34	NUM
bam-12937	194	20	(	(	PUNCT
bam-12937	194	21	3	3	NUM
bam-12937	194	22	)	)	PUNCT
bam-12937	194	23	12937	12937	NUM
bam-12937	194	24	,	,	PUNCT
bam-12937	194	25	2024	2024	NUM
bam-12937	194	26	doi	doi	NOUN
bam-12937	194	27	:	:	PUNCT
bam-12937	194	28	10.4081	10.4081	NUM
bam-12937	194	29	/	/	SYM
bam-12937	194	30	ejtm.2024.12937	ejtm.2024.12937	PROPN
bam-12937	194	31	3	3	NUM
bam-12937	194	32	.	.	PUNCT
bam-12937	194	33	azimi	azimi	PROPN
bam-12937	194	34	m	m	PROPN
bam-12937	194	35	,	,	PUNCT
bam-12937	194	36	ahmadi	ahmadi	PROPN
bam-12937	194	37	e	e	PROPN
bam-12937	194	38	,	,	PUNCT
bam-12937	194	39	aghaie	aghaie	PROPN
bam-12937	194	40	f	f	PROPN
bam-12937	194	41	,	,	PUNCT
bam-12937	194	42	et	et	PROPN
bam-12937	194	43	al	al	PROPN
bam-12937	194	44	.	.	PUNCT
bam-12937	195	1	the	the	DET
bam-12937	195	2	effect	effect	NOUN
bam-12937	195	3	of	of	ADP
bam-12937	195	4	alcoholic	alcoholic	ADJ
bam-12937	195	5	extract	extract	NOUN
bam-12937	195	6	of	of	ADP
bam-12937	195	7	thymus	thymus	ADJ
bam-12937	195	8	vulgaris	vulgaris	NOUN
bam-12937	195	9	on	on	ADP
bam-12937	195	10	hepatic	hepatic	ADJ
bam-12937	195	11	enzymes	enzyme	NOUN
bam-12937	195	12	activity	activity	NOUN
bam-12937	195	13	and	and	CCONJ
bam-12937	195	14	apoptosis	apoptosis	NOUN
bam-12937	195	15	-	-	PUNCT
bam-12937	195	16	related	relate	VERB
bam-12937	195	17	gene	gene	NOUN
bam-12937	195	18	expression	expression	NOUN
bam-12937	195	19	in	in	ADP
bam-12937	195	20	streptozotocin	streptozotocin	NOUN
bam-12937	195	21	-	-	PUNCT
bam-12937	195	22	induced	induce	VERB
bam-12937	195	23	diabetic	diabetic	ADJ
bam-12937	195	24	rats	rat	NOUN
bam-12937	195	25	.	.	PUNCT
bam-12937	196	1	evid	evid	PROPN
bam-12937	196	2	based	base	VERB
bam-12937	196	3	complement	complement	PROPN
bam-12937	196	4	alternat	alternat	NOUN
bam-12937	196	5	med	me	VERB
bam-12937	196	6	2022;2022	2022;2022	NOUN
bam-12937	196	7	:	:	PUNCT
bam-12937	196	8	2948966	2948966	NUM
bam-12937	196	9	.	.	PUNCT
bam-12937	197	1	4	4	X
bam-12937	197	2	.	.	X
bam-12937	197	3	vaezi	vaezi	PROPN
bam-12937	197	4	z	z	PROPN
bam-12937	197	5	,	,	PUNCT
bam-12937	197	6	amini	amini	PROPN
bam-12937	197	7	a.	a.	PROPN
bam-12937	197	8	familial	familial	ADJ
bam-12937	197	9	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	197	10	.	.	PUNCT
bam-12937	198	1	[	[	X
bam-12937	198	2	updated	update	VERB
bam-12937	198	3	2022	2022	NUM
bam-12937	198	4	sep	sep	PROPN
bam-12937	198	5	26	26	NUM
bam-12937	198	6	]	]	PUNCT
bam-12937	198	7	.	.	PUNCT
bam-12937	199	1	in	in	ADP
bam-12937	199	2	:	:	PUNCT
bam-12937	199	3	statpearls	statpearl	NOUN
bam-12937	200	1	[	[	X
bam-12937	200	2	internet	internet	NOUN
bam-12937	200	3	]	]	PUNCT
bam-12937	200	4	.	.	PUNCT
bam-12937	201	1	treasure	treasure	NOUN
bam-12937	201	2	island	island	NOUN
bam-12937	201	3	(	(	PUNCT
bam-12937	201	4	fl	fl	PROPN
bam-12937	201	5	):	):	PUNCT
bam-12937	201	6	statpearls	statpearl	NOUN
bam-12937	201	7	publishing	publishing	NOUN
bam-12937	201	8	;	;	PUNCT
bam-12937	201	9	2024	2024	NUM
bam-12937	201	10	jan	jan	PROPN
bam-12937	201	11	.	.	PROPN
bam-12937	201	12	available	available	ADJ
bam-12937	201	13	from	from	ADP
bam-12937	201	14	:	:	PUNCT
bam-12937	201	15	https://www.ncbi.nlm.nih.gov/	https://www.ncbi.nlm.nih.gov/	NOUN
bam-12937	201	16	books	book	NOUN
bam-12937	201	17	/	/	SYM
bam-12937	201	18	nbk556009/	nbk556009/	PROPN
bam-12937	201	19	5	5	NUM
bam-12937	201	20	.	.	PUNCT
bam-12937	201	21	jalili	jalili	NOUN
bam-12937	201	22	c	c	PROPN
bam-12937	201	23	,	,	PUNCT
bam-12937	201	24	darakhshan	darakhshan	PROPN
bam-12937	201	25	s	s	PROPN
bam-12937	201	26	,	,	PUNCT
bam-12937	201	27	azimi	azimi	PROPN
bam-12937	201	28	m.	m.	PROPN
bam-12937	201	29	harmine	harmine	PROPN
bam-12937	201	30	mitigates	mitigate	VERB
bam-12937	201	31	liver	liver	NOUN
bam-12937	201	32	injury	injury	NOUN
bam-12937	201	33	induced	induce	VERB
bam-12937	201	34	by	by	ADP
bam-12937	201	35	mercuric	mercuric	ADJ
bam-12937	201	36	chloride	chloride	NOUN
bam-12937	201	37	via	via	ADP
bam-12937	201	38	the	the	DET
bam-12937	201	39	inhibition	inhibition	NOUN
bam-12937	201	40	of	of	ADP
bam-12937	201	41	oxidative	oxidative	ADJ
bam-12937	201	42	stress	stress	NOUN
bam-12937	201	43	.	.	PUNCT
bam-12937	202	1	res	re	NOUN
bam-12937	202	2	j	j	PROPN
bam-12937	202	3	pharmacogn	pharmacogn	PROPN
bam-12937	202	4	2021	2021	NUM
bam-12937	202	5	;	;	PUNCT
bam-12937	202	6	8:13	8:13	NUM
bam-12937	202	7	-	-	SYM
bam-12937	202	8	23	23	NUM
bam-12937	202	9	.	.	PUNCT
bam-12937	203	1	6	6	NUM
bam-12937	203	2	.	.	PUNCT
bam-12937	203	3	rezaei	rezaei	PROPN
bam-12937	203	4	m	m	PROPN
bam-12937	203	5	,	,	PUNCT
bam-12937	203	6	rahmani	rahmani	X
bam-12937	203	7	e	e	NOUN
bam-12937	203	8	,	,	PUNCT
bam-12937	203	9	khouzani	khouzani	PROPN
bam-12937	203	10	sj	sj	PROPN
bam-12937	203	11	,	,	PUNCT
bam-12937	203	12	et	et	PROPN
bam-12937	203	13	al	al	PROPN
bam-12937	203	14	.	.	PROPN
bam-12937	203	15	role	role	NOUN
bam-12937	203	16	of	of	ADP
bam-12937	203	17	artificial	artificial	ADJ
bam-12937	203	18	intelligence	intelligence	NOUN
bam-12937	203	19	in	in	ADP
bam-12937	203	20	the	the	DET
bam-12937	203	21	diagnosis	diagnosis	NOUN
bam-12937	203	22	and	and	CCONJ
bam-12937	203	23	treatment	treatment	NOUN
bam-12937	203	24	of	of	ADP
bam-12937	203	25	diseases	disease	NOUN
bam-12937	203	26	.	.	PUNCT
bam-12937	204	1	kindle	kindle	NOUN
bam-12937	204	2	2023;3:1	2023;3:1	PROPN
bam-12937	204	3	-	-	SYM
bam-12937	204	4	60	60	NUM
bam-12937	204	5	.	.	PUNCT
bam-12937	205	1	7	7	X
bam-12937	205	2	.	.	X
bam-12937	205	3	albuquerque	albuquerque	PROPN
bam-12937	205	4	j	j	PROPN
bam-12937	205	5	,	,	PUNCT
bam-12937	205	6	alves	alves	PROPN
bam-12937	205	7	ac	ac	PROPN
bam-12937	205	8	,	,	PUNCT
bam-12937	205	9	medeiros	medeiros	PROPN
bam-12937	205	10	am	be	AUX
bam-12937	205	11	,	,	PUNCT
bam-12937	205	12	et	et	PROPN
bam-12937	205	13	al	al	PROPN
bam-12937	205	14	.	.	PUNCT
bam-12937	206	1	classification	classification	NOUN
bam-12937	206	2	methods	method	NOUN
bam-12937	206	3	applied	apply	VERB
bam-12937	206	4	to	to	ADP
bam-12937	206	5	familial	familial	ADJ
bam-12937	206	6	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	206	7	diagnosis	diagnosis	NOUN
bam-12937	206	8	at	at	ADP
bam-12937	206	9	pediatric	pediatric	ADJ
bam-12937	206	10	age	age	NOUN
bam-12937	206	11	:	:	PUNCT
bam-12937	206	12	comparison	comparison	NOUN
bam-12937	206	13	of	of	ADP
bam-12937	206	14	simon	simon	PROPN
bam-12937	206	15	broome	broome	PROPN
bam-12937	206	16	criteria	criteria	PROPN
bam-12937	206	17	with	with	ADP
bam-12937	206	18	modified	modified	ADJ
bam-12937	206	19	decision	decision	NOUN
bam-12937	206	20	tree	tree	NOUN
bam-12937	206	21	models	model	NOUN
bam-12937	206	22	.	.	PUNCT
bam-12937	207	1	atherosclerosis	atherosclerosis	NOUN
bam-12937	207	2	2020;315	2020;315	NUM
bam-12937	207	3	:	:	PUNCT
bam-12937	207	4	e205	e205	NUM
bam-12937	207	5	.	.	NOUN
bam-12937	207	6	8	8	NUM
bam-12937	207	7	.	.	PUNCT
bam-12937	207	8	safari	safari	PROPN
bam-12937	207	9	h	h	PROPN
bam-12937	207	10	,	,	PUNCT
bam-12937	207	11	ajudani	ajudani	ADJ
bam-12937	207	12	r	r	NOUN
bam-12937	207	13	,	,	PUNCT
bam-12937	207	14	savaie	savaie	NOUN
bam-12937	207	15	m	m	PROPN
bam-12937	207	16	,	,	PUNCT
bam-12937	207	17	et	et	PROPN
bam-12937	207	18	al	al	PROPN
bam-12937	207	19	.	.	PUNCT
bam-12937	208	1	intracerebral	intracerebral	ADJ
bam-12937	208	2	hemorrhage	hemorrhage	NOUN
bam-12937	208	3	in	in	ADP
bam-12937	208	4	methanol	methanol	NOUN
bam-12937	208	5	toxicity	toxicity	NOUN
bam-12937	208	6	patients	patient	NOUN
bam-12937	208	7	during	during	ADP
bam-12937	208	8	covid-19	covid-19	PROPN
bam-12937	208	9	pandemic	pandemic	ADJ
bam-12937	208	10	:	:	PUNCT
bam-12937	208	11	case	case	NOUN
bam-12937	208	12	report	report	NOUN
bam-12937	208	13	and	and	CCONJ
bam-12937	208	14	review	review	NOUN
bam-12937	208	15	of	of	ADP
bam-12937	208	16	literature	literature	NOUN
bam-12937	208	17	.	.	PUNCT
bam-12937	209	1	forensic	forensic	ADJ
bam-12937	209	2	toxicol	toxicol	PROPN
bam-12937	209	3	2024:1	2024:1	NUM
bam-12937	209	4	-	-	SYM
bam-12937	209	5	6	6	NUM
bam-12937	209	6	.	.	NOUN
bam-12937	209	7	9	9	NUM
bam-12937	209	8	.	.	X
bam-12937	209	9	kasichayanula	kasichayanula	PROPN
bam-12937	209	10	s	s	PROPN
bam-12937	209	11	,	,	PUNCT
bam-12937	209	12	grover	grover	PROPN
bam-12937	209	13	a	a	PROPN
bam-12937	209	14	,	,	PUNCT
bam-12937	209	15	emery	emery	PROPN
bam-12937	209	16	mg	mg	PROPN
bam-12937	209	17	,	,	PUNCT
bam-12937	209	18	et	et	PROPN
bam-12937	209	19	al	al	PROPN
bam-12937	209	20	.	.	PROPN
bam-12937	210	1	clinical	clinical	ADJ
bam-12937	210	2	pharmacokinetics	pharmacokinetic	NOUN
bam-12937	210	3	and	and	CCONJ
bam-12937	210	4	pharmacodynamics	pharmacodynamic	NOUN
bam-12937	210	5	of	of	ADP
bam-12937	210	6	evolocumab	evolocumab	NOUN
bam-12937	210	7	,	,	PUNCT
bam-12937	210	8	a	a	DET
bam-12937	210	9	pcsk9	pcsk9	NOUN
bam-12937	210	10	inhibitor	inhibitor	NOUN
bam-12937	210	11	.	.	PUNCT
bam-12937	211	1	clin	clin	PROPN
bam-12937	211	2	pharmacokin	pharmacokin	PROPN
bam-12937	211	3	2018;57	2018;57	NUM
bam-12937	211	4	:	:	PUNCT
bam-12937	211	5	769	769	NUM
bam-12937	211	6	-	-	SYM
bam-12937	211	7	79	79	NUM
bam-12937	211	8	.	.	PUNCT
bam-12937	211	9	10	10	NUM
bam-12937	211	10	.	.	PUNCT
bam-12937	212	1	wei	wei	PROPN
bam-12937	212	2	cc	cc	PROPN
bam-12937	212	3	,	,	PUNCT
bam-12937	212	4	razzak	razzak	PROPN
bam-12937	212	5	aa	aa	PROPN
bam-12937	212	6	,	,	PUNCT
bam-12937	212	7	ghasemi	ghasemi	PROPN
bam-12937	212	8	h	h	NOUN
bam-12937	212	9	,	,	PUNCT
bam-12937	212	10	et	et	PROPN
bam-12937	212	11	al	al	PROPN
bam-12937	212	12	.	.	PUNCT
bam-12937	213	1	ca2	ca2	PROPN
bam-12937	213	2	+	+	CCONJ
bam-12937	213	3	binding	bind	VERB
bam-12937	213	4	shifts	shift	NOUN
bam-12937	213	5	dimeric	dimeric	ADJ
bam-12937	213	6	dual	dual	ADJ
bam-12937	213	7	oxidase	oxidase	NOUN
bam-12937	213	8	’s	’s	PART
bam-12937	213	9	truncated	truncate	VERB
bam-12937	213	10	ef	ef	ADJ
bam-12937	213	11	-	-	ADJ
bam-12937	213	12	hand	hand	NOUN
bam-12937	213	13	domain	domain	NOUN
bam-12937	213	14	to	to	ADP
bam-12937	213	15	monomer	monomer	PROPN
bam-12937	213	16	.	.	PUNCT
bam-12937	214	1	biophys	biophys	PROPN
bam-12937	214	2	chem	chem	NOUN
bam-12937	214	3	2024:107271	2024:107271	NUM
bam-12937	214	4	.	.	PUNCT
bam-12937	215	1	11	11	NUM
bam-12937	215	2	.	.	PUNCT
bam-12937	216	1	liu	liu	PROPN
bam-12937	216	2	c	c	PROPN
bam-12937	216	3	,	,	PUNCT
bam-12937	216	4	chen	chen	PROPN
bam-12937	216	5	j	j	PROPN
bam-12937	216	6	,	,	PUNCT
bam-12937	216	7	chen	chen	PROPN
bam-12937	216	8	h	h	PROPN
bam-12937	216	9	,	,	PUNCT
bam-12937	216	10	et	et	PROPN
bam-12937	216	11	al	al	PROPN
bam-12937	216	12	.	.	PUNCT
bam-12937	217	1	pcsk9	pcsk9	PROPN
bam-12937	217	2	inhibition	inhibition	NOUN
bam-12937	217	3	:	:	PUNCT
bam-12937	217	4	from	from	ADP
bam-12937	217	5	current	current	ADJ
bam-12937	217	6	advances	advance	NOUN
bam-12937	217	7	to	to	ADP
bam-12937	217	8	evolving	evolve	VERB
bam-12937	217	9	future	future	NOUN
bam-12937	217	10	.	.	PUNCT
bam-12937	218	1	cells	cell	NOUN
bam-12937	218	2	2022;11	2022;11	NUM
bam-12937	218	3	:	:	PUNCT
bam-12937	218	4	2972	2972	NUM
bam-12937	218	5	.	.	PUNCT
bam-12937	219	1	12	12	NUM
bam-12937	219	2	.	.	PUNCT
bam-12937	219	3	kastelein	kastelein	PROPN
bam-12937	219	4	jj	jj	PROPN
bam-12937	219	5	,	,	PUNCT
bam-12937	219	6	ginsberg	ginsberg	PROPN
bam-12937	219	7	hn	hn	PROPN
bam-12937	219	8	,	,	PUNCT
bam-12937	219	9	langslet	langslet	VERB
bam-12937	219	10	g	g	PROPN
bam-12937	219	11	,	,	PUNCT
bam-12937	219	12	et	et	PROPN
bam-12937	219	13	al	al	PROPN
bam-12937	219	14	.	.	PROPN
bam-12937	220	1	odyssey	odyssey	PROPN
bam-12937	220	2	fh	fh	PROPN
bam-12937	221	1	i	i	PROPN
bam-12937	221	2	and	and	CCONJ
bam-12937	221	3	fh	fh	PROPN
bam-12937	221	4	ii	ii	PROPN
bam-12937	221	5	:	:	PUNCT
bam-12937	221	6	78	78	NUM
bam-12937	221	7	week	week	NOUN
bam-12937	221	8	results	result	NOUN
bam-12937	221	9	with	with	ADP
bam-12937	221	10	alirocumab	alirocumab	NOUN
bam-12937	221	11	treatment	treatment	NOUN
bam-12937	221	12	in	in	ADP
bam-12937	221	13	735	735	NUM
bam-12937	221	14	patients	patient	NOUN
bam-12937	221	15	with	with	ADP
bam-12937	221	16	heterozygous	heterozygous	ADJ
bam-12937	221	17	familial	familial	ADJ
bam-12937	221	18	hypercholesterolaemia	hypercholesterolaemia	NOUN
bam-12937	221	19	.	.	PUNCT
bam-12937	222	1	eur	eur	PROPN
bam-12937	222	2	heart	heart	NOUN
bam-12937	222	3	j	j	PROPN
bam-12937	222	4	2015;36:29963003	2015;36:29963003	NUM
bam-12937	222	5	.	.	PROPN
bam-12937	222	6	13	13	NUM
bam-12937	222	7	.	.	PUNCT
bam-12937	223	1	raal	raal	PROPN
bam-12937	223	2	fj	fj	PROPN
bam-12937	223	3	,	,	PUNCT
bam-12937	223	4	stein	stein	PROPN
bam-12937	223	5	ea	ea	PROPN
bam-12937	223	6	,	,	PUNCT
bam-12937	223	7	dufour	dufour	PROPN
bam-12937	223	8	r.	r.	PROPN
bam-12937	223	9	pcsk9	pcsk9	PROPN
bam-12937	223	10	inhibition	inhibition	VERB
bam-12937	223	11	with	with	ADP
bam-12937	223	12	evolocumab	evolocumab	NOUN
bam-12937	223	13	(	(	PUNCT
bam-12937	223	14	amg	amg	PROPN
bam-12937	223	15	145	145	NUM
bam-12937	223	16	)	)	PUNCT
bam-12937	223	17	in	in	ADP
bam-12937	223	18	heterozygous	heterozygous	ADJ
bam-12937	223	19	familial	familial	ADJ
bam-12937	223	20	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	223	21	(	(	PUNCT
bam-12937	223	22	rutherford-2	rutherford-2	NUM
bam-12937	223	23	):	):	PUNCT
bam-12937	223	24	a	a	DET
bam-12937	223	25	randomised	randomised	ADJ
bam-12937	223	26	,	,	PUNCT
bam-12937	223	27	double	double	ADJ
bam-12937	223	28	-	-	PUNCT
bam-12937	223	29	blind	blind	ADJ
bam-12937	223	30	,	,	PUNCT
bam-12937	223	31	placebo	placebo	NOUN
bam-12937	223	32	-	-	PUNCT
bam-12937	223	33	controlled	control	VERB
bam-12937	223	34	trial	trial	NOUN
bam-12937	223	35	.	.	PUNCT
bam-12937	224	1	j	j	PROPN
bam-12937	224	2	vascular	vascular	ADJ
bam-12937	224	3	surg	surg	NOUN
bam-12937	224	4	2015;62:1368	2015;62:1368	PROPN
bam-12937	224	5	.	.	PROPN
bam-12937	224	6	14	14	NUM
bam-12937	224	7	.	.	PUNCT
bam-12937	225	1	blom	blom	PROPN
bam-12937	225	2	dj	dj	PROPN
bam-12937	225	3	,	,	PUNCT
bam-12937	225	4	harada	harada	PROPN
bam-12937	225	5	-	-	PUNCT
bam-12937	225	6	shiba	shiba	PROPN
bam-12937	225	7	m	m	PROPN
bam-12937	225	8	,	,	PUNCT
bam-12937	225	9	rubba	rubba	NOUN
bam-12937	225	10	p	p	NOUN
bam-12937	225	11	,	,	PUNCT
bam-12937	225	12	et	et	PROPN
bam-12937	225	13	al	al	PROPN
bam-12937	225	14	.	.	PROPN
bam-12937	225	15	efficacy	efficacy	NOUN
bam-12937	225	16	and	and	CCONJ
bam-12937	225	17	safety	safety	NOUN
bam-12937	225	18	of	of	ADP
bam-12937	225	19	alirocumab	alirocumab	NOUN
bam-12937	225	20	in	in	ADP
bam-12937	225	21	adults	adult	NOUN
bam-12937	225	22	with	with	ADP
bam-12937	225	23	homozygous	homozygous	ADJ
bam-12937	225	24	familial	familial	ADJ
bam-12937	225	25	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	225	26	:	:	PUNCT
bam-12937	225	27	the	the	DET
bam-12937	225	28	odyssey	odyssey	ADJ
bam-12937	225	29	hofh	hofh	NOUN
bam-12937	225	30	trial	trial	NOUN
bam-12937	225	31	.	.	PUNCT
bam-12937	226	1	j	j	PROPN
bam-12937	226	2	am	be	AUX
bam-12937	226	3	coll	coll	PROPN
bam-12937	226	4	cardiol	cardiol	NOUN
bam-12937	226	5	2020;76:131	2020;76:131	NUM
bam-12937	226	6	-	-	SYM
bam-12937	226	7	42	42	NUM
bam-12937	226	8	.	.	PUNCT
bam-12937	227	1	15	15	NUM
bam-12937	227	2	.	.	PUNCT
bam-12937	228	1	toth	toth	PROPN
bam-12937	228	2	pp	pp	PROPN
bam-12937	228	3	,	,	PUNCT
bam-12937	228	4	bray	bray	PROPN
bam-12937	228	5	s	s	PROPN
bam-12937	228	6	,	,	PUNCT
bam-12937	228	7	villa	villa	PROPN
bam-12937	228	8	g	g	PROPN
bam-12937	228	9	,	,	PUNCT
bam-12937	228	10	et	et	PROPN
bam-12937	228	11	al	al	PROPN
bam-12937	228	12	.	.	PUNCT
bam-12937	229	1	network	network	PROPN
bam-12937	229	2	meta	meta	ADJ
bam-12937	229	3	-	-	PUNCT
bam-12937	229	4	analysis	analysis	NOUN
bam-12937	229	5	of	of	ADP
bam-12937	229	6	randomized	randomized	ADJ
bam-12937	229	7	trials	trial	NOUN
bam-12937	229	8	evaluating	evaluate	VERB
bam-12937	229	9	the	the	DET
bam-12937	229	10	comparative	comparative	ADJ
bam-12937	229	11	efficacy	efficacy	NOUN
bam-12937	229	12	of	of	ADP
bam-12937	229	13	lipid	lipid	NOUN
bam-12937	229	14	-	-	PUNCT
bam-12937	229	15	lowering	lower	VERB
bam-12937	229	16	therapies	therapy	NOUN
bam-12937	229	17	added	add	VERB
bam-12937	229	18	to	to	ADP
bam-12937	229	19	maximally	maximally	ADV
bam-12937	229	20	tolerated	tolerate	VERB
bam-12937	229	21	statins	statin	NOUN
bam-12937	229	22	for	for	ADP
bam-12937	229	23	the	the	DET
bam-12937	229	24	reduction	reduction	NOUN
bam-12937	229	25	of	of	ADP
bam-12937	229	26	low	low	ADJ
bam-12937	229	27	-	-	PUNCT
bam-12937	229	28	density	density	NOUN
bam-12937	229	29	lipoprotein	lipoprotein	ADJ
bam-12937	229	30	cholesterol	cholesterol	NOUN
bam-12937	229	31	.	.	PUNCT
bam-12937	230	1	j	j	PROPN
bam-12937	230	2	am	be	AUX
bam-12937	230	3	heart	heart	NOUN
bam-12937	230	4	assoc	assoc	NOUN
bam-12937	230	5	2022;11	2022;11	PROPN
bam-12937	230	6	:	:	PUNCT
bam-12937	231	1	e025551	e025551	INTJ
bam-12937	231	2	.	.	PUNCT
bam-12937	232	1	16	16	NUM
bam-12937	232	2	.	.	PUNCT
bam-12937	233	1	rosenson	rosenson	NOUN
bam-12937	233	2	rs	rs	PROPN
bam-12937	233	3	,	,	PUNCT
bam-12937	233	4	jacobson	jacobson	PROPN
bam-12937	233	5	ta	ta	PROPN
bam-12937	233	6	,	,	PUNCT
bam-12937	233	7	preiss	preiss	PROPN
bam-12937	233	8	d	d	PROPN
bam-12937	233	9	,	,	PUNCT
bam-12937	233	10	et	et	PROPN
bam-12937	233	11	al	al	PROPN
bam-12937	233	12	.	.	PROPN
bam-12937	233	13	efficacy	efficacy	NOUN
bam-12937	233	14	and	and	CCONJ
bam-12937	233	15	safety	safety	NOUN
bam-12937	233	16	of	of	ADP
bam-12937	233	17	the	the	DET
bam-12937	233	18	pcsk9	pcsk9	NOUN
bam-12937	233	19	inhibitor	inhibitor	NOUN
bam-12937	233	20	evolocumab	evolocumab	NOUN
bam-12937	233	21	in	in	ADP
bam-12937	233	22	patients	patient	NOUN
bam-12937	233	23	with	with	ADP
bam-12937	233	24	mixed	mixed	ADJ
bam-12937	233	25	hyperlipidemia	hyperlipidemia	NOUN
bam-12937	233	26	.	.	PUNCT
bam-12937	234	1	cardiovasc	cardiovasc	PROPN
bam-12937	234	2	drugs	drug	NOUN
bam-12937	234	3	ther	ther	VERB
bam-12937	234	4	2016;30:305	2016;30:305	NUM
bam-12937	234	5	-	-	SYM
bam-12937	234	6	13	13	NUM
bam-12937	234	7	.	.	PUNCT
bam-12937	235	1	17	17	NUM
bam-12937	235	2	.	.	PUNCT
bam-12937	236	1	zhang	zhang	PROPN
bam-12937	236	2	y	y	PROPN
bam-12937	236	3	,	,	PUNCT
bam-12937	236	4	suo	suo	PROPN
bam-12937	236	5	y	y	PROPN
bam-12937	236	6	,	,	PUNCT
bam-12937	236	7	yang	yang	PROPN
bam-12937	236	8	l	l	PROPN
bam-12937	236	9	,	,	PUNCT
bam-12937	236	10	et	et	PROPN
bam-12937	236	11	al	al	PROPN
bam-12937	236	12	.	.	PROPN
bam-12937	236	13	effect	effect	NOUN
bam-12937	236	14	of	of	ADP
bam-12937	236	15	pcsk9	pcsk9	PROPN
bam-12937	236	16	inhibitor	inhibitor	NOUN
bam-12937	236	17	on	on	ADP
bam-12937	236	18	blood	blood	NOUN
bam-12937	236	19	lipid	lipid	NOUN
bam-12937	236	20	levels	level	NOUN
bam-12937	236	21	in	in	ADP
bam-12937	236	22	patients	patient	NOUN
bam-12937	236	23	with	with	ADP
bam-12937	236	24	high	high	ADJ
bam-12937	236	25	and	and	CCONJ
bam-12937	236	26	very	very	ADV
bam-12937	236	27	-	-	PUNCT
bam-12937	236	28	high	high	ADJ
bam-12937	236	29	cvd	cvd	PROPN
bam-12937	236	30	risk	risk	NOUN
bam-12937	236	31	:	:	PUNCT
bam-12937	236	32	a	a	DET
bam-12937	236	33	systematic	systematic	ADJ
bam-12937	236	34	review	review	NOUN
bam-12937	236	35	and	and	CCONJ
bam-12937	236	36	metaanalysis	metaanalysis	NOUN
bam-12937	236	37	.	.	PUNCT
bam-12937	237	1	cardiol	cardiol	NOUN
bam-12937	237	2	res	re	NOUN
bam-12937	237	3	pract	pract	PROPN
bam-12937	237	4	2022;2022:8729003	2022;2022:8729003	NUM
bam-12937	237	5	.	.	PROPN
bam-12937	237	6	18	18	NUM
bam-12937	237	7	.	.	PUNCT
bam-12937	238	1	sabatine	sabatine	PROPN
bam-12937	238	2	ms	ms	PROPN
bam-12937	238	3	.	.	PROPN
bam-12937	238	4	pcsk9	pcsk9	PROPN
bam-12937	238	5	inhibitors	inhibitor	NOUN
bam-12937	238	6	:	:	PUNCT
bam-12937	238	7	clinical	clinical	ADJ
bam-12937	238	8	evidence	evidence	NOUN
bam-12937	238	9	and	and	CCONJ
bam-12937	238	10	implementation	implementation	NOUN
bam-12937	238	11	.	.	PUNCT
bam-12937	239	1	nature	nature	NOUN
bam-12937	239	2	rev	rev	VERB
bam-12937	239	3	cardiol	cardiol	NOUN
bam-12937	239	4	2019;16:155	2019;16:155	PROPN
bam-12937	239	5	-	-	SYM
bam-12937	239	6	65	65	NUM
bam-12937	239	7	.	.	NOUN
bam-12937	240	1	19	19	NUM
bam-12937	240	2	.	.	PUNCT
bam-12937	240	3	paquette	paquette	PROPN
bam-12937	240	4	m	m	PROPN
bam-12937	240	5	,	,	PUNCT
bam-12937	240	6	faubert	faubert	PROPN
bam-12937	240	7	s	s	SYM
bam-12937	240	8	,	,	PUNCT
bam-12937	240	9	saint	saint	NOUN
bam-12937	240	10	-	-	PUNCT
bam-12937	240	11	pierre	pierre	NOUN
bam-12937	240	12	n	n	CCONJ
bam-12937	240	13	,	,	PUNCT
bam-12937	240	14	et	et	PROPN
bam-12937	240	15	al	al	PROPN
bam-12937	240	16	.	.	PROPN
bam-12937	241	1	sex	sex	NOUN
bam-12937	241	2	differences	difference	NOUN
bam-12937	241	3	in	in	ADP
bam-12937	241	4	ldl	ldl	NOUN
bam-12937	241	5	-	-	PUNCT
bam-12937	241	6	c	c	NOUN
bam-12937	241	7	response	response	NOUN
bam-12937	241	8	to	to	ADP
bam-12937	241	9	pcsk9	pcsk9	NOUN
bam-12937	241	10	inhibitors	inhibitor	NOUN
bam-12937	241	11	:	:	PUNCT
bam-12937	241	12	a	a	DET
bam-12937	241	13	real	real	ADJ
bam-12937	241	14	world	world	NOUN
bam-12937	241	15	experience	experience	NOUN
bam-12937	241	16	.	.	PUNCT
bam-12937	242	1	j	j	PROPN
bam-12937	242	2	clini	clini	PROPN
bam-12937	242	3	lipidol	lipidol	VERB
bam-12937	242	4	2023;17:142	2023;17:142	NOUN
bam-12937	242	5	-	-	PUNCT
bam-12937	242	6	9	9	NUM
bam-12937	242	7	.	.	NOUN
bam-12937	242	8	20	20	NUM
bam-12937	242	9	.	.	PUNCT
bam-12937	243	1	hess	hess	PROPN
bam-12937	243	2	cn	cn	PROPN
bam-12937	243	3	,	,	PUNCT
bam-12937	243	4	low	low	PROPN
bam-12937	243	5	wang	wang	PROPN
bam-12937	243	6	cc	cc	PROPN
bam-12937	243	7	,	,	PUNCT
bam-12937	243	8	hiatt	hiatt	PROPN
bam-12937	243	9	wr	wr	PROPN
bam-12937	243	10	.	.	PUNCT
bam-12937	244	1	pcsk9	pcsk9	PROPN
bam-12937	244	2	inhibitors	inhibitor	NOUN
bam-12937	244	3	:	:	PUNCT
bam-12937	244	4	mechanisms	mechanism	NOUN
bam-12937	244	5	of	of	ADP
bam-12937	244	6	action	action	NOUN
bam-12937	244	7	,	,	PUNCT
bam-12937	244	8	metabolic	metabolic	NOUN
bam-12937	244	9	effects	effect	NOUN
bam-12937	244	10	,	,	PUNCT
bam-12937	244	11	and	and	CCONJ
bam-12937	244	12	clinical	clinical	ADJ
bam-12937	244	13	outcomes	outcome	NOUN
bam-12937	244	14	.	.	PUNCT
bam-12937	245	1	ann	ann	PROPN
bam-12937	245	2	rev	rev	VERB
bam-12937	245	3	med	med	PROPN
bam-12937	245	4	2018;69:133	2018;69:133	PROPN
bam-12937	245	5	-	-	SYM
bam-12937	245	6	45	45	NUM
bam-12937	245	7	.	.	NOUN
bam-12937	246	1	21	21	NUM
bam-12937	246	2	.	.	PUNCT
bam-12937	247	1	mohamed	mohamed	PROPN
bam-12937	247	2	f	f	PROPN
bam-12937	247	3	,	,	PUNCT
bam-12937	247	4	mansfield	mansfield	PROPN
bam-12937	247	5	b	b	PROPN
bam-12937	247	6	,	,	PUNCT
bam-12937	247	7	raal	raal	PROPN
bam-12937	247	8	fj	fj	PROPN
bam-12937	247	9	.	.	PUNCT
bam-12937	247	10	targeting	target	VERB
bam-12937	247	11	pcsk9	pcsk9	NOUN
bam-12937	247	12	and	and	CCONJ
bam-12937	247	13	beyond	beyond	ADP
bam-12937	247	14	for	for	ADP
bam-12937	247	15	the	the	DET
bam-12937	247	16	management	management	NOUN
bam-12937	247	17	of	of	ADP
bam-12937	247	18	low	low	ADJ
bam-12937	247	19	-	-	PUNCT
bam-12937	247	20	density	density	NOUN
bam-12937	247	21	lipoprotein	lipoprotein	ADJ
bam-12937	247	22	cholesterol	cholesterol	NOUN
bam-12937	247	23	.	.	PUNCT
bam-12937	248	1	j	j	PROPN
bam-12937	248	2	clin	clin	PROPN
bam-12937	248	3	med	me	VERB
bam-12937	248	4	2023;12:5082	2023;12:5082	PROPN
bam-12937	248	5	.	.	PUNCT
bam-12937	249	1	22	22	NUM
bam-12937	249	2	.	.	PUNCT
bam-12937	250	1	ginsberg	ginsberg	PROPN
bam-12937	250	2	hn	hn	PROPN
bam-12937	250	3	,	,	PUNCT
bam-12937	250	4	rader	rader	PROPN
bam-12937	250	5	dj	dj	PROPN
bam-12937	250	6	,	,	PUNCT
bam-12937	250	7	raal	raal	PROPN
bam-12937	250	8	fj	fj	PROPN
bam-12937	250	9	,	,	PUNCT
bam-12937	250	10	et	et	PROPN
bam-12937	250	11	al	al	PROPN
bam-12937	250	12	.	.	PROPN
bam-12937	250	13	efficacy	efficacy	NOUN
bam-12937	250	14	and	and	CCONJ
bam-12937	250	15	safety	safety	NOUN
bam-12937	250	16	of	of	ADP
bam-12937	250	17	alirocumab	alirocumab	NOUN
bam-12937	250	18	in	in	ADP
bam-12937	250	19	patients	patient	NOUN
bam-12937	250	20	with	with	ADP
bam-12937	250	21	heterozygous	heterozygous	ADJ
bam-12937	250	22	familial	familial	ADJ
bam-12937	250	23	hypercholesterolemia	hypercholesterolemia	NOUN
bam-12937	250	24	and	and	CCONJ
bam-12937	250	25	ldl	ldl	NOUN
bam-12937	250	26	-	-	PUNCT
bam-12937	250	27	c	c	NOUN
bam-12937	250	28	of	of	ADP
bam-12937	250	29	160	160	NUM
bam-12937	250	30	mg	mg	PROPN
bam-12937	250	31	/	/	SYM
bam-12937	250	32	dl	dl	PROPN
bam-12937	250	33	or	or	CCONJ
bam-12937	250	34	higher	high	ADJ
bam-12937	250	35	.	.	PUNCT
bam-12937	251	1	cardiovasc	cardiovasc	PROPN
bam-12937	251	2	drugs	drug	NOUN
bam-12937	251	3	ther	ther	VERB
bam-12937	251	4	2016;30:473	2016;30:473	NOUN
bam-12937	251	5	-	-	SYM
bam-12937	251	6	83	83	NUM
bam-12937	251	7	.	.	PUNCT
bam-12937	252	1	23	23	NUM
bam-12937	252	2	.	.	PUNCT
bam-12937	253	1	iqbal	iqbal	PROPN
bam-12937	253	2	f	f	PROPN
bam-12937	253	3	,	,	PUNCT
bam-12937	253	4	baker	baker	PROPN
bam-12937	253	5	ws	ws	PROPN
bam-12937	253	6	,	,	PUNCT
bam-12937	253	7	khan	khan	PROPN
bam-12937	253	8	mi	mi	PROPN
bam-12937	253	9	,	,	PUNCT
bam-12937	253	10	et	et	PROPN
bam-12937	253	11	al	al	PROPN
bam-12937	253	12	.	.	PROPN
bam-12937	254	1	current	current	ADJ
bam-12937	254	2	and	and	CCONJ
bam-12937	254	3	future	future	ADJ
bam-12937	254	4	therapies	therapy	NOUN
bam-12937	254	5	for	for	ADP
bam-12937	254	6	addressing	address	VERB
bam-12937	254	7	the	the	DET
bam-12937	254	8	effects	effect	NOUN
bam-12937	254	9	of	of	ADP
bam-12937	254	10	inflammation	inflammation	NOUN
bam-12937	254	11	on	on	ADP
bam-12937	254	12	hdl	hdl	PROPN
bam-12937	254	13	cholesterol	cholesterol	PROPN
bam-12937	254	14	metabolism	metabolism	NOUN
bam-12937	254	15	.	.	PUNCT
bam-12937	255	1	br	br	PROPN
bam-12937	256	1	j	j	PROPN
bam-12937	256	2	pharmacol	pharmacol	PROPN
bam-12937	256	3	2017;174:3986	2017;174:3986	NUM
bam-12937	256	4	-	-	SYM
bam-12937	256	5	4006	4006	NUM
bam-12937	256	6	.	.	PUNCT
bam-12937	257	1	24	24	NUM
bam-12937	257	2	.	.	PUNCT
bam-12937	257	3	ma	ma	PROPN
bam-12937	257	4	w	w	PROPN
bam-12937	257	5	,	,	PUNCT
bam-12937	257	6	guo	guo	PROPN
bam-12937	257	7	x	x	PROPN
bam-12937	257	8	,	,	PUNCT
bam-12937	257	9	ma	ma	PROPN
bam-12937	257	10	y	y	PROPN
bam-12937	257	11	,	,	PUNCT
bam-12937	257	12	hu	hu	PROPN
bam-12937	258	1	z.	z.	PROPN
bam-12937	258	2	meta	meta	PROPN
bam-12937	258	3	-	-	PUNCT
bam-12937	258	4	analysis	analysis	NOUN
bam-12937	258	5	of	of	ADP
bam-12937	258	6	randomized	randomized	ADJ
bam-12937	258	7	clinical	clinical	ADJ
bam-12937	258	8	trials	trial	NOUN
bam-12937	258	9	comparing	compare	VERB
bam-12937	258	10	pcsk9	pcsk9	NOUN
bam-12937	258	11	monoclonal	monoclonal	NOUN
bam-12937	258	12	antibody	antibody	NOUN
bam-12937	258	13	versus	versus	ADP
bam-12937	258	14	ezetimibe	ezetimibe	NOUN
bam-12937	258	15	/	/	SYM
bam-12937	258	16	placebo	placebo	NOUN
bam-12937	258	17	in	in	ADP
bam-12937	258	18	patients	patient	NOUN
bam-12937	258	19	at	at	ADP
bam-12937	258	20	high	high	ADJ
bam-12937	258	21	cardiovascular	cardiovascular	ADJ
bam-12937	258	22	risk	risk	NOUN
bam-12937	258	23	.	.	PUNCT
bam-12937	259	1	atherosclerosis	atherosclerosis	NOUN
bam-12937	259	2	2021;326:25	2021;326:25	NOUN
bam-12937	259	3	-	-	SYM
bam-12937	259	4	34	34	NUM
bam-12937	259	5	.	.	PUNCT
bam-12937	259	6	25	25	NUM
bam-12937	259	7	.	.	PUNCT
bam-12937	260	1	berman	berman	PROPN
bam-12937	260	2	an	an	PROPN
bam-12937	260	3	,	,	PUNCT
bam-12937	260	4	blankstein	blankstein	PROPN
bam-12937	260	5	r.	r.	PROPN
bam-12937	260	6	optimizing	optimize	VERB
bam-12937	260	7	dyslipidemia	dyslipidemia	NOUN
bam-12937	260	8	management	management	NOUN
bam-12937	260	9	for	for	ADP
bam-12937	260	10	the	the	DET
bam-12937	260	11	prevention	prevention	NOUN
bam-12937	260	12	of	of	ADP
bam-12937	260	13	cardiovascular	cardiovascular	ADJ
bam-12937	260	14	disease	disease	NOUN
bam-12937	260	15	:	:	PUNCT
bam-12937	260	16	a	a	DET
bam-12937	260	17	focus	focus	NOUN
bam-12937	260	18	on	on	ADP
bam-12937	260	19	risk	risk	NOUN
bam-12937	260	20	assessment	assessment	NOUN
bam-12937	260	21	and	and	CCONJ
bam-12937	260	22	therapeutic	therapeutic	ADJ
bam-12937	260	23	options	option	NOUN
bam-12937	260	24	.	.	PUNCT
bam-12937	261	1	curr	curr	PROPN
bam-12937	261	2	cardiol	cardiol	PROPN
bam-12937	261	3	rep	rep	PROPN
bam-12937	261	4	2019;21:1	2019;21:1	PROPN
bam-12937	261	5	-	-	PUNCT
bam-12937	261	6	0	0	NUM
bam-12937	261	7	.	.	NOUN
bam-12937	261	8	26	26	NUM
bam-12937	261	9	.	.	PUNCT
bam-12937	262	1	karantas	karanta	NOUN
bam-12937	262	2	i	i	PROPN
bam-12937	262	3	d	d	PROPN
bam-12937	262	4	,	,	PUNCT
bam-12937	262	5	okur	okur	VERB
bam-12937	262	6	me	i	PRON
bam-12937	262	7	,	,	PUNCT
bam-12937	262	8	okur	okur	PROPN
bam-12937	262	9	nü	nü	PROPN
bam-12937	262	10	,	,	PUNCT
bam-12937	262	11	siafaka	siafaka	PROPN
bam-12937	262	12	pi	pi	VERB
bam-12937	262	13	.	.	PUNCT
bam-12937	263	1	dyslipidemia	dyslipidemia	NOUN
bam-12937	263	2	management	management	NOUN
bam-12937	263	3	in	in	ADP
bam-12937	263	4	2020	2020	NUM
bam-12937	263	5	:	:	PUNCT
bam-12937	263	6	an	an	DET
bam-12937	263	7	update	update	NOUN
bam-12937	263	8	on	on	ADP
bam-12937	263	9	diagnosis	diagnosis	NOUN
bam-12937	263	10	and	and	CCONJ
bam-12937	263	11	therapeutic	therapeutic	ADJ
bam-12937	263	12	perspectives	perspective	NOUN
bam-12937	263	13	.	.	PUNCT
bam-12937	264	1	endocr	endocr	PROPN
bam-12937	264	2	metabol	metabol	PROPN
bam-12937	264	3	immune	immune	ADJ
bam-12937	264	4	disorders	disorder	NOUN
bam-12937	264	5	-	-	PUNCT
bam-12937	264	6	drug	drug	NOUN
bam-12937	264	7	targets	target	NOUN
bam-12937	264	8	2021;21:815	2021;21:815	NOUN
bam-12937	264	9	-	-	SYM
bam-12937	264	10	34	34	NUM
bam-12937	264	11	.	.	PUNCT
bam-12937	264	12	27	27	NUM
bam-12937	264	13	.	.	PUNCT
bam-12937	265	1	lorenzatti	lorenzatti	PROPN
bam-12937	265	2	aj	aj	PROPN
bam-12937	265	3	,	,	PUNCT
bam-12937	265	4	eliaschewitz	eliaschewitz	PROPN
bam-12937	265	5	fg	fg	PROPN
bam-12937	265	6	,	,	PUNCT
bam-12937	265	7	chen	chen	PROPN
bam-12937	265	8	y	y	PROPN
bam-12937	265	9	,	,	PUNCT
bam-12937	265	10	et	et	PROPN
bam-12937	265	11	al	al	PROPN
bam-12937	265	12	.	.	PROPN
bam-12937	265	13	rationale	rationale	NOUN
bam-12937	265	14	and	and	CCONJ
bam-12937	265	15	design	design	NOUN
bam-12937	265	16	of	of	ADP
bam-12937	265	17	a	a	DET
bam-12937	265	18	randomized	randomized	ADJ
bam-12937	265	19	study	study	NOUN
bam-12937	265	20	to	to	PART
bam-12937	265	21	assess	assess	VERB
bam-12937	265	22	the	the	DET
bam-12937	265	23	efficacy	efficacy	NOUN
bam-12937	265	24	and	and	CCONJ
bam-12937	265	25	safety	safety	NOUN
bam-12937	265	26	of	of	ADP
bam-12937	265	27	evolocumab	evolocumab	NOUN
bam-12937	265	28	in	in	ADP
bam-12937	265	29	patients	patient	NOUN
bam-12937	265	30	with	with	ADP
bam-12937	265	31	diabetes	diabetes	NOUN
bam-12937	265	32	and	and	CCONJ
bam-12937	265	33	dyslipidemia	dyslipidemia	NOUN
bam-12937	265	34	:	:	PUNCT
bam-12937	265	35	the	the	DET
bam-12937	265	36	berson	berson	NOUN
bam-12937	265	37	clinical	clinical	ADJ
bam-12937	265	38	trial	trial	NOUN
bam-12937	265	39	.	.	PUNCT
bam-12937	266	1	clin	clin	PROPN
bam-12937	266	2	cardiol	cardiol	VERB
bam-12937	266	3	2018;41:1117	2018;41:1117	NUM
bam-12937	266	4	-	-	SYM
bam-12937	266	5	22	22	NUM
bam-12937	266	6	.	.	PUNCT
bam-12937	267	1	28	28	NUM
bam-12937	267	2	.	.	PUNCT
bam-12937	268	1	alhajri	alhajri	PROPN
bam-12937	268	2	l	l	PROPN
bam-12937	268	3	,	,	PUNCT
bam-12937	268	4	alhadhrami	alhadhrami	VERB
bam-12937	268	5	a	a	PRON
bam-12937	268	6	,	,	PUNCT
bam-12937	268	7	almheiri	almheiri	NOUN
bam-12937	268	8	s	s	PART
bam-12937	268	9	,	,	PUNCT
bam-12937	268	10	et	et	PROPN
bam-12937	268	11	al	al	PROPN
bam-12937	268	12	.	.	PUNCT
bam-12937	269	1	the	the	DET
bam-12937	269	2	efficacy	efficacy	NOUN
bam-12937	269	3	of	of	ADP
bam-12937	269	4	evolocumab	evolocumab	NOUN
bam-12937	269	5	in	in	ADP
bam-12937	269	6	the	the	DET
bam-12937	269	7	management	management	NOUN
bam-12937	269	8	of	of	ADP
bam-12937	269	9	hyperlipidemia	hyperlipidemia	NOUN
bam-12937	269	10	:	:	PUNCT
bam-12937	269	11	a	a	DET
bam-12937	269	12	systematic	systematic	ADJ
bam-12937	269	13	review	review	NOUN
bam-12937	269	14	.	.	PUNCT
bam-12937	270	1	ther	ther	PROPN
bam-12937	270	2	adv	adv	PROPN
bam-12937	271	1	cardiovasc	cardiovasc	PROPN
bam-12937	271	2	dis	dis	PROPN
bam-12937	271	3	2017;11:155	2017;11:155	PROPN
bam-12937	271	4	-	-	SYM
bam-12937	271	5	69	69	NUM
bam-12937	271	6	.	.	PUNCT
bam-12937	271	7	29	29	NUM
bam-12937	271	8	.	.	PUNCT
bam-12937	272	1	lazarte	lazarte	PROPN
bam-12937	272	2	j	j	PROPN
bam-12937	272	3	,	,	PUNCT
bam-12937	272	4	hegele	hegele	PROPN
bam-12937	272	5	ra	ra	PROPN
bam-12937	272	6	.	.	PUNCT
bam-12937	273	1	dyslipidemia	dyslipidemia	NOUN
bam-12937	273	2	management	management	NOUN
bam-12937	273	3	in	in	ADP
bam-12937	273	4	adults	adult	NOUN
bam-12937	273	5	with	with	ADP
bam-12937	273	6	diabetes	diabetes	NOUN
bam-12937	273	7	.	.	PUNCT
bam-12937	274	1	can	can	AUX
bam-12937	274	2	j	j	PROPN
bam-12937	274	3	diabetes	diabetes	VERB
bam-12937	274	4	2020;44:53	2020;44:53	NUM
bam-12937	274	5	-	-	SYM
bam-12937	274	6	60	60	NUM
bam-12937	274	7	.	.	PUNCT
bam-12937	274	8	30	30	NUM
bam-12937	274	9	.	.	PUNCT
bam-12937	275	1	muscoli	muscoli	PROPN
bam-12937	275	2	s	s	PROPN
bam-12937	275	3	,	,	PUNCT
bam-12937	275	4	ifrim	ifrim	PROPN
bam-12937	275	5	m	m	PROPN
bam-12937	275	6	,	,	PUNCT
bam-12937	275	7	russo	russo	PROPN
bam-12937	275	8	m	m	PROPN
bam-12937	275	9	,	,	PUNCT
bam-12937	275	10	et	et	PROPN
bam-12937	275	11	al	al	PROPN
bam-12937	275	12	.	.	PUNCT
bam-12937	276	1	current	current	ADJ
bam-12937	276	2	options	option	NOUN
bam-12937	276	3	and	and	CCONJ
bam-12937	276	4	future	future	ADJ
bam-12937	276	5	perspectives	perspective	NOUN
bam-12937	276	6	in	in	ADP
bam-12937	276	7	the	the	DET
bam-12937	276	8	treatment	treatment	NOUN
bam-12937	276	9	of	of	ADP
bam-12937	276	10	dyslipidemia	dyslipidemia	NOUN
bam-12937	276	11	.	.	PUNCT
bam-12937	277	1	j	j	PROPN
bam-12937	277	2	clin	clin	PROPN
bam-12937	277	3	med	med	PROPN
bam-12937	277	4	2022;11:4716	2022;11:4716	PROPN
bam-12937	277	5	.	.	PUNCT
bam-12937	278	1	disclaimer	disclaimer	PROPN
bam-12937	278	2	all	all	DET
bam-12937	278	3	claims	claim	NOUN
bam-12937	278	4	expressed	express	VERB
bam-12937	278	5	in	in	ADP
bam-12937	278	6	this	this	DET
bam-12937	278	7	article	article	NOUN
bam-12937	278	8	are	be	AUX
bam-12937	278	9	solely	solely	ADV
bam-12937	278	10	those	those	PRON
bam-12937	278	11	of	of	ADP
bam-12937	278	12	the	the	DET
bam-12937	278	13	authors	author	NOUN
bam-12937	278	14	and	and	CCONJ
bam-12937	278	15	do	do	AUX
bam-12937	278	16	not	not	PART
bam-12937	278	17	necessarily	necessarily	ADV
bam-12937	278	18	represent	represent	VERB
bam-12937	278	19	those	those	PRON
bam-12937	278	20	of	of	ADP
bam-12937	278	21	their	their	PRON
bam-12937	278	22	affiliated	affiliated	ADJ
bam-12937	278	23	organizations	organization	NOUN
bam-12937	278	24	,	,	PUNCT
bam-12937	278	25	or	or	CCONJ
bam-12937	278	26	those	those	PRON
bam-12937	278	27	of	of	ADP
bam-12937	278	28	the	the	DET
bam-12937	278	29	publisher	publisher	NOUN
bam-12937	278	30	,	,	PUNCT
bam-12937	278	31	the	the	DET
bam-12937	278	32	editors	editor	NOUN
bam-12937	278	33	and	and	CCONJ
bam-12937	278	34	the	the	DET
bam-12937	278	35	reviewers	reviewer	NOUN
bam-12937	278	36	.	.	PUNCT
bam-12937	279	1	any	any	DET
bam-12937	279	2	product	product	NOUN
bam-12937	279	3	that	that	PRON
bam-12937	279	4	may	may	AUX
bam-12937	279	5	be	be	AUX
bam-12937	279	6	evaluated	evaluate	VERB
bam-12937	279	7	in	in	ADP
bam-12937	279	8	this	this	DET
bam-12937	279	9	article	article	NOUN
bam-12937	279	10	or	or	CCONJ
bam-12937	279	11	claim	claim	NOUN
bam-12937	279	12	that	that	PRON
bam-12937	279	13	may	may	AUX
bam-12937	279	14	be	be	AUX
bam-12937	279	15	made	make	VERB
bam-12937	279	16	by	by	ADP
bam-12937	279	17	its	its	PRON
bam-12937	279	18	manufacturer	manufacturer	NOUN
bam-12937	279	19	is	be	AUX
bam-12937	279	20	not	not	PART
bam-12937	279	21	guaranteed	guarantee	VERB
bam-12937	279	22	or	or	CCONJ
bam-12937	279	23	endorsed	endorse	VERB
bam-12937	279	24	by	by	ADP
bam-12937	279	25	the	the	DET
bam-12937	279	26	publisher	publisher	NOUN
bam-12937	279	27	.	.	PUNCT
bam-12937	280	1	submitted	submit	VERB
bam-12937	280	2	:	:	PUNCT
bam-12937	280	3	18	18	NUM
bam-12937	280	4	august	august	PROPN
bam-12937	280	5	2024	2024	NUM
bam-12937	280	6	.	.	PUNCT
bam-12937	281	1	accepted	accept	VERB
bam-12937	281	2	:	:	PUNCT
bam-12937	281	3	2	2	NUM
bam-12937	281	4	september	september	PROPN
bam-12937	281	5	2024	2024	NUM
bam-12937	281	6	.	.	PUNCT
bam-12937	282	1	early	early	ADJ
bam-12937	282	2	access	access	NOUN
bam-12937	282	3	:	:	PUNCT
bam-12937	282	4	13	13	NUM
bam-12937	282	5	september	september	PROPN
bam-12937	282	6	2024	2024	NUM
bam-12937	282	7	.	.	PUNCT
bam-12937	283	1	121	121	NUM
bam-12937	283	2	non	non	ADJ
bam-12937	283	3	-co	-co	PROPN
bam-12937	283	4	mmerc	mmerc	PROPN
bam-12937	283	5	ial	ial	PROPN
bam-12937	283	6	us	us	PROPN
bam-12937	283	7	e	e	NOUN
bam-12937	283	8	o	o	NOUN
bam-12937	283	9	nly	nly	ADV